Development of a receptor targeted nanotherapy using a proapoptotic peptide by Sibuyi, Nicole Remaliah Samantha
   
 
 
          
 
Development of a receptor targeted nanotherapy using a pro-
apoptotic peptide 
 
    Nicole Remaliah Samantha Sibuyi 
 
A thesis submitted in partial fulfilment of the requirements for the degree of Doctor 
Philosophiae in the Department of Biotechnology, University of the Western Cape. 
2015 
 
Supervisors:    Prof M Meyer  
Co-Supervisor:  Dr AM Madiehe 
                
 
 
 
 
i 
 
Abstract 
Development of a receptor targeted nanotherapy using a pro-apoptotic peptide 
NRS Sibuyi 
 
PhD Thesis, Department of Biotechnology, Faculty of Natural Science, University of the 
Western Cape, South Africa  
The prevalence of obesity amongst South Africans is alarming, with more than 29% of 
men and 56% of women considered to be obese. Angiogenesis, a process for development 
of new blood vessels play a major role in growth and survival of the adipose tissues. 
Pharmacological inhibitors of angiogenesis are therefore a sensible strategy to reduce 
excess body weight. Current anti-obesity drugs have limitations because of their lack of 
selectivity and specificity, which lead to undesirable side effects and reduced drug 
efficacy. Future anti-obesity therapeutic strategies should be target-specific, with minimal 
toxicity towards healthy tissues will be more appropriate for obesity treatment. Targeted 
nano-therapeutic agents are currently being developed to overcome the drawbacks 
associated with conventional drug therapies. The nano-based delivery vehicles that 
specifically target diseased cells are appealing as they could reduce drug toxicity towards 
healthy tissues and be more effective at lower dosages. 
The main aim of this study was to develop a receptor-mediated nanotherapy that 
specifically targets the white adipose tissue vasculature and trigger the death of these cells 
through apoptosis. The 14 nm gold nanoparticles (AuNPs) were synthesized using the 
Turkevich method following reduction of gold aurate by sodium citrate salt. Different 
 
 
 
 
ii 
 
chemistries were used to functionalise the AuNPs for biological application by conjugating 
with either vascular targeting peptide or pro-apoptotic peptide on their surface or both. The 
nanomaterials were characterised by UV-Vis, Zeta potential and transmission electron 
microscopy (TEM). The sensitivity and specificity of various AuNP conjugates were tested 
in vitro on colon and breast cancer cell lines. A human (Caco-2) cell line that expresses the 
receptor for the adipose homing peptide was chosen as an in vitro model system. Cellular 
toxicity and uptake of the nanoparticles was evaluated using the WST-1 assay, Inductively 
Coupled Plasma-Optical Emission Spectra (ICP-OES) and TEM. The induction of 
apoptosis following exposure to the nanoparticles was examined by Western blot and flow 
cytometric analysis.  
 
The anti-proliferative activity of the targeted therapeutic nanoparticles on the cells was 
more pronounced on the cells expressing the receptor for the adipose homing peptide. The 
uptake of unfunctionalised AuNPs was higher compared to functionalised nanoparticles, 
but this did not impair cell viability. The activity of the therapeutic peptide was retained 
and enhanced following conjugation to AuNPs as shown by Western blot and flow 
cytometric analysis. The nanotherapy under study demonstrated receptor mediated 
targeting, and enhanced activity on the cells expressing the receptor. However, the 
therapeutic and efficacy of the targeted nanotherapy still need to be tested in animal 
models of obesity to confirm the treatment specificity. 
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Chapter 1: Literature Review  
Introduction 
Pharmaceutical drugs used for treatment of chronic diseases such as obesity and cancer, 
suffer from lack of specificity which reduces the sensitivity and efficacy of the prescribed 
drugs. Due to side effects these drugs cannot be used indefinitely, discontinuation is often 
followed by disease relapse. Alternative strategies that can treat chronic diseases are of 
utmost significance in health economics, life expectancy and reduction of mortality. As 
such, treatment strategies that can reduce the burden of chronic diseases are urgently 
required. For this purpose, precision or targeted therapy is receiving a considerable amount 
of attention as a potential therapy that can alleviate chronic diseases. Ability to ferry 
therapeutic materials directly to desired targets (pathological cells) with no effect to 
healthy tissues could overcome certain drawbacks associated with current treatment 
regimen. Disease-associated antigens can be exploited to develop targeted nanotherapy by 
using nanoparticles as stealth drug carriers. In this manner, toxicity could be limited to 
target cells, reducing side effects and preventing immune response. This will significantly 
enhance the half-life of the therapy, mask the therapy from attack by phagocytes and 
reduce early drug clearance from the blood system. 
The future of nanomedicine is projected towards detection and eradication of diseased 
cells through targeted nanotherapy.  For targeted therapy to be effective, disease specific 
targets have to be identified. The targeting peptide used in this study targets a cell surface 
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receptor in the white adipose tissue (WAT) vasculature of obese subjects. The feasibility 
of the vascular targeted nanotherapy in obese subjects is reviewed in this chapter. 
 
1.1 OBESITY 
Obesity is a complex, multifaceted medical condition that is prevalent in both developing 
and industrialized countries (Trayhurn, 2007). It is a global epidemic and health problem 
that does not discriminate between adults, children and adolescents. Worldwide, women 
are found to be more obese than men, while there are a higher proportion of overweight 
men than overweight women (WHO, 2010). The same trend in obesity statistics was 
observed in both African and white populations in South Africa (Puone et al., 2002, Van 
der Merwe and Pepper, 2006).  
Obesity is a major risk factor for development of serious chronic diseases, such as 
cardiovascular diseases (CVDs) including hypertension, stroke, coronary heart diseases 
(Carl et al., 2009; Narkiewicz, 2006), type 2 diabetes mellitus (T2D) (Eckel et al., 2011) 
and various forms of cancer, such as breast cancer, colon and prostate cancer (Bray, 2002). 
Obesity as a medical condition endangers millions of lives through its association with the 
chronic diseases mentioned above. These chronic diseases are further associated with 
adverse health events, increased medical care costs that further decrease life expectancy 
leading to premature death. It was projected that 60% of deaths worldwide by 2025 will be 
caused by obesity-associated chronic diseases. This evidence suggests that the prevention 
and control of obesity needs to be taken very seriously in both industrialized and 
developing countries (World Health Organization, 2000).  
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Obesity is a metabolic condition that results from energy imbalance in genetically 
susceptible individuals. The genetic basis of obesity was proven through animal studies, 
and strongly correlates to human trials, as discussed in section 1.1.1 (Arner, 2000; 
O’rahilly et al., 2003; Sorensen and Echwald, 2001). Thus, obesity results from positive 
energy imbalance where energy intake (EI) chronically exceeds energy expenditure (EE) 
in terms of basal metabolic rate, thermogenesis or physical activity. The excess energy or 
fat is normally stored as triacylglycerols (TAGs) in the specialized storage organ, the 
adipocytes in the WATs. Excessive and chronic fat accumulation in the adipocytes 
consequently causes metabolic alterations within the WATs. The WAT mass expands 
beyond its physiological limit to accommodate the excess energy leading to increased total 
body fat mass leading to obesity (Trayhurn, 2007).  
 
Obesity is the most undermined medical condition in both developed and developing 
countries throughout world. It is an observable trait that is used to be regarded as a sign of 
wealth and health status mostly in African countries where diseases such as HIV/Aids 
exist (Arojo and Osungbade, 2013; Renzaho, 2004). Sadly, there is still doubt by 
healthcare professionals and the public to regard obesity as a disease. As such, it is 
difficult to get a proper prescription to help in its management. Chronic accumulation of 
the excess fat in different fat depots has been associated with progression to chronic 
diseases that has detrimental health effects and non-fatal conditions (gout, sleep apnoea, 
respiratory conditions, gastro-oesophageal reflux disease, osteoarthritis and infertility) 
when not taken care of (Ofei, 2005). 
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1.1.1 Aetiology of obesity 
The causes of obesity are classified into genetic and environmental factors. Most of these 
discoveries are owed to animal models of obesity (Dubnov et al., 2003; Kennedy et al., 
2010). There is also strong evidence from human trials pointing to genes as role players in 
obesity, however, the overwhelming evidence shows that increasing prevalence of obesity 
is triggered by environmental factors.  Environmental factor, such as sedentary lifestyle 
encourages consumption of high caloric diets and discourages physical activity leading to 
weight gain. Therefore, the interaction between genetic and environmental factors is a 
major determinant for the development of obesity (Dubnov et al., 2003; Hill and Peters, 
1998). 
Genetic factors 
The development of obesity has a potential genetic component as proven through animal 
models of obesity, however, the mechanism thereof is still not known. Various genes play 
a major role in body functioning, not limited to appetite, metabolism and deposition of fat 
in the body. For instance several genes such as fat, obese (ob), diabetes (db), tubby (tub) 
and agouti yellow (Ay) that predispose animals to obesity have been identified and their 
actions studied (Chen and Garg, 1999; Kennedy et al., 2010). Mutations of these genes 
lead to development of obesity following different mechanisms of action. The ob gene 
encode for leptin (a satiety signalling protein predominantly secreted by adipocytes), db 
gene encode for the leptin receptor (Ob-R) (Zhang et al., 1994). Leptin effects are 
mediated by binding to the Ob-R in the hypothalamus through the Jak/STAT pathway 
(Hegyi et al., 2004). Leptin receptor mutations in mice resulted in severe obesity and T2D 
(Fei et al., 1997). Conversely, leptin deficiency in mice and humans causes obesity and 
 
 
 
 
 5     
may also cause diabetes syndromes such as hyperinsulinaemia. Administration of leptin in 
ob/ob mice inhibits food intake and reduces body weight via activation of specific brain 
receptors (Montague, 2003).  
 
The fat gene encodes for carboxypeptidase E or prohormone convertase 1, the enzyme 
responsible for conversion of pro-hormones into active and functional hormones. Fat 
defects predispose mice to a range of abnormalities: progressive adult onset obesity and 
obesity-induced disorders such as hyperinsulinaemia and infertility (Naggert et al., 1997). 
The Ay gene defect is associated with maturity onset obesity, pigmentation defects, insulin 
resistance and development of tumours in mice (Kennedy et al., 2010). The yellow coat 
colour observed in mice is due to defects in melanocortin (MC)-1 receptor to synthesize 
eumelanin in the hair follicle, this is involved in counteracting the actions of MC4 
receptors expressed in the hypothalamus resulting in development of obesity (Naggert et 
al., 1997). These monogenic forms of obesity in rodents have shed some light into human 
obesity. Most of the genes responsible for development of obesity in rodents correspond to 
juvenile-onset morbid obesity in humans (Arner, 2000; O’Rahilly et al., 2003). 
 
Genetic influences are difficult to elucidate and identification of the genes is not easily 
achieved in familial studies. Moreover, the influence that genotype might have on the 
aetiology of obesity is generally attenuated by non-genetic factors including high caloric 
diets (Afridi and Khan, 2004). The tendency to gain weight is hereditary; however, family 
members share not only genes but also diet and lifestyle habits that may contribute to 
obesity. Separating these lifestyle factors from genetic factors is often difficult, especially 
with evidence pointing to heredity as a strong determinant of obesity (Afridi and Khan, 
2004). Genetic studies of monozygotic (identical) and dizygotic (non-identical) twins 
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proved beyond doubt that obesity development is influenced by genetic factors, which 
account for as much as 50 to 80% of variance in monozygotic twins (Mitchell et al., 2007; 
Sorensen and Echwald, 2001). Moreover, studies of adopted twins showed no relationship 
between the body weight of those children and their adoptive parents, but a close 
correlation with their biological parents (Sorensen and Echwald, 2001). 
 
Environmental factors 
Although genetic factors certainly play an important role in the susceptibility for obesity, 
the real culprit is the environment that promotes a sedentary lifestyle and long-term energy 
imbalance due to excessive caloric intake relative to energy expenditure (Fruhbeck et al., 
2001). Thus, the development of obesity is dependent on the disequilibrium between 
energy intake and energy expenditure (Brandt et al., 2006; Racette et al., 2003).  
The human body is designed in a way that will help it maintain and regulate the metabolic 
processes and maintain the healthy body weight in return. Under physiological conditions, 
energy intake and expenditure is highly regulated and kept in balance at all times. 
However, when subjected to the environment that allows excessive food intake and 
discourages physical activity it is very challenging to avoid weight gain. Consumption of 
high energy diet should be followed by physical activity to expend the excess energy in 
order to protect the body against weight gain. In an environment where fast foods are 
readily available it is very difficult to maintain healthy dietary habits, and makes it 
difficult for healthcare givers to help obese patients lose and maintain a healthy weight. 
Hence more effort is directed towards prevention of weight gain by educating and alerting 
people through educational trainings starting from Primary schools (Hill and Peters, 1998).  
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1.1.2 Management of obesity 
Different clinical and non-clinical strategies have been tried over the years with exciting 
but unsustainable results. Clinically, obesity management is preferably directed to 
individuals that are at a greater risk of developing medical complications associated with 
obesity (Guri et al., 2006).  Managing healthy body weight can reduce or treat the medical 
consequences of obesity. The clinical approach to management of obesity involves three 
stages of interventions: lifestyle modification, pharmacotherapy and surgery. 
Pharmacotherapy as discussed below is most preferred over the other two management 
strategies as it is easily accessible and promises immediate weight loss (Bray, 2000). 
1.1.2.1 Pharmacotherapy 
Pharmacotherapy is the second phase of clinical management of obesity after lifestyle 
modification. It is an option for patients with a body mass index of ≥ 30 kg/m2 with at least 
one of the obesity health hazards (Bray, 2000). The therapy is prescribed for patients who 
have gone through lifestyle modification with no success for the first six months. It was 
initially an option for obese adults (≤ 65 years), however children and adolescents are now 
allowed to use anti-obesity drugs (Bray, 2000; Hainer et al., 2008).  
Pharmacotherapy still remains an area of ongoing research with only three groups of drugs 
approved by Food and Drug Administration (FDA): (1) those that reduce food intake, (2) 
increase thermogenesis, and (3) alter the body’s energy metabolism (Bray, 2000; Lee and 
Aronne, 2007). Monoamines act on noradrenergic, serotonin, dopamine and histamine 
receptors to reduce food intake. The noradrenergic drugs such as phentermine, mazindol, 
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and phendimetrazine, are approved only for short-term use (Bray, 2000; Lee and Aronne, 
2007). The only thermogenic drug combination that has shown efficiency in weight 
reduction is ephedrine and caffeine. Although the two did not receive FDA approval as 
anti-obesity drugs (Bray, 2000; Coffey et al., 2004), their combination can be used as 
supplements to help reduce body weight without prescription (Cheung et al., 2013; Coffey 
et al., 2004).  
There were only two FDA approved long-term anti-obesity drugs: orlistat and sibutramine. 
However, sibutramine has been withdrawn due to its adverse cardiovascular health effects 
(Williams, 2010). Orlistat is used to inhibit the actions of gastric and pancreatic lipase in 
the small intestine thereby reducing the dietary fat intake and inhibits fat absorption by 
30% (Carriere et al, 2001; Hollander et al., 1998; Sternby et al., 2002). The efficacy and 
safety of orlistat is short lived, its use is limited to 2 years as it can be accompanied by 
adverse health effects. The effects include oily spotting, fatty stool, flatus and discharge, 
increased defecation and faecal incontinence. Fat soluble drugs (vitamins A, D, E, and K) 
when taken together with orlistat lose their effect, 5-15% of long term users need vitamin 
supplements (Hauner, 2001).  
1.1.3 Adipose tissue 
Adipose tissue (AT) simply referred to as ‘fat’, is a loose connective tissue comprised of 
various cells held together by a matrix of collagen fibres. The main cellular components in 
the ATs are mature, lipid-filled fat cells (adipocytes) which make up a two third of the 
entire tissue, preadipocytes and endothelial cells (ECs). Additional components include 
fibroblasts, mesenchymal stem cells, nerve fibres, monocytes, macrophages, pericytes and 
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immune cells. The AT is distributed throughout the body and shows plasticity throughout 
life (Hauner, 2004). The ATs in mammals are classified into two types: the WAT and 
brown AT (BAT). The two types (WAT and BAT) share many metabolic characteristics 
despite their distinct functions. The WAT mainly stores excess energy for subsequent 
needs whereas the BAT serves as an energy dissipating organ (Gustafson et al, 2007).  
Adipocytes are the main components in the ATs and play a crucial role in its development 
and function. Adipocytes size varies depending on the size of individuals, lean humans 
have an average cell diameter of approximately 70 µm whereas in obese subjects it can 
expand up to 120 µm (Hauner, 2004). The adipocytes are made of 60-85% of lipid, 5-30% 
water and 2-3% protein. The lipid droplets in the adipocytes can be unilocular (WATs) or 
multilocular (BATs). In WATs the lipid droplet contains 90-99% TAGs and does not 
contain any organelles. The cell nucleus is pushed against the plasma membrane by the 
lipid droplet to the side (Hausman et al., 2001). 
The WATs are located primarily in three major anatomical areas: subcutaneous (inguinal, 
dorsosubcutaneous and interscapular fat depots), dermal (a relatively continuous sheath of 
lipid) and intraperitoneal (mesenteric, omental, perirenal, retroperitoneal, epididymal) fat 
depots (Hausman et al., 2001). The major WATs in human are subcutaneous and visceral 
or intraperitoneal (omental and mesenteric) depots. The visceral depot has been on the 
forefront as the most metabolically active tissue that transports WAT secreted molecules to 
the portal venous system. However, the amount of subcutaneous WAT depot is 3-4 fold 
bigger than the visceral depot. These two depots can interact in a coordinate and 
compensatory manner and both are responsible for obesity and obesity-induced diseases 
(Gustafson et al, 2007). Hence the study will focus mainly on the functions of WAT and 
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its effect on the development of obesity and the obesity induced diseases. The WATs are 
especially interesting in this study as they are major organs affected during development of 
obesity. A better understanding of the tissue development and their physiological roles 
may help in identifying new, safer and better therapeutic approaches for obesity. 
1.1.3.1 Physiological functions of white adipose tissue 
White adipose tissues provide insulation, mechanical support to the body and also serve as 
the storage organ. The primary function of WATs is to store energy in the form of TAGs 
during periods of energy excess, and to release energy during fasting or starvation as free 
fatty acids (FFAs) and glycerol as shown in Figure 1.1 (Lucas et al, 2009). During chronic 
positive energy balance, the excess calories are converted into TAGs mainly under the 
control of insulin. The TAGs are rapidly mobilized through the actions of catecholamines 
and other lipolytic hormones (Hauner, 2004). 
Fat or lipid metabolism is an important factor in the functioning of WAT as depicted in 
Figure 1.1. Lipid metabolism is a highly regulated process in a normal or healthy 
individual that determines the fate of excess fat in the adipocytes through lipogenesis and 
lipolysis. The two processes are mediated by several key enzymes found in the adipocytes, 
for instance: the lipases are required for TAGs break down into glycerol and FFAs that can 
then be transported to the liver, muscle and BAT where they are used in fatty acid 
oxidation (Sethi and Vidal-Puig, 2007). The storage of excess fat as TAGs in WATs in 
humans and animals is crucial for the normal functioning of the entire body. In order to 
keep up with the metabolic processes, consumption of more calories than is required is a 
must (The Endocrine Society, 2005). The excess fat is regulated through two opposing 
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processes that are equally important for survival: lipogenesis and lipolysis. The two 
processes are highly dependent on energy status within the WATs and secreted hormonal 
signals. For example decrease in systemic glucose and insulin and increase in counter-
regulatory hormones (epinephrine, growth hormone and glucocorticoids) will inhibit 
lipogenesis and stimulate lipolysis. Adipocytes are well equipped with the machinery to 
respond to both hormonal and sympathetic (adrenergic) stimulation for both cellular and 
biochemical mechanisms (Ahima and Flier, 2000; Sethi and Vidal-Puig, 2007). 
 
Figure 1.1: Lipid metabolism in adipocytes. Adipocytes are equipped with the biochemical machinery to 
function effectively as the body’s fuel store. To do this, it must mediate lipogenesis and lipolysis. It is also 
sensitive to changing nutritional cues. For example, it is insulin-sensitive [insulin stimulates glucose uptake 
and lipogenesis and inhibits lipolysis] and subject to adrenergic regulation [stimulates lipolysis and adaptive 
thermogenesis (BAT)]. AC, adenylate cyclase; ACS, acyl-CoA synthase; AKT, AKR mouse thymoma viral 
proto-oncogene; AR, adrenergic receptor; HSL; IR, insulin receptor; PI3K, phosphatidylinositol 3-kinase; 
PKA, protein kinase A (Sethi and Vidal-Puig,  2007). Figure reprinted with permission from American 
Society for Biochemistry and Molecular Biology. 
 
Lipogenesis or lipid synthesis is defined as a process in which carbohydrates, glucose or 
other energy sources from the diet are converted into TAGs for storage in WATs. 
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Lipogenesis occurs in liver and WAT in rodents, whereas in humans it occurs mostly 
in liver and to a lesser extent in WAT. Lipid synthesis is activated during postprandial 
state and food consumption and inhibited during starvation or fasting conditions.  FFAs are 
hydrolysed from the diet through the actions of lipoprotein lipase (LPL) found in the 
adipocytes.  FFAs are transported into adipocytes via fatty acid transporter and are 
converted into TAGs following multiple enzymatic steps. The rate limiting enzyme being 
acyl-CoA synthetase. Glycolysis is another cellular route for oxidation of excess glucose 
in the adipocyte to acetyl-CoA. Glucose is translocated via glucose transporters 1 and 4 
into the adipocytes where it is converted into acetyl-CoA through acetyl-CoA carboxylase 
and fatty acid synthase. Acetyl-CoA is then converted into acyl-CoA. Acyl-CoA is 
esterified in the endoplasmic reticulum to TAG and transported into the lipid droplet 
within the adipocyte (Ahima and Flier, 2000; Vázquez-Vela et al., 2008; Warne, 2003).  
The increased amount of TAGs is reduced by lipolysis during fasting, starvation or during 
energy expenditure (exercise). Lipolysis is the breakdown of stored TAGs into FFAs and 
glycerols during energy deprivation (The Endocrine Society, 2005). This process is also 
regulated by hormonal signals such as glucagon and catecholamines, their increased levels 
in blood stimulate lipolysis in the adipocytes by activating protein kinase A and several 
lipases (Langin, 2006; Vázquez-Vela et al., 2008). The G-protein-coupled receptors 
become activated, increasing cAMP levels. The increased cAMP levels lead to 
phosphorylation of perilipin (phospho-protein located in the membrane of the lipid droplet 
inside the adipocytes and inhibits lipolysis) and hormone-sensitive lipase (HSL). HSL 
translocate from the cytoplasm into the lipid droplet and initiates hydrolysis of TAG into 
FFA and glycerol. The reaction starts by hydrolysis of TAGs by adipose triglyceride lipase 
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to diacylglycerol (DAG) moiety and FFA. The DAG moiety is hydrolyzed by HSL and 2-
monoacylglycerol lipase to release another FFAs and monoglyceride molecules. The 
monoglycerides are transported to nonadipose tissues for gluconeogenesis (synthesis of 
glucose from glycerol) and the FFAs are available for β-oxidation in the liver and muscle 
(Ahima and Flier, 2000; Warne, 2003).  
These processes play an important role within the body, as the other organs are dependent 
on them for energy. Therefore, the major role of WATs and their functioning are crucial 
for the whole body functioning as they provide other tissues with energy when required. 
Failure or disturbances in these processes lead to undesired consequences. For instance, 
dysfunctions in lipolysis lead to increased fat mass that will result in obesity. Thus, lipid 
metabolism balance has to be maintained at all times to stay healthy (Langin, 2006). 
1.1.3.2 White adipose tissue as an endocrine organ 
White adipose tissues have been perceived as a passive organ responsible for energy 
storage and providing insulation to the body. However, the discovery of leptin in 1994, a 
satiety factor produced predominantly by WAT proved that WATs are capable of other 
functions (Ronti et al., 2006).  Since then, many secretory products of WATs have been 
discovered through independent studies. The WAT products include cytokines, growth 
factors (GFs), acylation stimulating protein, plasminogen activator inhibitor-1 and LPL 
(Goossens, 2008). This led to WAT regarded as highly active and an endocrine organ 
secreting several adipokines that regulate body functioning. The adipokines and other 
WAT secreted factors are responsible for the body’s metabolism and energy homeostasis 
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by influencing a variety of biological and physiological processes (Hajer et al., 2008; Krug 
and Ehrhart-Bornstein, 2005; Sethi and Vidal-Puig, 2007).  
The endocrine function of WAT is best explained through their secreted adipokines. 
Circulating adipokine levels appear to correlate closely with adiposity in animals and 
humans, increasing levels have been observed in obese and insulin resistant states (Otero 
et al., 2005; Zieba et al., 2005). Various adipokines are involved in different roles within 
the body.  The first to be discovered and most studied adipokine in obesity research is 
leptin, a satiety signal that regulates appetite and body weight in both humans and rodents 
(Koerner et al., 2005; Zhang et al., 1994). Leptin acts on the central circuits in the 
hypothalamus in order to reduce food intake and increase energy expenditure. Leptin 
controls the body fat stores, appetite and maintenance of body weight through coordinated 
regulation of metabolism, the autonomic nervous system, and body energy balance (Otero 
et al., 2005; Zieba et al., 2005). Adiponectin is involved in insulin action, resistin regulates 
glucose metabolism while chemerin regulates angiogenesis. Other functions include 
regulation of energy balance, vascular remodelling, regulation of blood pressure and blood 
coagulation (Hajer et al., 2008; Krug and Ehrhart-Bornstein, 2005; Sethi and Vidal-Puig, 
2007).   
The endocrine functioning of WATs is attributed to the presence of different cell types as 
mention in 1.1.3.  These additional cell types play important roles in regulating WAT 
function and are involved in WAT secretory function. The secreted molecules are mostly 
responsible for communication between AT and different organs within the body. 
Dysregulation in adipokines’ secretion is associated with the development of obesity and 
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obesity-induced diseases such as insulin resistance, T2D and CVD (Hauner, 2004; Sethi 
and Vidal-Puig, 2007).  
1.1.3.3 Effect of obesity on white adipose tissues 
Weight gain during adulthood is characterized by adipocyte hypertrophy, a process by 
which adipocytes increase in size to accommodate the excess lipid. In an evolutionary 
context, the ability to store excess energy in WATs is essential for survival, because 
energy could be drawn from this storage depot in times of famine. Paradoxically, this 
survival characteristic is disadvantageous when food is continuously abundant and 
palatable (Racette et al., 2003). Another disadvantage is that adipocytes can only increase 
to a certain limit and can never expand beyond this critical size. The maximum volume of 
each adipocyte is genetically determined and varies among different fat depot. Once the 
available adipocytes are saturated, the hypertrophic adipocytes produce and release 
proliferative paracrine factors to trigger preadipocyte proliferation and differentiation to 
new adipocytes, thus increasing their cell number (Cinti, 2005). Males have 9-18% fat 
mass and 14-28% in females in relation to bodyweight, and can increase to 22% in males 
and 32% in females (Hausman et al., 2001).  
Increased WAT mass alters glucose metabolism and insulin sensitivity in muscles and 
liver due to impaired secretion of insulin by β-cells leading to systemic insulin resistance 
as depicted in Figure 1.2. Insulin resistance can be attributed to increased lipolysis and 
secretion of FFAs and glycerol (Galic et al., 2009; Vázquez-Vela et al., 2008). The 
increased flux of FFAs impairs insulin secretion and induces insulin resistance in muscle 
and the liver by interfering with glucose transport and insulin-mediated glucose uptake, 
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exerting negative influences on cardiovascular health (Lau et al., 2005). Adipocytes are at 
the centre of obesity development, cellular and molecular dysfunctions occur in WAT as a 
consequence of excess TAGs stored in adipocytes and spread throughout the rest of the 
organs via the adipokines secreted by the WAT cells, leading to the events mentioned 
above (Greenberg and Obin, 2006).  
 
Figure 1.2:  Obesity-induced changes in adipokine secretion and the development of insulin resistance. 
Expansion of AT in obesity leads to increased macrophage infiltration and inflammation with enhanced 
production of pro-inflammatory cytokines such as TNF-α and IL-6. This is accompanied by an increased 
release of FFAs and dysregulated secretion of leptin, adiponectin, resistin and retinol binding protein-4. 
Together, these adipocyte- and macrophage-derived substances can act in a paracrine or autocrine fashion to 
further exacerbate AT inflammation. On the systemic level, altered adipokine secretion can lead to increased 
food intake and reduced energy expenditure through actions in the hypothalamus and to decrease muscle and 
liver insulin sensitivity through enhanced ectopic lipid deposition and inflammation (Galic et al., 2009). 
Figure reprinted with permission from Elsevier. 
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The stored TAGs cannot be hydrolyzed and metabolized due to deficiency of perilipin. 
Perilipins are considered gatekeepers for lipases, which are involved in the hydrolysis of 
TAG to facilitate the release of FFAs. Under normal conditions the dephosphorylated 
perilipins are bound to the surface of TAGs droplets to prevent hydrolysis of TAGs by 
lipases during obesity. In starvation, perilipins are activated by protein kinase A and the 
phosphorylated perilipins move from the surface allowing lipases access to TAGs and 
FFAs. However, their expression in obese individuals is downregulated, which is 
associated with their reduced basal rate of lipolysis (Galic et al., 2009; Guo et al., 2009). 
 
1.2 CELL TARGETING AS A STRATEGY FOR OBESITY REVERSAL 
Cell targeting also known as targeted therapy refers to the use of ligands that interact with 
disease-associated biomarkers to deliver therapeutic agents that will inhibit certain cellular 
actions leading to cell death and treatment of the disease (Ofei, 2005).  Since targeting 
moieties are specific for the diseased cells or tissues (e.g. WATs in obesity), targeted 
therapies will have little or no effect on the surrounding normal cells or tissues. Cell 
targeting as a strategy for obesity reversal is reviewed below. A receptor targeted 
nanotherapy that could be used as anti-obesity therapy will be developed in this study. The 
targeted nanotherapy will result in elimination of hypertrophic adipocytes by targeting a 
WAT vascular marker. Obesity is a major risk factor for the development of serious 
chronic diseases as discussed in section 1.1. Its treatment and management may lead to an 
early intervention for prevention of these maladies and their consequences (Ofei, 2005).  
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Nanotechnology will be useful in minimizing the treatment dosage and help the treatment 
to circulate longer within a biological system. The targeting molecules will aid to 
transverse their cargo through the lipid bilayer into the cells for the treatment to be 
effective. Direct delivery of ligand-directed nanoparticles (treatment) to the relevant site 
will increase its efficacy. On binding to the target cells, the treatment will result in killing 
the cells in a controlled manner (apoptosis). The importance of nanotechnology, vascular 
targeting (angiogenesis) and apoptosis in development of receptor targeted therapy is 
discussed in the following section. 
1.2.1 Cell penetrating peptides  
Cell penetrating peptides (CPPs) are amino acids short sequences (<30 amino acids) which 
can translocate across the cell membrane in an energy, receptor and temperature-
independent manner (El-Andaloussi et al., 2007; Palm-Apergi et al., 2012). They are 
cationic and hydrophilic peptides consisting of basic amino acids, arginine (R) and lysine 
(K) that allows them to pass through cell membrane with ease (Herce and Garcia, 2007; 
Palm-Apergi et al., 2012; Sandoval et al., 2007). Biologically useful CPPs, such as trans-
activator of transcription (TAT) from HIV-1, the herpes simplex virus VP22 protein, 
penetratin from the Drosophila Antennapedia homeodomain, and transportan have been 
identified (Herce and Garcia, 2007; Sandoval et al., 2007). The main and commonly used 
CPPs are shown in Table 1.1. The first CPP to be discovered was TAT with the 11 amino 
acid sequence responsible for its translocation into cells (Frankel and Pabo, 1988). All the 
available CPPs have similar translocatory properties that are attributed to the polyarginines 
and polylysines in their sequences as highlighted in Table 1.1 (Leifert et al., 2002). 
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Table 1.1: Types of commonly used cell penetrating peptides 
 
Cell Penetrating Peptides PTD Sequence 
HIV-1 TAT YGRKKRRQRRR 
Drosophila Antennapedia homeodomain 
(penetratin) 
RQIKIWFQNRRMKWKK 
Herpes simplex virus VP22 protein DAATATRGRSAASRPTERPRAPA
-RSASRPRRPVE 
Transportan GWTLNSAGYLLGKINLKALAAL-
AKKIL 
 
In medical research, the CPPs are used to translocate cargoes such as nucleic acids, 
enzymes, proteins and drug-loaded liposomes through biological membranes (Herce and 
Garcia,   2007; Leifert et al., 2002; Ziegler and Seelig, 2004). The exact mechanisms by 
which the CPPs perform their function are not clearly understood. However, several 
mechanisms of intracellular transport have been proposed for these peptides and vary 
among different CPPs as discussed in section 1.2.2 (Herce and Garcia, 2007; Sandoval et 
al., 2007).  
1.2.2 Mechanisms of uptake 
Every living cell within the body is composed of a plasma membrane that serves as a 
boundary between the intracellular and extracellular environment. The plasma membrane 
controls what goes in and out of the cell. Smaller and polar molecules can readily diffuse 
in and out of the cell while larger molecules require transporter proteins that will alter the 
structure of the cell to transport them inside the cell. Due to selective permeability of cell 
membrane, several CPPs are often used to help molecules pass through into the cell in 
order to perform their functions. Translocation of the CPPs and their cargoes through cell 
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membranes can be achieved through different mechanisms indicated in Figure 1.3 (Green 
et al., 2003; Trehin and Merkle, 2004).  
 
Figure 1.3: Cellular delivery of target validation tools by protein transduction domains. Initial binding 
of the PTD (green)-linked target validation tools (blue; including peptides, proteins and antisense) is 
mediated via an electrostatic interaction between the positively charged PTD and the negatively charged 
plasma membrane. Subsequent uptake was speculated to occur via a rapid, ATP- and receptor-dependent 
mechanism through formation of either an inverted micelle (Model 1) or direct insertion through the 
membrane (Model 2). However, recent studies suggest that PTD-conjugates are taken up by endocytosis 
from which small quantities of the conjugates are released via an unknown mechanism (Model 3) (Green et 
al., 2003). Figure reprinted with permission from Elsevier 
 
The three proposed mechanisms include the formation of micelles with the plasma 
membrane, direct penetration through the membrane that results in pore formation, and 
through engulfment of the molecule (phagocytosis). Some of these mechanisms require 
energy and are not necessarily receptor dependent or cell specific (Green et al., 2003; 
Trehin and Merkle, 2004). The Antennapedia homeodomain-derived antennapedia (Antp) 
CPP for instance, transports their cargos through endocytosis. The interaction between the 
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CPP and the cell membrane results in formation of micelles that are then transferred into 
the cytoplasm and releases its cargo. Translocation of Antp across the membrane is due to 
the presence of R and K in its amino acid sequence and energy independent (Console et 
al., 2003; Sebbage, 2009). 
Due to the non-toxic nature of CPPs, they have been extensively used to deliver cargoes 
such as peptides and nucleic acids for therapeutic purposes (Heitz et al., 2009). Cellular 
uptake and toxicity have been shown to be cargo dependent. However, CPPs are only 
effective for in vitro studies (Lindgren et al., 2000; Sandoval et al., 2007), their ability to 
translocate every given cell independent of route of administration, makes it impossible to 
use in animals for drug delivery.  In vivo studies require specificity, the kind offered by 
targeting peptides (Herce and Garcia, 2007; Vivès et al., 2008).  
1.2.3 Targeting peptides 
Targeting peptides are moieties or ligands that bind to specific cell receptors with higher 
sensitivity and affinity. They can be useful in targeting disease-specific markers that are 
upregulated or exclusively expressed in diseased cells in relation to normal tissues and 
often used as targets for diagnostic and therapeutic purposes. The targeting peptides are 
also able to bind to specified receptors and translocate their cargoes into the cell. Unlike 
CPPs they bind to specific cell-surface receptors to exert their functions (Leifert et al., 
2002). The targeting peptides are used in drug delivery as they allow more specificity and 
sensitivity of the drug, even at minute dosage it’s possible to accumulate at specified site. 
Targeting peptides offers a promising opportunity for development of targeted therapy for 
chronic diseases, not limited to obesity (Kolonin et al., 2004) and cancer (Li and Cho, 
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2012). Various targeting moieties are used to deliver molecules to specified areas such as 
carbohydrates, short peptides, aptamers and antibodies. For therapeutic purposes these 
moieties are usually targeted to extracellular domains of cell membrane receptors (Li and 
Cho, 2012). 
1.2.3.1 Vascular targeting peptide: Adipose homing domain 
Some important targets for therapeutic intervention in obesity have been discovered. Of 
interest to this research is the peptide known to associate with the cell surface receptor 
over expressed by endothelial cells (ECs) in the WAT vasculature of obese mice. Adipose 
Homing peptide (AHP) was coined to refer to this peptide. The peptide was discovered 
through phage display (screening method to determine interactions between receptors and 
ligands) by Kolonin and colleagues in ob/ob mice. The peptide has a nine amino acid 
sequence (CKGGRAKDC) and will be referred to as AHP now henceforth. The domain 
binds specifically to a cell membrane associated protein in the WAT vasculature, 
prohibitin (PHB). The protein (PHB, as discussed in section 1.2.3.2) was found to be 
abundant in the vascular ECs of the WAT of obese mice and human subjects (Kolonin et 
al., 2004).  
In the study done in 2004 by Kolonin and colleagues, a pro-apoptotic peptide 
D(KLAKLAK)2 was coupled to AHP and systemically injected to obese mice. The AHP- 
conjugate was localized and internalized by the blood vessels of subcutaneous and 
peripheral white fat, but not other organs. This led to vascular EC death by apoptosis, 
resorption of fat in the WAT, normalization of metabolic processes and weight loss. Due 
to the specificity of the targeting ligand, no systemic or bystander effects was observed. 
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The desired effect of treatment was dependent on the internalization of treatment through 
the interaction between the PHB and the AHP-complex (Kolonin et al., 2004). 
Internalization usually occurs via receptor-mediated endocytosis. The example of the 
folate receptor as shown in Figure 1.4 will be used to demonstrate the receptor-mediated 
mechanism of action (Cho et al, 2008).  
 
Figure 1.4: Internalization of nanoparticles via receptor-mediated endocytosis. Tumour-specific ligands 
or antibodies on the nanoparticles bind to cell-surface receptors, which trigger internalization of the 
nanoparticles into the cell through endosome. As a pH value in the interior of the endosome becomes acidic, 
the drug is released from the nanoparticles and goes into the cytoplasm. Drug-loaded nanoparticles bypass 
the P-glycoprotein efflux pump not being recognized when the drug enters cells, leading to high intracellular 
concentration (Cho et al., 2008). Figure reprinted with permission from American Association for Cancer 
Research. 
 
 
A folate-targeted conjugate binds to a folate receptor on the cell surface, the invaginating 
plasma membrane envelopes the complex of the receptor and ligand to form an endosome. 
Newly formed endosomes are transported inside the cell. The drug is then released from 
the conjugate and enters the cytoplasm. Released drugs are then trafficked by their target 
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organelle, the fate of the cell depends on the drug action. Meanwhile, the folate receptor is 
released from the conjugate and returns to the cell membrane to start a second round of 
transport by binding with new folate-targeted conjugates (Cho et al, 2008).  
 
AHP is presumably internalized in a similar manner. On binding to the PHB receptor, the 
AHP-conjugate gets internalized. The AHP-conjugate is released inside the cell and PHB 
receptor is then recycled and available for the next cycle if the cell is still alive (Kolonin et 
al., 2004). The AHP serves as an ideal targeting ligand for development of anti-obesity 
therapy or drugs. Most anti-obesity drugs that are withdrawn from the market due to their 
toxicity towards normal tissues could benefit from this strategy. For therapeutic purposes, 
the targeting peptides must also meet certain requirements, first and foremost they should 
be target specific. PHB is highly expressed by the vascular ECs in the WAT of obese 
subjects as a cell surface protein not exposed in any other organs, as observed by Kolonin 
et al., 2004. This is very important as it can increase the treatment’s effectiveness without 
affecting other tissues. Another important requirement, the treatment has to be able to 
reach the desired target without losing their activity and also manage to escape phagocytic 
cells after passing through the circulatory system. These can potentially improve 
effectiveness of treatment by concentrating the drug at the diseased tissue and reduces 
systemic and bystander toxicity (Cho et al., 2008). 
This strategy suggests that membrane associated protein (PHB) in the vascular 
endothelium could serve as a useful target for the delivery of therapeutic compounds to 
enhance fat resorption in obese subjects (Hossen et al., 2010; Thovhogi et al., 2015). The 
data obtained through two independent studies proves that the vascular PHB can serve as a 
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biomarker for obesity treatment. The AHP-pro-apoptotic peptide conjugate through its 
interaction with the PHB was able to translocate the cell membrane, disrupt the 
mitochondrial functions causing cell death. Therefore, PHB targeting by its associate 
ligand (AHP) coupled to therapeutics is an appealing strategy for obesity treatment and 
prevention of its related diseases (Hossen et al., 2010; Kolonin et al., 2004).  
1.2.3.2 Prohibitin 
Prohibitin is of interest in this study as it is highly expressed by ECs in the WAT 
vasculature of obese rats and human subjects and will be used as target for obesity therapy 
intervention. It was found to be expressed as the cell surface receptor by vascular ECs of 
obese mice and human (Kolonin et al, 2004).  
Prohibitin is a highly conserved protein among different animal species and has a 
molecular weight of 30–32 kDa. The mouse and rat PHB amino acid sequences are 
identical, and differ from the human sequence by a single amino acid. Prohibitin, as shown 
in Figure 1.5, localizes in many cellular compartments such as the cell membrane, 
mitochondria, nucleus and other intracellular organelles (Mishra et al., 2005).  Regardless 
of its location, PHB might have distinct but overlapping functions in all the organs. In the 
plasma membrane, PHB functions as a chaperone for newly imported proteins and exerts 
its cellular function by binding to other biomolecules. The mitochondria-localized PHBs 
plays a role in cellular homeostasis and mitochondrial biogenesis by interacting with 
complex I and subunits of cytochrome c oxidase of the respiratory chain. Loss of 
mitochondria PHB impairs the mitochondrial respiratory chain function resulting in 
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oxidative stress and alters the mitochondrial morphology and membrane potential in most 
cells (Merkwirth and Langer, 2009; Artal-Sanz and Tavernarakis, 2009).  
 
 
Figure 1.5: The subcellular localization of prohibitin and potential mechanisms involved in PHB action. 
PHB is present on the cell membrane where it can interact with peptides and possibly endogenous ligand or 
ligands. Such ligands could be potentially translocated to the mitochondria and disrupt mitochondrial 
function, resulting in apoptosis. Membrane-bound PHB might be involved in modulating the expression of 
cytokines, such as IL-6, by MAP kinase and other signalling pathways. PHB might also be translocated from 
the cell membrane to the nuclear compartment. In the nuclear compartment, PHB might function as a 
modulator of transcription. The phosphorylation of PHB, possibly by the JNK1 pathway, might be necessary 
for the anti-proliferative effects of PHB. The latter involves the interaction with Brg1–Brm, inhibition of the 
E2F pathway and both p53- and pRB-dependent and p53- and pRB-independent mechanisms (Mishra et al., 
2005). Figure reprinted with permission from Elsevier. 
 
When translocated to the nucleus, PHB modulates transcriptional activity. Phosphorylation 
of PHB through the JNK1 signalling pathway is thought to play a part in transcription and 
exerts its anti-proliferative effects and other biological functions. PHB interacts with 
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ATPase components, Brg1 and Brm and repress the E2F transcriptional activity through 
remodelling of local chromatin (Mishra et al., 2005).  
The role of PHB in adipocyte differentiation is elusive. Interestingly, overexpression of 
MicroRNA-27 in human adipose-derived stem cells led to downregulation of its 
expression and adipocyte differentiation (Kang et al., 2013). This further confirms that AT 
growth can be regulated by targeting PHB in the EC surface of WAT vasculature serve as 
a target for therapeutic intervention in obesity. As a cell surface protein it can easily 
interact with antibodies, peptides and ligands that bind to it and translocate their cargoes 
into the cells to disrupt their biological functions (Mishra et al., 2005; Kolonin et al, 
2004). The cargoes can be therapeutic peptides or diagnostic agents, used to detect the 
presence of certain disease markers or induce cell death in order to reverse the disease 
effects on target tissues (Mishra et al., 2005). Physiologically, PHB is a multifunctional 
protein that plays crucial roles as a tumour suppressor gene, a chaperone protein that 
stabilizes mitochondrial proteins and as a regulator of cell cycle (Gamble et al., 2004; 
Mishra et al., 2005). However, our interest in PHB originates from being a cell surface 
receptor that can be used as a vascular target for obesity treatment (Kolonin et al., 2004). 
1.3 VASCULAR TARGETING 
Vascular targeting has been used in recent years for treatment of chronic diseases, different 
forms of cancer and arthritis.  Vascular targeting through angiogenesis offers an attractive 
strategy for disease treatment with minimal toxicity and resistance. Cells involved in 
angiogenesis tend to overexpress cell membrane receptors during development of a disease 
state. Targeting these cells disturbs the growth and functioning of the diseased cells or 
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tissues as they rely on them for oxygen and nutrient supply. The vascular ECs are at the 
centre of vascular targeting as they are the cells that are responsible for most tissue 
haemostasis by supplying all necessary components for cell growth. They are easily 
accessible, one EC is responsible for more than one adipocyte and disrupting their function 
indirectly disturbs the survival and growth of the unwanted cells (Ruoslahti, 2000). 
1.3.1 Angiogenesis 
Angiogenesis was first introduced by John Hunter in 1787 and gained popularity in 1971 
in cancer research through Judah Folkman’s hypothesis that tumour growth is dependent 
on angiogenesis. The term angiogenesis or neovascularisation refers to the growth of new 
blood vessels from pre-existing capillaries (Gupta and Zhang, 2005). Angiogenesis is a 
physiological process that plays an important role in distribution of oxygen and nutrients 
to different cells and organs throughout the body, as well as removal of waste products. 
Angiogenesis is a sequential process that occurs throughout life with minimal occurrence 
in healthy adults. Angiogenesis starts early in life from development of embryos, continues 
through menstrual cycles in women and also takes part in wound healing and repair 
(Griffioen and Molema, 2000; Liekens et al., 2001). 
Angiogenesis is a tightly regulated process and dysfunction in the growth of blood vessels 
contributes to the pathogenesis of numerous disorders. Angiogenesis dysfunction has been 
implicated in a number of serious chronic diseases such as obesity, diabetic retinopathy, 
cancer, rheumatoid arthritis, AIDS and autoimmune disease. These are some of the 
conditions in which angiogenesis is switched on when they develop (Colville-Nash and 
Scott, 1992). In conditions where angiogenic switch is insufficient; blood vessel 
 
 
 
 
 29     
revascularization, healing and regeneration is prevented (Carmeliet, 2005; Liekens et al., 
2001). 
1.3.1.1 The process of angiogenesis 
Life form begins with the development of vascular systems that leads to formation of 
essential tissues or organs. This is a highly regulated and sequential process that maintains 
blood flow throughout the tissues and organs within the body. Blood vessels regeneration 
in response to wound healing or cellular growth involves several steps and complex 
interaction between vascular cells (ECs, pericytes, smooth muscle cells, etc) and the 
corresponding extracellular environment. The process of angiogenesis is stimulated when 
the damaged or diseased tissues require nutrients and oxygen (Nishida et al., 2006). The 
interaction between ECs with the extracellular matrix (ECM) is very crucial for induction 
of angiogenesis. The whole process is coordinated by integrins and a number of growth 
factors (GFs). The integrins are responsible for specific cell–ECM interactions for EC 
adhesion and migration to growing tissues or organs (Eliceiri and Cheresh, 2001).  
Angiogenesis is regulated by both modulator (vascular endothelial growth factor (VEGF), 
integrins, matrix metalloproteinase (MMPs) and inhibitor (Angiostatin, Endostatin) 
molecules. Under physiological conditions, the activity of these molecules is kept on a 
balance.  Shift in the balance between the modulators and inhibitors of angiogenesis will 
determine whether to switch on or off. For instance, up-regulation of angiogenic or 
activator molecules favours angiogenesis, the opposite discourages its occurrence (Nishida 
et al., 2006).   
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Angiogenesis is a complex process that follows a series of steps in diseased or growing 
tissues as illustrated in Figure 1.6 (Pandya et al., 2006).  
 
 
Figure 1.6: The process of angiogenesis. (1) Tumours produce and release angiogenic GFs that diffuse into 
the nearby tissues. (2) The angiogenic GFs bind to specific receptors located on the ECs of nearby pre-
existing blood vessels. (3) Once GFs bind to their receptors, the ECs become activated. Signals are sent from 
the cell's surface to the nucleus. The EC's machinery begins to produce new molecules including enzymes. (4) 
Enzymes dissolve tiny holes in the sheath-like covering (basement membrane) surrounding all existing blood 
vessels. (5) The ECs begin to divide (proliferate), and they migrate out through the dissolved holes of the 
existing vessel towards the diseased tissue (tumour). (6) Specialized molecules called adhesion molecules, or 
integrins (a v b 3, a v b 5) serve as grappling hooks to help pull the sprouting new blood vessel sprout 
forward. (7) Additional enzymes (MMP) are produced to dissolve the tissue in front of the sprouting vessel 
tip in order to accommodate it. As the vessel extends, the tissue is remoulded around the vessel. (8) Sprouting 
ECs roll up to form a blood vessel tube. (9) Individual blood vessel tubes connect to form blood vessel loops 
that can circulate blood. (10) Finally, newly formed blood vessel tubes are stabilized by specialized muscle 
cells (smooth muscle cells, pericytes) that provide structural support. Blood flow then begins (Pandya et al., 
2006). Figure reprinted with permission from Elsevier. 
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Development of diseases such as cancer and adiposity (obesity) characterized by increased 
size or number of cells beyond their critical size limit are said to be dependent on this 
process (Cao, 2010). The proliferating cells produce and release angiogenic GFs (such as 
fibroblast growth factor (FGF), angiopoietin-1 (Ang-1), VEGF) that diffuse into the 
nearby tissues in order to interact with the existing vascular bed. The GFs bind to specific 
receptors on the ECs of pre-existing blood vessels within the affected tissue or organ. The 
ECs are then stimulated to send signals from the cell's surface to the nucleus that will lead 
to production of angiogenic factors including proteolytic enzymes such as MMPs. The 
proteolytic enzymes punch holes in the basement membrane surrounding the existing 
blood vessels. The ECs branch out from the holes in the pre-existing blood vessels by 
sprouting and migrating towards their target cells (diseased tissue) in order to extend the 
vasculature (Tassi and Wellstein, 2006; Ucuzian and Greisler, 2007). 
The entire process in diseased and physiological states is dependent on proliferation and 
migration of ECs to growing cells (Gupta and Zhang, 2005). The proliferation and 
migration of ECs followed by its invasion to growing or diseased organs is dependent on 
the activities of the plasminogen activator (PA) system and the MMPs. The urokinase-type 
plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) are serine 
proteases that are responsible for conversion of plasminogen into plasmin within the 
vascular network. Plasmin is required for degradation of ECM components such as fibrin, 
fibronectin, laminin, the protein core of proteoglycans and is suspected to activate MMP-1, 
3 and 9 (Liekens et al., 2001).  
The tPA mainly controls the fibrinolytic activity in blood whereas uPA is responsible for 
activation of plasminogen in tissues. The pro-uPA binds to the uPA receptor, plasmin and 
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several molecules (Factor XIIa, or cathepsin B) responsible for activation of pro-uPA. 
Activation of uPA enhances its activity on the cell surface and stimulates signal 
transduction through the uPA receptor, leading to cell migration and invasion (Liekens et 
al., 2001).  
The coordination between adhesion molecules () and GFs are also equally important. The 
GFs are required to interact with its surrounding ECM for the cells to proliferate and 
migrate to the diseased cells. This process helps these cells escape cell death via apoptosis 
or starvation (Gupta and Zhang, 2005). The vascular ECs takes time to divide (about every 
1000 days), integrins (avb3, avb5) directs the whole process. The sprouting ECs move 
towards the diseased cells, the new forming vessel extends and surrounds the cells. The 
new vessels are stabilized by smooth muscle cells and pericytes in the vascular bed. The 
blood now begins to flow to the cells and supply all the necessary ingredients for their 
survival (Eliceiri and Cheresh, 2001; Ucuzian and Greisler, 2007).  
Cells all over the body grow to a certain diameter. Beyond this limit, it becomes difficult 
to grow because blood supply is insufficient to reach the hypertrophic or over-sized cells. 
When blood supply is limited, the supply of nutrients and oxygen, and removal of waste 
from the growing cells become problematic. Under these conditions, the cells secrete 
angiogenic stimulators that will switch on the angiogenic process and new blood vessels 
are formed. This process supports growth of the diseased cells and in return causes over 
expression of certain angiogenesis associated proteins (e.g. VEGF receptor-II) that are 
distinct from quiescent ECs in healthy adult tissues. The differential expressed disease 
markers are potential targets for therapeutic interventions, targeting the vasculature could 
be effective for treating diseases as the cells are dependent on angiogenesis for growth. 
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Insufficient food and oxygen supply will slow down the growth of diseased cells or kill 
them in the process as these cells are dependent on newly formed blood vessels, a process 
that is highly regulated by proliferation of ECs. Vascular targeting is an appealing strategy 
as the toxic effects of treatment will be restricted to the targeted cells, thereby increasing 
the therapy efficacy and reduce undesirable effects (Okaji et al., 2006; Tassi and 
Wellstein, 2006).   
1.3.2 Clinical significance of angiogenesis 
Angiogenesis as a potential therapy for cancer was discovered in the early 1970s. 
However, research in angiogenesis began in the 1990s after the discovery of the first 
compounds with specific angiostatic effects. These discoveries proved that cancer growth 
can be prevented by inhibition of angiogenesis (Ingber et al., 1990; O'Reilly et al., 1994). 
Various diseases including cancer and obesity are highly dependent on the formation of 
new vasculature for their progression (Cao, 2010; Hausman and Richardson, 2004). 
Therefore, the diseased areas will be highly vascularised in order to support the continually 
growing tissues, following the formation of blood vessels triggered by ECs migration and 
proliferation, as explained in section 1.3.1.1. The excessive blood vessel growth renders 
these areas vulnerable at the level of their blood supply. Thus, angiogenesis inhibition 
serves as a better therapeutic option for these diseases. The angiogenic process is mostly 
vulnerable at the proliferation stage of ECs, as their growth during disease development is 
often followed by over secretion of pro-angiogenic factors which might be useful as 
targets for therapeutic intervention (Griffioen and Molema, 2000).  
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Angiogenesis inhibitors have gained popularity in cancer research and shown great 
potential in its treatment in preclinical and clinical studies (Griffioen and Molema, 2000; 
Tassi and Wellstein, 2006). The anti-angiogenic inhibitors are mostly targeted at arresting 
vascular EC’s growth in the diseased areas, this prevents the diseased cell’ growth and 
metastasis. It is believed that one EC is responsible for several cells, therefore delaying or 
prevention of their proliferation will starve the diseased cells/ tissue leading to cell death. 
Moreover, occurrence of physiological angiogenesis is minimal in adults and side effects 
associated with long-term treatment effects will be reduced (Tassi and Wellstein, 2006). 
Another crucial fact about ECs is that they are always in contact with the blood vessels and 
the surrounding tissues, this makes them easily assessable by systemically administered 
treatment (Okaji et al., 2006).  
Anti-angiogenic agents such as monoclonal antibodies and synthetic molecules in animal 
models has generated useful information about their mechanisms of action and the 
desirable effects, and some of them are recently used in clinical trials (Carmeliet, 2005). 
The first FDA clinically approved and mostly studied anti-angiogenic agent is 
Bevacizumab (its trade name is Avastin). Bevacizumab is a humanized mouse monoclonal 
antibody that binds to VEGF-A receptor in the blood vessels. In the United State 
Bevacizumab is approved for treatment of metastatic cancers (colorectal, lung, and kidney 
cancer) and eye disease. Bevacizumab is undergoing phase III of clinical studies in 
patients with metastatic colorectal cancer. Most of the anti-angiogenic agents studied 
inhibits EC growth by binding to VEGF receptors, prevents vessel growth, but also 
induces regression of existing vessels by increasing EC death. VEGF inhibitors being 
studied include a VEGF trap (Regeneron) and antibodies against VEGFR-1 (Imclone) or 
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VEGFR-2 and placenta GF (a VEGF homologue). Targeting VEGF receptors is a safer 
option as it is highly expressed in disease state than in healthy tissues. Although VEGF 
inhibitors have exciting outcomes in pre- and clinical studies, it is cytotoxic to some extent 
in some malignant cells. These inhibitors are also associated with immune response that 
suppresses the proangiogenic activity of haematopoietic cells (Carmeliet, 2005).  
Furthermore, the monoclonal antibodies used are produced in mice and when used in 
human subjects can elicit an immune response. To avoid this action, they will have to be 
humanized before clinical applications (Carmeliet, 2005). These antibodies have a short 
half-life and higher dosage for extended period will be required to obtain a desired effect. 
The shortfalls can be overcome by development of cell specific anti-angiogenic treatment. 
Vascular ECs produce receptors that are cell and disease specific, as such can be used as 
biomarkers. Research is being conducted in pre-clinical animal models using the targeted-
therapy mainly in cancer research (Carmeliet, 2005; Okaji et al., 2006).  
1.3.3 Angiogenesis in obesity  
Angiogenesis is an important factor in the expansion of WATs. Adipose tissue growth and 
expansion through hypertrophy or hyperplasia is highly dependent on the plasticity of the 
vasculature (Cao, 2010). During development of obesity, hypertrophy and hyperplasia are 
excessive and require the extension of blood vessels to reach the newly formed and the 
overgrown adipocytes. This extensive blood vessel network maintains the WAT’s 
physiological role by secreting GFs, hormones, cytokines and angiogenic factors required 
for tissue remodelling. For this purposes angiogenesis is an attractive target for therapeutic 
intervention for reversal of obesity, as these vessels are readily accessible for targeted 
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therapy particularly when administered systemically. There are several studies 
demonstrating the efficiency of antiangiogenic therapy in animal models of obesity (Cao, 
2010, Kolonin et al., 2004, Barnhart et al., 2011).  
Angiogenesis in WATs is dependent on the balance between pro-angiogenic and anti-
angiogenic factors. Increase in proangiogenic factors, mainly VEGF-A and hepatocyte 
growth factor (HGF) in WATs initiates the angiogenesis process (Christiaens and Lijnen, 
2010). Adipocytes growth in WATs is highly dependent on angiogenesis, thus, inhibition 
of this process through proangiogenic factors can be helpful in regulating WAT mass and 
prevent weight gain (Hajer et al., 2008). This was proven with both in vitro and in vivo 
models of obesity (Bråkenhielm et al., 2004). Antibodies or ligands that target angiogenic 
GFs in WAT vasculature have been shown to inhibit angiogenesis by blocking activities of 
receptors such as VEGFR-2 to prevent WAT growth in a genetic and diet-induced animal 
models of obesity (Christiaens and Lijnen, 2010; Tam et al., 2009).  
Angiogenesis inhibitors with anti-obesity effects were discovered through in vitro studies. 
The widely studied include TNP 470, angiostatin, endostatin and leptin; all discovered to 
reduce body mass in obese subjects. Inhibition of angiogenesis in WATs by the use of 
these inhibitors proves that these tissues are vulnerable at their vasculature, and 
angiogenesis serve as a desirable target for therapy intervention. Different inhibitors have 
different targets, working towards the same goal (Bråkenhielm et al., 2004; Rupnick et al., 
2002). TNP 470 for instance, targets Methionine aminopeptidase-2 in the ECs 
(Bråkenhielm et al., 2004). TNP 470 analogs (CDK 732) also showed similar effects.  
CDK 732 acts by decreasing food intake, the size of adipocytes, fat mass, and body weight 
in selected rodent models of obesity (C57BL/6J ob/ob mice, Otsuka Long–Evans 
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Tokushima fatty (OLETF) rats, Sprague-Dawley rats, Long-Evans Tokushima Otsuka 
(LETO) rats). The efficacy of CDK 732 was found to be higher than TNP 470 in both in 
vitro and animal studies (Kim et al., 2007).  
Angiogenesis can also be disrupted at a gene level by knocking down genes that promote 
blood vessel growth. WATs secretes a number of proangiogenic factors including HGF, 
VEGF-B, VEGF-C, placental GF, FGF-2, Ang-1, Ang-2, tumour necrosis factor (TNF) 
and MMPs (Christiaens and Lijnen, 2010). One of the major genes responsible for 
angiogenesis in WAT is HGF, it is exclusively secreted by WAT and has angiogenic and 
mitogenic effects. Their levels are increased in serum of obese subjects than healthy 
subjects. The HGF effects on WAT angiogenesis was determined in vitro (3T3-F442A 
preadipocytes) and in vivo (BALB/c athymic nude mice) studies. The HGF gene was 
silenced in 3T3-F442A preadipocytes through siRNA technology and injected in BALB/c 
athymic nude mice. Differentiation of the preadipocytes into adipocytes and formation of 
functional fat pads in the mice occurred at a slower rate compared to the normal controls. 
The ability of developing fat pads to recruit ECs for neovascularization in the treated mice 
was impaired (Bell et al., 2008).  
 
1.3.3.1 Adipose tissue vasculature  
The development and maturation of adipocytes (adipogenesis) and various cells in the ATs 
is dependent on angiogenesis, for this purpose the ATs are highly vascularised.  The AT 
vascularity is very crucial for the functioning of AT as an endocrine organ (Cao, 2010; 
Hausman and Richardson, 2004). Adipocytes in WAT are in contact with one or more 
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capillaries, thus their growth is always associated with the neovascularisation and 
remodelling of the vascular network. Neovascularization promotes the hyperplastic 
adipocyte through pre-adipocyte differentiation and remodelling and also accommodates 
the hypertrophic adipocytes (Christiaens and Lijnen, 2010; Lijnen, 2008). 
The vasculature plays a key role in the development of obesity as expansion of AT is 
supported by angiogenesis.  Angiogenic factors promote differentiation of pre-adipocytes 
to adipocytes through several mechanisms as illustrated in Figure 1.7 (Cao, 2010). The 
growing AT cells requires nutrients and oxygen for tissue growth, and to maintain their 
physiological functions and for their maintenance. Blood supply is very crucial for the 
body’s functions: tissue homeostatic and the metabolic activities. Adipocytes also require 
blood supply for their metabolic or endocrine functioning that occurs in the thin rim of 
cytoplasm surrounding the lipid droplet. For this reason, each adipocyte in ATs is 
constantly in contact with blood capillaries. The amount of blood flow to these adipocytes 
is dependent upon the body weight and nutritional state, with blood flow increasing during 
fasting. Blood flow to AT seems minimal to other organs, 3–7% of cardiac output is 
required to supply 0.2–0.6L of blood per minute in normal human adipose organ and 
increases to 15–30% in morbid obesity. This causes a lot of strain to the heart and can 
cause hypertension and congestive heart failure in obese subjects, however weight loss can 
reverse these hemodynamic factors (Hausman et al., 2001). 
 
Blood vessels are enriched with the GFs and cytokines that are important in growth and 
survival of adipocytes and maintenance of their physiological functions.  Stem cells 
derived from bone marrow and other tissues destined to be AT cells are transported 
through blood vessels. The most important function of the WAT vascular cells is their 
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ability to secrete cell surface receptors which can be useful targets for disease treatment. 
The ECs are the major key factors in execution of angiogenesis, they secrete GFs, 
cytokines and act as a mediator between vascular cells and the ECM (Cao, 2010. 
 
 
Figure 1. 7: Functions of adipose tissue vasculature. Outgrowth of blood vessels in adipose tissue provides 
oxygen, nutrients, GFs, hormones, inflammatory cells (ICs) and bone marrow derived mesenchymal stem 
cells (BM-MSCs) for maintaining homeostatic functions of adipocytes and expanding adipose tissue. Adipose 
tissue vasculature also removes metabolic products from the adipocytes. In the circulation, bone marrow-
derived ICs, BM-MSCs and endothelial progenitor cells actively participate in adipogenesis and 
angiogenesis. Endothelial cells in angiogenic vessels produce growth factors and adipokines to maintain 
homeostatic functions and expand AT. Perivascular cells such as pericytes can differentiate into WAT 
preadipocytes that become adipocytes. Adipocytes also produce angiogenic factors and adipokines that 
induce angiogenesis (Cao, 2010). Figure reprinted with permission from Nature Publishing Group. 
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The ECs once activated during pathological angiogenesis, overexpress surface receptors 
that can serve as targets for drug discovery (Cao, 2010; Sengenès et al., 2007).  This led to 
discovery of PHB, overexpressed by EC in WAT vasculature of obese ob/ob mice. 
Targeting PHB with pro-apoptotic peptide led to reversal of obesity, proving that the 
concept is feasible (Kolonin et al., 2004). 
Vascular growth and remodelling in WATs is responsible for several functions such as 
cellular growth and tissue homeostasis and communication with the surrounding organs. 
WATs as a fat storage organ grows, expands and shrinks throughout life, these functions 
are regulated through their angiogenic capability (Cao, 2010; Kolonin et al., 2004). Thus, 
hypervascularization of WAT occurs during obesity development. Increase in WAT mass 
affect various cells in the WATs through their secreted adipokines. Adipocytes interact 
with ECs leading to production of proangiogenic factors and cytokines during their 
(adipocytes) developmental stages. Vascular dysfunctions in the WATs can lead to 
dysfunction between the interplay between ECs and adipocytes. Alteration in EC’s 
function in obese individuals has a negative impact in surrounding tissues and organs by 
affecting their roles in lipid metabolism, tissue homeostasis leading to the development of 
disorders such as CVD, insulin resistance, T2D and cancer (Cao, 2010). Thus, disturbance 
of endothelium function in WAT’s vasculature of obese rats and eventually human beings 
is an appealing approach for the prevention and treatment of obesity and obesity-induced 
diseases. This is likely to force the hypertrophic adipocytes to metabolize the excess fat, 
thereby reducing the WAT mass leading to body weight loss that can be maintained for a 
longer period. In this study, a pro-apoptotic peptide will be attached to the ligand that 
binds to PHB to induce EC death by apoptosis. 
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1.4 APOPTOSIS 
Apoptosis is a physiological cell death process, a suicide death that a cell undergoes in 
response to internal or external stimuli to remove damaged and infected cells from the 
body. The stimuli can be anything that can induce DNA damage in the nucleus, such as 
radiation or toxicants. Apoptosis is a sequential signalling pathway that involves protein-
cleaving proteases known as cysteinyl-aspartate-specific proteases, caspases. Caspases 
plays a critical role in the execution phase of apoptosis. The formation of proteolytic 
caspase cascade activates or deactivates substrates, amplifying and integrating pro-
apoptotic signals as detailed in section 1.4.1 (Derakhshan, 2007; Gullicksen et al, 2003). 
Morphologically, apoptosis is characterized by loss of cellular contact with the 
surrounding cells, cytoplasmic contraction and chromatin condensation. Biochemically, 
several changes can be observed: this include genomic DNA fragmentation, 
externalization of phosphotidylserine (PS) component of the phospholipid bilayer, and 
formation of apoptotic bodies that are removed through endocytosis by macrophages 
before the cells lose their plasma membrane integrity (McConkey, 1998; Nelson-Dooley et 
al., 2005).  
Although a number of stimuli appear to trigger the process of apoptosis, there are two 
major signalling pathways: the death receptor pathway and the mitochondrial pathway 
(McConkey, 1998; Nelson-Dooley et al., 2005). The stimuli in which the cell will trigger 
its self-destruction determine the mode of cell death. Extrinsic death signals such as Fas 
ligand and TNF-α induce cell death from the outside of the cell, whereas DNA damage, 
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oxidative stress, toxigens and deficiency of survival factors, are communicated through 
mitochondria to evoke intrinsic cell death (Asoh and Ohta, 2008). 
 
1.4.1 Apoptosis pathways 
Programmed cell death, as the name suggests is a naturally occurring process. Every cell 
within the body is equipped with all the necessary machinery to activate apoptosis when an 
irreparable DNA damage occurs. Apoptosis continually take place throughout the growing 
process, it can be initiated by intrinsic or extrinsic signal pathways and executed by 
caspases (Mallat and Tedgui, 2000). Both these pathways involve a series of molecular 
and biochemical steps that leads to the activation of pro-caspases. The activated caspases 
cleaves nuclear and cytoplasmic substrates responsible for the maintenance of nuclear 
integrity, cell cycle progression and DNA repair, causing cell death (Nelson-Dooley et al., 
2005).  
 
Intrinsic pathway 
The intrinsic or mitochondrial pathway is initiated when stress molecules (ROS, reactive 
nitrogen species), chemotherapeutic agents, UV radiation, withdrawal of survival factors 
and changes in hemodynamic parameters occurs within the cell (Nelson-Dooley et al., 
2005). As the name suggests, the mitochondrial pathway is dependent on the release of 
cytochrome c from the mitochondria induced by irreparable DNA damage. Failure to sense 
and repair damaged DNA at checkpoint stimulates this pathway. Depending on the extent 
of DNA damage, apoptosis can be an immediate or delayed reaction within the cell.  
Nuclear transcription factor, p53 is often involved in apoptosis. p53 upregulation activates 
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genes such as Bcl-2 associated protein-X (Bax), resulting in either a decrease in the inner 
mitochondrial transmembrane potential or opening of the voltage-dependent anion channel 
(VDAC). Cytochrome c is released from the mitochondria, apoptotic protease activating 
factor-1 (Apaf-1), procaspase 9 and either ATP or dATP forms a complex called 
apoptosome. Formation of the apoptosome activates caspase 3 leading to cell death 
(Kiechle and Zhang, 2002). 
Intrinsic pathway is dependent on the permeability of mitochondrial membranes and 
release of cytochrome c as outlined in Figure 1.8. Briefly, the mitochondrial permeability 
transition pore (PTP) is the key regulator of intrinsic pathway. The PTP’s crucial 
components in activation of apoptosis are VDAC-1 in the outer mitochondrial membrane 
(OMM) and adenine nucleoside translocator (ANT) in the inner mitochondrial membrane 
(IMM) (Nelson-Dooley et al., 2005; Shore, 2009; Shoshan-Barmatz et al., 2010).  
Mitochondria are the power house of the cells, they contain all the necessary equipment 
for cell survival and death. Mitochondria are gatekeepers for apoptosis, under normal 
conditions they maintain a balance in production of ROS. Most of their functions are 
executed via ion channels, VDAC in apoptosis.  Mitochondria are made up two distinct 
and important compartments: the matrix surrounded by the IMM, contains enzymes 
responsible for β-oxidation and citric acid cycle; the intermembrane space surrounded by 
the OMM contains several apoptosis-inducing factors (cytochrome c, procaspases and 
AIF). Thus apoptotic stimuli increase permeability of the OMM and/or IMM, and induce 
cytochrome c release (Nelson-Dooley et al., 2005; Shoshan-Barmatz et al., 2010). Release 
of cytochrome c seals the fate of the cell, which is death. This process can be counteracted 
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by anti-apoptotic proteins (Bcl-2 and Bcl-xL), their increased expression prevents 
cytochrome c release and promotes cell survival (Kutuk and Basaga, 2006).  
  
 
Figure 1.8: Three models for the cytosolic escape of mitochondrial proteins in response to apoptotic 
stimuli. Upon an apoptotic stimulus such as cellular stress (oxidative stress, UV irradiation, growth factor 
withdrawal) or activation of death receptors, a mitochondrial channel could be formed by: 1.Voltage-
dependent anion channel (VDAC) and adenine nucleotide translocase (ANT), 2. VDAC-ANT-Bcl-2 proteins 
(Bax, Bak), 3. Only Bcl-2 proteins (Bax, Bak). Anti-apoptotic members of Bcl-2 protein family (Bcl-2, Bcl-
xL) may interfere with the apoptotic process through the inhibition of cytosolic escape of mitochondrial 
proteins (Kutuk and Basaga, 2006). Figure reprinted with permission from Springer. 
 
Extrinsic pathway 
Extrinsic signals such as cytokines, hormones, oxidized lipids, chemotherapeutic, ionizing 
or viral agents are also capable of inducing apoptosis. Extrinsic pathway compared to 
Intrinsic is more acute and massive (Nelson-Dooley et al., 2005). Cell death through this 
pathway involves recognition of cell membrane death receptors by the ligands from TNF 
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gene family, the most studied being Fas. Binding of a ligand to the death receptor recruits 
two signal transducing molecules: TNF receptor-1associated death domain protein 
(TRADD) and Fas-associated protein with death domain (FADD). Either molecule binds 
procaspase-8 leading to formation of an intracellular complex known as death-inducing 
signal complex (DISC). The formation DISC results in proteolytic cleavage and activation 
of procaspase 8 to caspase 8 leading to DNA degradation by cleaving procaspase 3, or 
truncate Bid to tBid resulting in mitochondrial release of proapoptotic peptides through 
binding to Bak. Binding of tBid to Bak initiates similar steps as in intrinsic apoptotic 
pathway, the release of cytochrome c leading to formation of apoptosome followed by cell 
death (Nelson-Dooley et al., 2005; Kiechle and Zhang, 2002).  
The morphological and biochemical events in the two pathways can be detected through 
different assays and techniques: for instance translocation of PS can be detected by flow 
cytometry using annexin V which binds to externalized PS. This translocation is necessary 
for marking the apoptotic cells for their removal by macrophages. DNA fragmentation into 
180–200 base-pair units initiated by caspase-3 activation can be determined by agarose gel 
electrophoresis. Morphological changes: cell shrinkage, chromatin condensation, 
membrane blebbing can be observed under light microscopy (Kiechle and Zhang, 2002; 
Sorisky et al, 2000).  
1.4.2 Apoptosis in obesity 
Apoptosis is a process that has been known to occur during development of obesity in the 
ATs. Apoptosis in the hypertrophic adipocytes of obese rodents and humans was naturally 
triggered by either extrinsic or intrinsic pathway as shown in Figure 1.9 (Alkhouri et al., 
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2009). Increase in AT mass during the development of obesity induces cell death by 
activating one of the apoptotic signalling pathways. The mode of cell death is dependent 
on the stimuli of DNA damage, death receptor or internal stimuli that results in 
mitochondrial dysfunction. Adipocyte apoptosis results in recruitment of AT macrophages 
(ATM) that localizes in dead adipocytes for their removal (Alkhouri et al., 2009; Cinti et 
al., 2005).  
 
Figure 1.9: Proposed model for the role of adipocyte apoptosis in the metabolic complications of 
obesity. During the development of obesity, expansion of adipose tissue results in activation of apoptotic 
signalling including death receptor and mitochondrial pathways. These cytotoxic signalling pathways result 
in activation of effector caspases and adipocyte apoptosis. Pathologic increase in apoptosis results in ATM 
recruitment, with subsequent development of insulin resistance, hepatic steatosis, and dyslipidemia. Anti-
apoptotic therapy target at inhibiting either the Fas- or mitochondrial-mediated pathways may be a new 
therapeutic strategy for treatment of obesity-associated metabolic complications (Alkhouri et al, 2009). 
Figure reprinted with permission from American Society for Biochemistry and Molecular Biology. 
Unfortunately, macrophage recruitment in diet-induced obese mice was associated with 
development of insulin resistance, fat accumulation in the liver (hepatic steatosis) and 
dyslipidemia. A study done by Alkhouri et al, (2009), confirmed that adipocyte apoptosis 
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naturally occurs in obese mice and humans. This was proved by the high amount of pro-
apoptotic protein (Bax) and the ratio of Bax: Bcl-xL detected in the epidydimal fat from 
mice and human omental fat pads. And knocking out Bid gene in C57BL/6 mice reduced 
apoptosis and prevented macrophage infiltration of ATs and protected the mice from 
developing insulin resistance and hepatic steatosis (Alkhouri et al., 2009; Cinti et al., 
2005). 
Although the adipocytes were initially assumed to remain constant throughout life, 
independent studies have shown that new adipocytes can be generated by hyperplasia and 
old or damaged ones lost. Loss of the WAT mass due to apoptosis has been observed in 
various conditions associated with weight loss, such as in the HIV patients treated with 
protease inhibitors, rats with streptozotocin induced diabetes, in omental and subcutaneous 
ATs of humans with malignancy-associated weight loss (Prins et al., 1994). The idea that 
apoptosis can be of value in obesity reversal was encouraged by surgical removal of fat in 
obese people such as liposuction, surgical removal of fat reduced body weight and 
improves metabolic activity. Weight loss achieved after liposuction can be maintained for 
at least a year in 80% of patients, this confirms that any strategy that can be able to 
eliminate adipocytes can be an effective way to reduce WAT mass and total body weight. 
A natural and non-invasive strategy could be a best option and elimination of adipocytes in 
the WAT could be a better strategy for obesity reversal (Nelson-Dooley et al., 2005; Prins 
et al., 1994).  However lipectomy as seen in animal models of obesity is always followed 
by fat restoration within weeks accompanied by adverse metabolic effects (Mauer et al., 
2001) and a year in humans (Hernandez et al., 2011). Fat redistribution to compensate the 
decrease in AT mass was observed also in non-surgical area, compensated for by 
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neurohormonal signals that increases appetite, food intake and irregular cytokine secretion 
(Mauer et al., 2001; Hernandez et al., 2011)  
Apoptosis as strategy to treat obesity has been tested through in vitro and in vivo studies 
using leptin and TNF-α (Prins et al., 1997).  In both instances the ATs served as a target. 
Leptin was shown to have apoptotic effects in Sprague-Dawley rats through intra-
cerebroventricular administration in rat brain and reduced fat mass by increasing lipolysis 
and stimulating adipocyte apoptosis (Gullicksen et al., 2003; Qian et al., 1998). The same 
leptin effects were observed in obese (C57Bl-ob/ob) female mice after transfection with 
differentiated 3T3-F442A that over-express leptin. The weight loss occurred within 48 
hours of treatment, with this study apoptosis was observed in the microvasculature of 
WAT (Cohen et al., 2001; Gullicksen et al., 2003). TNF-α induced apoptosis in human AT 
explants and preadipocytes isolated from human AT (Sorisky et al., 2000). 
Apoptosis is a highly regulated process responsible for removal of damaged, toxic or 
diseased cells within the body, and thus should be expected to perform the same function 
during development of obesity. However, induction of apoptosis in the adipocytes might 
result in inflammation and other obesity-induced diseases as highlighted in the study done 
by Alkhouri et al., (2009). Obesity is characterized by an increase in adipocytes number 
and size. Therefore, the AT mass can be regulated at adipocytes proliferation and 
differentiation from preadipocytes to reduce body weight (Sorisky et al., 2000).  
 
Most treatment strategies for obesity are aimed at reducing the cell size, however, the 
treatment that will reduce the cell size as well as number might work best. Induction of 
apoptosis in the WAT vasculature could be a nonsurgical approach for reducing total 
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WAT mass and provides long-term maintenance of the weight lost as observed in 
individuals that underwent liposuction and maintained weight loss for a year (Nelson-
Dooley et al., 2005). The problems that might result after the adipocyte has undergone 
apoptosis are discussed by Alkhouri et al., (2009), stressing that accumulation of the fat in 
blood vessels and liver is detrimental to the body. Strategies that are able to help the 
adipocytes metabolize the excess energy could potentially suffice.  Thus, induction of 
apoptosis in the cells (ECs) that promote adipocyte growth could increase lipolysis and 
starve the cells to death, and prevent development of secondary diseases mentioned above.  
1.5 NANOTECHNOLOGY 
The field of nanotechnology was first predicted in 1959 by Richard P Feynman (Nobel 
laureate in Physics, 1965) with his famous lecture entitled: “There’s plenty of Room at the 
Bottom”. The prefix ‘nano’ derives from Greek word for ‘dwarf’. Nanotechnology is a 
multi-disciplinary field derived from engineering, biology, physics and chemistry and 
deals with formation of particles that range in size from 1 to 100 nm. These particles are 
made in a nanometer scale for manipulation of physical, chemical or biologic processes, 
and therefore regarded as nanoparticles. One nanometer (nm) is equal to one billionth of a 
meter (1 nm = 10-9 m) (Pal and Nayak, 2010; Provenzale and Silva, 2009).  
 
To understand these sizes in a biological context, an atom is 0.15 nm diameter, a double 
stranded DNA is 2 nm diameter, viruses range in size from 20 to 300 nm and cells are 
1000 nm in diameter (Provenzale and Silva, 2009). The sizes of nanoparticles allow for 
their manipulation for biological processes, the functions that would have been otherwise 
impossible using larger particles including transporting materials across the blood-brain 
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barrier (Martinac and Metelko, 2006; Provenzale and Silva, 2009). Nanotechnology 
application in medicine has been growing, especially in the field of diagnostics and 
targeted delivery of treatment as discussed in 1.5.3. Nanotechnology can provide essential 
breakthroughs in the fight against different diseases by direct targeting of the problem 
areas with no harm to healthy tissues (Moghimi et al, 2005; Yan et al., 2012).  
1.5.1 Nanomaterials 
Nanomaterials also referred to as nanoparticles (NPs) first came to light almost 50 years 
ago. Nanomaterials are microscopic particles with at least one dimension that is < 100 nm 
(Provenzale and Silva, 2009). Nanomaterials are classified based on their composition. 
There are two major types of nanomaterials: particles that contain organic molecules as a 
major building material (biodegradable polymer, lipid materials such as liposomes) and 
those that use inorganic elements (metals) as a core such quantum dots (QDs) and as gold 
nanoparticles (AuNPs) which are discussed in section 1.5.2.1. The basic structure for most 
inorganic nanomaterials is shown in Figure 1.10, the metal core is coated by the shell that 
can be modified for biological or medical applications (Yezhelyev et al., 2006). 
In medicine they are developed as carriers or drug delivery agents for vaccines and 
therapeutic purposes. Liposomes were the first organic NPs used as drug delivery systems 
(Yezhelyev et al., 2006). Liposomes are nanovectors made of lipids surrounding an 
aqueous core. The bilayered phospholipid particles were discovered over 40 years ago. 
Liposome structure mimics the lipid bilayer in biological systems, as such regarded 
biocompatible and ideal drug delivery agents. They are bio-degradable, a drug or 
therapeutic peptides can be incorporated inside a lipid layer. When internalized within the 
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cell, the lipid bilayer will be degraded releasing its contents or drugs to perform their 
functions (Kingsley et al., 2006; Sengupta et al., 2005).  
 
Figure 1.10: Basic structure of inorganic nanoparticles (Yezhelyev et al., 2006). Figure reprinted with 
permission from Elsevier. 
 
1.5.2 Nanomaterials used for drug delivery  
 
Most commonly used nanomaterials in biological research are AuNPs, liposomes, 
dendrimers and QDs. These nanomaterials have interesting properties that were exploited 
in cancer research as either drug delivery agents or imaging agents (Thakor et al., 2011). 
Gold nanoparticles are discussed below as they are used in this study as drug delivery 
agents.  
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1.5.2.1 Gold nanoparticles 
Gold nanoparticles are stable, solid colloidal particles that range in size from 1 to 100 nm.  
The biological application of AuNPs is rooted in from their physico-chemical properties. 
The most important being their smaller size that allows modification of AuNPs to cross 
any biological barrier by attaching targeting and therapeutic peptides on their surface (Cho 
et al., 2009). This property together with its unique optical properties is advantageous for 
use as diagnostic applications. Their synthesis is based on the method developed by 
Turkevich in 1985 through reduction of gold aurate by citrate (Kimling et al., 2006).  The 
AuNPs are stabilized by addition of proteins such as bovine serum albumin (BSA) on their 
surface, and can be used to attach targeting peptides and prevent their aggregation and 
precipitation that occurs at their isoelectric point (Liu and Franzen, 2008). 
The biocompatibility of AuNPs is attributed to the long application of gold in human 
diseases. The therapeutic application of gold started centuries ago when gold compounds 
were used for medical purposes since 2500–2600 BC by Chinese and Indian people. For 
medical purposes, gold was used to treat conditions such as male impotence, epilepsy, 
syphilis, rheumatic diseases and tuberculosis. China was the first to discover the longevity 
effect of red colloidal gold. The application of red colloidal gold still continues in India for 
the same purposes (Ayurvedic medicine for rejuvenation and revitalization) as China by 
the elderly. Cinnabar-gold (Makaradhwaja) is used for fertility purposes in India. Gold has 
also been used to   treat nervous disorder and epilepsy in Western countries and no toxicity 
was observed in both in vitro and in vivo studies (Bhattacharya et al., 2007). Since then 
oral and injectable gold compounds continued to be used especially as treatment of 
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arthritis due to the bacteriostatic effects and also proved to have anti-cancer effects (Fraser, 
1945; Rau and Rheumatol, 2005).  
Since the approval of Cisplatin (platinum containing inorganic compound) in 1978 by 
FDA for cancer treatment, research for medical effects of inorganic metal has been rising. 
Since then Gold I and III compounds has been used to enhance activities of anti-tumour 
compounds (Bhattacharyya et al., 2010). This led to hypothesis that gold at the nanoscale 
will also be not toxic and can be useful as a vehicle for drug delivery to diseased cells by 
targeting the overexpressed receptors such as the folate receptors in cancer (Bhattacharya 
et al., 2007) and prohibitin in AT’s vasculature (Kolonin et al., 2004). 
Gold has many applications in medicine and in nanotechnology it was found to have anti-
angiogenic effect (Arvizo et al., 2011) but is mostly used as a drug delivery agent. AuNPs 
are highly stable and have a distinct surface plasmon resonance (SPR) bands, thus provide 
easy characterization. They are highly biocompatible when conjugated to functional 
ligands for in vivo drug targeting (Sun et al., 2008). There are currently two AuNP-
formulations that have under gone human clinical trial in treatment of solid tumours. 
Aurrimune (CYT-6091) was the first citrate coated AuNPs to go through clinical trials 
which started in 2005 for delivery of anti-cancer therapy. CYT-6091 gold-based 
nanoparticles are made up of 27 nm AuNPs encapsulated with recombinant TNF-α and 
PEG.  The clinical trial was conducted in late-stage pancreatic, breast, colon, melanoma, 
sarcoma and lung cancer patients. The CYT-6091 nanodrug achieved safe and targeted 
biologic response at the tumour site by using a dose lower than required for TNF-α alone 
(Libutti et al., 2009; Libutti et al., 2010). Phase II clinical trials of Aurimmune 
(CytImmune Sciences) are under investigation (ClinicalTrials.gov numbers, 
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NCT00356980 and NCT00436410). Aurolase nanoshells with a 15 nm gold shell are in the 
first human clinical trial for head and neck tumours as photothermal therapy 
(ClinicalTrials.gov number, NCT00848042).  
1.5.3 Biological and medical application of nanotechnology  
Application of nanotechnology in medical sciences referred to as nanomedicine by the 
National Institutes of Health, has been growing in recent years. Nanotechnology employs 
the use of nanomaterials such as AuNPs and QDs for treatment, diagnosis and imaging 
purposes. Bio-conjugated nanomaterials have been useful as drug delivery agents, clinical 
studies are being conducted in cancer research (Moghimi et al., 2005; Yezhelyev et al., 
2006).  Nanomedicine offers higher efficacy for treating diseased cells without causing 
any harm to normal cells or tissues, and the effects can be monitored noninvasively 
(Caruthers et al, 2007; Moghimi et al, 2005). 
Bio-distribution of nanomaterials is depended on their physico-chemical properties, these 
include parameters such as size, charge and shape. These properties can be manipulated 
for biological use to help increase their circulation times within the body and therapeutic 
index.  Nanomaterials less than 20 nm in size for instance, can pass through blood vessel 
walls, and allows for intravenous, intramuscular and subcutaneous applications. Targeted 
nanomaterials can minimize the irritant reactions at the injection site that occurs when 
using conventional treatments. Conventional treatment is limited by the bystander effects 
to normal tissues, short circulation time, insolubility and non-selectivity; limiting or 
reducing their therapeutic efficacy to desired cells. Bio-conjugated NPs can be developed 
with qualities that can help overcome these drawbacks for delivery of smaller doses of 
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drugs directly to the diseased tissues as discussed in 1.5.3.1 and be used to monitor their 
effect in biological system. Targeted NPs could mask the drug from proteolysis and 
prevent contact with healthy tissues increasing the dosage that reaches the diseased tissue 
(Praetorius and Mandal, 2007). 
1.5.3.1 Drug delivery using nanoparticles 
The most common and major application of NPs especially AuNPs, is in drug delivery. 
Nanomaterials as drug delivery agents are attractive in that they help in reduction of 
dosage of drugs and transportation of the insoluble treatment. They are also useful in 
protecting the drugs from proteolytic degradation as they travel through the circulatory 
system when attached to PEG or biological active molecules. These readily increase the 
efficacy of the targeted drugs by concentrating them in the diseased tissue with little or no 
effect to the normal tissues (Brigger et al., 2002).  
Nanoparticles as drug delivery agents are able to overcome most of the problems 
encountered when using conventional therapies such as drug resistance due to cellular 
barriers, distribution and early clearance from the biological system (Cho et al., 2008; 
Ruoslahti et al., 2010). Their use as vaccines and chemotherapy carriers for cancer 
treatment has been extensively studied. These treatments concentrate on diseased areas by 
taking advantage of the enhanced permeability and retention (EPR) effect on the 
vasculature of the diseased tissue when used without targeting molecules. In a pathological 
state, EPR is characterized by pathological and excessive angiogenesis and increased 
secretion of a various permeability mediators that can be target for disease intervention. 
These characteristics only occur in pathological states and not in normal tissues and 
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provide an opportunity for more selective targeting of NPs to diseased tissues (Kingsley et 
al., 2006). 
The NPs as outlined in 1.5.3 have numerous advantages as drug delivery agents.   They 
have a high pay load capacity and capable of carrying both hydrophilic and hydrophobic 
drugs into a cell. The treatment once inside a cell can be released in a controlled manner 
through active or passive targeting. Active targeting occurs in a manner discussed in 
1.2.3.1. In some cases it might require external stimulus such as light in a photodynamic 
therapy or heat when using heat-labile liposomes to activate release of treatment. Passive 
targeting takes advantage of EPR effect and not as cell specific as active targeting. Active 
targeting make sure that the therapy is directly delivered in the desired cell and minimize 
systemic effects achieving a balance between efficacy and toxicity (Provenzale and Silva, 
2009; Lysik and Wu-Pong, 2003). 
The earliest application of nanomedicine was in cancer research where liposomes were 
used to deliver chemotherapy payloads to the tumour tissues (Moghimi et al, 2005). 
Abraxane (NP albumin-bound paclitaxel) was the first chemotherapeutic NP to be 
approved by the FDA for treatment of metastatic breast cancer in the USA. Nanotreatment 
has greater efficacy with an improved safety profile than conventional paclitaxel 
(Caruthers et al., 2007; Yezhelyev et al., 2006). Doxorubicin is another drug used to treat 
cancer and is associated with cardiac toxic side effects. The nanodrug version of the same 
drug has now been approved by FDA for treatment of refractory ovarian cancer, breast 
cancer and Kaposi’s sarcoma in the USA. Biodegradable liposome nanoparticles are used 
to deliver doxorubicin to the tumour site, help retain the drug efficacy and circulate longer 
than the normal drug (Sengupta and Sasisekharan, 2007; Yezhelyev et al., 2006).  
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Selective cell targeting is a best strategy because the toxicity of the therapy will only be 
directed to diseased cells and spares the normal cells. Active targeting increases the 
therapeutic efficacy and reduces systemic toxic effects as observed with nanodoxorucibin 
and nanopaclitaxel. The interesting part is that the strategy can be applied in various 
diseases as long as biomarkers exclusively expressed during development of the disease 
are known or have been  identified (Yezhelyev et al., 2006). The nano-drug delivery 
system has been booming in active targeted therapy, the targeted NPs provide better 
efficacy and limited cytotoxicity. Targeted therapy targets disease-specific biomarkers and 
can therefore discriminate between normal and diseased cells or tissues (Breunig et al., 
2008; Kim and Nie, 2005; Pal and Nayak, 2010).  
1.5.4 Challenges and advantages of nanotechnology  
Nanotechnology application in biomedical research is still in its infancy, therefore still 
lacks assurance for in vivo usage. There is still reluctance to use nanotechnology-based 
products, especially the ones that are used in human (Cunningham, 2014). Changing the 
size of molecules is accompanied by altered physical and chemical properties that have 
consequences within the body, such as the change in clearance from the body from 
minutes to hours to days and maybe even years. These changes are likely to be associated 
with a lot of uncertainties, and therefore safety of the nanomaterials within the body still 
raises questions and should not be undermined (Caruthers et al., 2007).  
Gold has been used for decades for medical purposes and is thus regarded as nontoxic. 
However, the same may not be true for AuNPs. AuNPs have been observed to be toxic in 
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both cell culture and animals (Pompa et al., 2011; Sabella et al., 2011). Their toxicity has 
been associated with their physicochemical properties such as size and shape. 
Nanoparticles were often attacked by immune cells as they were considered foreign by the 
body (Cho et al., 2009; Nel et al., 2006).  
The field of nanotechnology has been growing lately in theranostics despite the 
uncertainties that surround it. Nanotechnology together with molecular techniques, offer a 
great opportunity for development of treatment and diagnostic strategies for chronic 
diseases not limited to diabetes, cancer and obesity. Cancer and arthritis research has 
covered most of application with exciting outcomes. The characteristics of the nano-drugs 
or therapeutic agents such as solubility, circulating times, drug release over short or long 
durations and site-directed delivery can be controlled. Nanomaterials for drug delivery and 
molecular imaging have been developed that can overcome most of the challenges faced 
by current available tools. The NPs have increased surface area and very large payloads to 
accommodate attachment of targeting, therapeutic and imaging agents. Targeting permits 
quantification of the extent of disease and deliver therapeutic doses to the desired diseased 
tissue (Kim et al., 2010). The efficacy of the targeted therapeutic NPs can be monitored by 
non-invasive imaging and quantified. The NPs can achieve therapeutic effect on the 
targeted tissues even at the lowest dose than the conventional dosage (Caruthers et al., 
2007).  The use nanotechnology-based drug delivery strategies coupled with targeted 
therapy can significantly improve the safety profile of the drug by lowering dosage, reduce 
bystander side effects, increase drug half-life and maximize the efficacy of the drug at the 
desired site.  
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 Despite the challenges associated with NPs, nanotechnology offers a great potential for 
treatment of obesity and its associated conditions. Ways of overcoming the short falls 
surrounding the use of NPs has been identified, such as the use of functionalized 
nanomaterials (Yan et al., 2012).  Targeted NPs are expected to be able to reach the 
desired diseased tissue, and in so doing overcome cellular barriers in the body without 
losing their efficacy while travelling through the blood circulation. Upon interacting with 
the diseased cells the nanotherapy should exert the drug action specifically on the target 
cells following a controlled release mechanism, and destroy these cells without any harm 
to normal cells. Nonspecific adsorption of NPs is normally overcome by addition of 
polymers such as PEG (Kelly and Kim, 2007; Provenzale and Silva, 2009; Yan et al., 
2012). This strategy will be able to improve chances of patient’s survival by targeting and 
eliminating the diseased cells/ tissues with no bystander effect, therapeutic intervention for 
chronic diseases (obesity) can benefit a lot from both targeted therapy and 
nanotechnology.  
1.5.5 Potential application of nanotechnology in obesity 
After years of basic nanoscience research, followed by many on research and 
development, application of nanotechnology in medical science is delivering on its 
promises for a better nanomedicine. Nanomaterials customized for desired actions have 
been developed, capable of delivering, tracking of drugs to specified targets and evaluating 
drug response.  Their size range and stability makes it possible for NPs to pass through the 
blood stream and circulate a bit longer than conventional therapy without altering their 
behaviour and biochemical properties. These properties allow time for the treatment to 
concentrate at the diseased area regardless of the route of administration. Use of targeting 
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moieties reduces systemic and bystander effects on the surrounding tissues (Praetorius and 
Mandal, 2007). 
Nanoparticles have been extensively used for highly specific and efficient delivery of the 
treatment into target cells (Kim et al., 2010; Praetorius and Mandal, 2007; Yan et al., 
2012). Nanoparticles can be designed for specific diseased tissues (in this case of obesity, 
WAT vascular ECs) through targeted therapy. Targeted therapy is mainly composed of a 
targeting molecule (e.g. aptamers, antibodies, ligands, dendrimers) specific for cellular 
receptors, drug load (therapeutic peptides) and/ or imaging agents (QDs). Surface 
modifications of the NPs can be exploited in order to resolve some of the noncompliance 
issues associated with the current therapy by increasing the biocompatibility. Specificity of 
the nanomaterials can be achieved by attaching targeting peptides (Praetorius and Mandal, 
2007; Yan et al., 2012).  
The differentially expressed vascular receptors (PHB) on the endothelium are easily 
accessible for the binding of blood-borne compounds and can be used to indirectly target 
the diseased cells.  PHB is upregulated in the vasculature of obese WAT compared to the 
normal blood vessels and therefore may serve as a target for obesity therapeutic 
intervention (Kolonin et al., 2004). Vascular targeted nanotherapy can be beneficial for 
treatment of obesity. The WAT vascular marker (PHB) with its associated ligand (AHP) 
has already been identified (Kolonin et al., 2004).  Using AHD-nanodrug conjugate to 
target PHB receptors is expected to selectively induce cell death in the vascular ECs 
leading to fat resorption that will reduce WAT mass leading to total body weight loss. The 
PHB receptors are accessible to circulating AHP-conjugate in the blood (Arap et al., 2002; 
Ruoslahti et al., 2010), and home to specified vascular receptor in the WATs. Targeted 
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nanotherapy strategy is expected to enhance the drug toxic effects to only vasculature of 
diseased WATs. The drugs will be concentrated at a desired target sparing the healthy 
surrounding cells. This will definitely increase the treatment efficacy, reduce toxicity to 
healthy cells as opposed to non-targeted drugs that relies on passive targeting. By cutting 
off the adipocyte’s blood supply, the adipocytes that are fed by the cut vasculature will be 
forced to metabolize excess fat and be destroyed (Arap et al., 2002; Ruoslahti et al., 2010).  
The concept of targeted drug delivery is an attractive strategy for obesity reversal. 
Vascular targeted therapy has been tested and gave exciting outcomes in animal models of 
obesity (Hossen et al., 2010; Kolonin et al, 2004). Through nanotechnology, vascular 
targeted nanotherapy’s action can be enhanced. Nano-based delivery systems will increase 
drug circulation, reduce off-target effects and renders the therapy effective even at lower 
dosages. 
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1.6 Aim(s) of the study  
The aim of the study was to develop a nanotherapy that specifically targets a vascular 
network which supplies the pathologic adipose tissue with essential nutrients and 
trigger the death of these cells through apoptosis allowing greater efficacy at lower 
doses.  
1.6.1 Objectives of the Study 
 To express TK3 pro-apoptotic and mTK recombinant proteins using recombinant 
DNA technology (RDT)  
  To determine the effects of recombinant proteins in Caco-2  model cell line 
  To develop nanotherapy by conjugating the recombinant proteins and WAT vascular 
targeting peptides to AuNPs 
 To determine the effects of the PHB-targeted-nanotherapy, its cellular uptake, 
localization, specificity and the cytotoxicity effects on the model cell line.
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Chapter 2: Materials and Methods 
2.1 Reagents and their suppliers 
All chemicals used in this study were purchased in their highest purity from the 
following suppliers listed in Table 2.1: 
Table 2.1: List of reagents and suppliers 
    
      Suppliers 
    
                          Reagents 
BioLegend® Purified rabbit anti-prohibitin antibody 
Biorad 40% Acrylamide/ bis-acrylamide, Bradford dye reagent 
Fermentas Nde I, Xho I 
Gibco Dulbecco’s Modified Eagle’s Medium (DMEM), foetal 
bovine serum (FBS), penicillin, streptomycin, Trypan 
blue stain (0.4%)  
Inqaba T7 forward (F+) and reverse(R-)  primers 
Invitrogen Competent cells (MC 1061, BL21 (DE3) PlysS, BL21-
codon plus, Rosetta (DE3) and ArcticExpress) 
Kimix (Hydroxymethyl) aminomethan (Tris), Ethanol,  
Life Technologies 2-mercaptoethanol  
Lonza Dulbecco's phosphate buffered saline (D-PBS) 
Merck Acetic acid, Bacteriological agar, Bromophenol blue, 
KCL, Methanol,  NaCl, tryptone, Na2HPO4, KH2PO4, 
sucrose, Urea crystals, Yeast extract 
 
Novagen CytoBuster Protein Extraction Reagent 
OncoImmunin, Inc CaspaLux 9-M1D2 substrate 
Promega dNTPs, MgCl2, Green Go Taq Flexi buffer, Go Taq pol  
Roche 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium (WST-1), bovine serum 
albumin (BSA) 
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2.2 Preparation of solutions and reagents  
2.2.1 Cloning, protein expression and purification 
 
IPTG: 1M IPTG was dissolved in distilled water (dH2O), filter sterilized and stored at -
20oC in 2 ml aliquots 
 
Ampicillin antibiotic: 100 mg/ml Ampicillin was prepared in dH2O, filter sterilised. 
Aliquots of 2ml were stored at -20oC 
 
Kanamycin and G418 antibiotics: 50 mg/ml of both antibiotics was prepared in dH2O, 
filter sterilised. Aliquots of 2 ml per antibiotic were stored at -20oC 
 
Luria Bertani (LB) Broth (1Liter): 10 g of tryptone  
5 g of NaCl  
5 g of yeast extract  
 
 
Santa Cruz 
Biotechnology 
 
His-probe (H-3) mouse monoclonal antibody,  Caspase-
3  rabbit polyclonal antibody, Caspase -9 mouse 
polyclonal antibody, Actin-HRP mouse monoclonal 
IgG1 
Sigma-Aldrich 2′,7′-dichlorofluorescin diacetate (DCFH-DA), 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT), Ampicillin sodium salt (ampicillin), 
Bradford dye reagent concentrate, coomassie brilliant 
blue R-250, FlouroshieldTM with Dapi (Dapi), 
glutaraldehyde, glycine, G418 disulfate Salt, hydrogen 
tetrachloroaurate (HAuCl4), kanamycin sulphate 
(Kanamycin), lauryl sulfate (SDS), HIS-Select® Nickel 
Affinity Gel,  TEMED, trisodium citrate,  
Thermo Scientific SuperSignal® West Pico Chemiluminescent Substrate 
WhiteScientific Agarose molecular grade 
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TYM Broth (500 ml): 2% tryptone  
0.5% Yeast extract 
    0.1 M NaCl  
     10 mM MgCl2   
 
LB Agar (per litre): 10 g tryptone  
           5 g yeast extract  
         5 g NaCl  
          15 g bacteriological agar   
 
The ingredients for TYM, LB broth and agar were dissolved in dH2O, the pH was 
adjusted to 7.0 with NaOH. The final volume was adjusted to 1 litre with dH2O. The 
solutions were autoclaved. The LB and TYM broths were stored at room temperature 
(RT) without antibiotics.  
The LB agar was cooled to ≤55°C and appropriate concentration of antibiotics was 
added. Then poured into Petri dishes~25 ml/100-mm plate, the plates were allowed to 
set at RT. The plates were covered with foil and stored at 4oC lid side down.  
Transformation (Tfb) 1 buffer: 30 mM KOAc    
50 mM MnCl2   
  100 mM KCl   
10 mM CaCl2    
15% glycerol  
 
Tfb 2 buffer: 10 mM NaMops   
75 mM CaCl2    
10 mM KCl    
15% Glycerol  
   
The Tfb buffer ingredients were dissolved in half of the required volume of dH2O the 
adjusted to required volume with dH2O. The buffers were filter sterilized and stored at 
4oC 
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0.5 M EDTA (pH 8.0): 18.6 g disodium EDTA was dissolved in 80 ml of dH2O, the 
pH was adjusted to 8.0 with NaOH. The final volume was adjusted to 100 ml, the buffer 
was sterilized by autoclaving and stored at RT. 
 
Tris-EDTA (TE) Buffer: 10 mM Tris (pH 7.5) 
1 mM EDTA (pH 8.0) 
The buffer was adjusted to required volume with dH2O. 
50 X TAE DNA Electrophoresis Buffer: 242 g Tris base 
57.1 ml acetic acid 
100 ml 0.5 M EDTA (pH 8.0) 
 
The Tris base was dissolved in ~600 ml dH2O, the glacial acetic acid was added 
followed by the EDTA buffer. The volume was brought to a litre with dH2O. 
Note: Final working buffer concentration at 1 X (40 mM Tris-acetate; 1 mM EDTA) 
 
10 X Phosphate Buffered Saline (PBS):  80 g NaCl 
2.0 g KCl (Merck) 
14.4 g Na2HPO4 (Merck) 
2.4 g KH2PO4 (Merck) 
The ingredients were dissolved in ~800ml distilled H2O, adjusted pH to 7.4. Then final 
volume was adjusted to 1L with dH2O. The buffer was sterilized by autoclaving and 
stored at RT. 
 
1X PBS (makes 1 litre): 100 ml 10X PBS used to make up 1L with dH2O, pH 7.2 
 
Binding and equilibration buffer: 20 mM Tris-HCl (pH 8.0) 
500 mM NaCl 
5 mM imidazole (pH 7.9) 
8 M urea 
1 mM phenylmethylsulfonyl fluoride  
0.5 mM DTT 
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Wash Buffers: 20 mM Tris-HCl (pH 8.0) 
500 mM NaCl 
0, 30, 50, 100 mM imidazole (pH 7.9) 
8 M urea 
1 mM phenylmethylsulfonyl fluoride 
0.5 mM DTT 
 
Elution buffer: 20 mM Tris-HCl 
500 mM NaCl 
300 mM imidazole (pH 7.9) 
8 M urea 
The buffers were made up to required volume with dH2O 
 
2.2.2 SDS-PAGE analysis 
 
Protein quantification: One mg/ml stock solution of bovine serum albumin (BSA) was 
prepared in dH2O and stored at 4
OC. 
SDS-PAGE: 
2X Laemmli sample buffer: 4% SDS  
1% 2-Mercaptoethanol  
0.01% Bromophenol blue 
15% Glycerol  
0.125 M Tris-HCl, pH 6.8   
SDS-PAGE Gels: 
1.5 M Tris pH 8.8: Dissolve 90.86 g Tris in 400 ml distilled water (dH2O), used   
 HCl/NaOH to adjust pH to 8.8 and filled up to 500 ml. Stored at 4oC. 
 
0.5 M Tris pH 6.8: For 200 ml, mixed 66.6 ml of 1.5 M Tris pH 8.8 to 150 ml with  
 dH2O, adjusted pH to 6.8 with HCl/ NaOH then filled up to 200ml. 
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10% SDS: Dissolved 10 g of SDS in dH2O to make up 100 ml solution and stored at 
room temperature. 
 
10% APS:  Dissolved 1 g APS in 10 ml dH2O and stored aliquots of 2 ml at -20
oC.  
 
Table 2.2: Preparation of resolving and stacking gels 
 
 
COMPONENTS 
         Resolving Gels (ml)    Stacking Gel 
(ml) 
  12% Acrylamide             15% 
Acrylamide 
   (5% 
Acrylamide) 
dH2O  4.3 3.55 3.6 
40% Acrylamide/bis-                                   
acrylamide  
3 3.75 0.625 
0.5 M Tris pH 6.8 0 0 0.630 
1.5 M Tris pH 8.8 2.5 2.5 0 
10% SDS  0.1 0.1 0.05 
10% APS  0.1 0.1 0.05 
TEMED  0.004 0.004 0.005 
 
10X SDS electrophoresis running buffer: 10 g SDS 
  30.3 g Tris 
  144.1 g Glycine (make to 1L with dH2O)  
 
Coomassie stain: 0.1% Coomassie brilliant blue R-250  
  40% Methanol  
  10% Acetic acid in dH2O 
 
Destaining solution: 40% Methanol 
10% Acetic acid in dH2O 
 
2.2.3 Western Blot Analysis 
 
10X TBST/ Wash buffer: 250 mM Tris 
1400 mM NaCl  
 30 mM KCl  
 0.5% Tween-20 
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The ingredients were dissolved in dH2O, adjusted pH to 7.4 then filled up to required 
volume with dH2O. 
 
10X Blotting / Transfer buffer:  0.025 M Tris – 30.28 g 
0.192 M Glycine – 144 g  
0.1% SDS – 1 g (optional) 
Make up to a litre with dH2O, made in advance and   refrigerated.  
 
1X Blotting: 100 ml 10X blotting buffer 
  200 ml Methanol – make up to a litre with dH2O. 
 
Blocking buffer: 5% Carnation non-fat dry milk in TBST. The same buffer was used 
for preparation of the primary and the secondary antibodies as the Antibody binding 
buffer. 
(Caution: The 1X blotting buffer must be stored at 4°C before the electrophoretic 
transfer). 
Stripping Buffer: 0.2 M NaOH prepared in dH2O 
Paraformaldehyde (PFA) fixation solution: 4% PFA was dissolved in 1X PBS 
(NOTE:  PFA must be heated to >65oC to dissolve), 1-2 drops 10 M NaOH was added 
while mixing. 
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2.3 Research Methodology 
2.3.1 Recombinant DNA technology 
 
2.3.1.1 mTK and TK3 constructs 
 
mTK and TK3 constructs were a previous gift from Kwon et al., 2008. TK3 was 
constructed by inserting a PTD sequence expressing a HIV-1-TAT (TAT) domain 
(amino acids 49-57: RKKRRQRRR) fused with three tandem repeats of pro-apoptotic 
oligonucleotides that codes for D(KLAKLAK)2-DEVD-GG in a pET30a(+) vector. 
mTK was generated by inserting a double-stranded oligonucleotide encoding 
DLSLARLATARLAI in place of D(KLAKLAK)2 (Kwon et al., 2008). 
 
2.3.1.2 Preparation of chemically competent cells  
The glycerol stocks containing Escherichia coli MC 1061, BL21 (DE3) PlysS, BL21-
codon plus, Rosetta (DE3) and ArcticExpress competent cells were streaked out on a 
Luria agar plate without antibiotics. The plates were incubated at 37oC overnight in a 
Heraeus B5042 incubator (ThermoScientific), with the lid side down. A single colony 
per plate was inoculated into a 20 ml TYM broth and incubated overnight at 37oC in a 
shaker incubator (Multitron II Shaker Incubator, Infors HT). The overnight culture was 
diluted 1:10 to 100 ml with fresh TYM broth in a 2L flask and incubated at 37oC until it 
reached an optical density at 550 nm (OD550nm) of 0.2. A fresh TYM broth (400 ml) was 
added to the flask and incubated until the OD550nm reached 0.5.  
The cells were cooled by gently swirling in ice water and then transferred to 
polypropylene tubes and centrifuged with Sorvall RC6 plus centrifuge 
(Thermoscientific) at 6000 rpm for 10 minutes. The media was discarded and the pellets 
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resuspended in 100 ml of transformation buffer (Tb) 1 and incubated on ice for 30 minutes. 
The cells were spun at 3000 rpm for 8 minutes at 4oC. The supernatant was discarded and 
the cell pellets were gently resuspended in 30 ml of Tb 2. The aliquots of 0.2 ml were 
transferred into microcentrifuge tubes that were pre-cooled on ice. The competent cells 
were snap-frozen in liquid nitrogen and stored at -80oC. 
2.3.1.3 Transformation of mTK and TK3 into cloning cells 
Upon arrival the plasmid DNA spotted in the filter papers was reconstituted in 1X TE 
buffer. The DNA was quantified by NanoDrop® ND-1000 Spectrophotometer 
(ThermoScientific) and 10 ng of mTK and TK3 was used to transform the E.coli MC1061 
competent cells.  
Note: at this stage the mTK had been moved to pET-22b(+) vector after few attempts to 
express the protein of interest while still in the original vector (pET-30a(+)).  
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Figure 2.1: A circular map of pET-22b(+) prokaryotic expression plasmid DNA (vector) and the 
multiple cloning site used to insert foreign DNA for expression of recombinant proteins. The proteins are 
expressed as is-fusion protein with the His tag (6XHis) at the C-terminal used for affinity purification of 
the proteins. The vector has a β-lactamase gene for Ampicillin resistance that is used to screen for pET-
22b(+) constructs. Ori denotes the origin of replication. 
 
The MC 1061 competent cells were retrieved from -80oC and thawed on ice. The cells 
were kept on ice for ±10 minutes, swirling gently every 2 minutes and gently mixed by 
tapping the tube. For each plasmid transformation, 100 μl of competent cells were 
transferred into a prechilled 1.5 ml eppendorf tube. The plasmid DNA containing either 
TK3 or mTK genes was added at a final concentration of 10 ng, to each tube of cells and 
swirled gently. For the transformation reaction controls, an aliquot of 100 μl of 
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competent cells with 10 ng of the pUC18 control plasmid and cells without plasmid 
DNA were prepared. All the reactions were incubated on ice for 30 minutes, then heat-
shocked by placing each transformation reaction on a heating block (HB/01 digital 
heating block, OMEG Scientific) set at 37°C for 30 seconds.  The reactions were 
returned to ice for further 2 minutes.  Then 0.9 ml of LB medium without antibiotic was 
added to each transformation reaction and incubated at 37°C for 1 hour with shaking at 
250 rpm in Multitron II Shaker Incubator.  
Using a sterile spreader, 100 μl of the cells transformed with the experimental DNA and 
cells only were spread onto LB agar plates that contained the appropriate antibiotic for 
selection of test plasmids.  Kanamycin antibiotic at 40 µg/ml was used for TK3 and 
mTK and ampicillin antibiotic for pUC18 (100 µg/ml). The plates were incubated at 
37°C overnight with the lid side upside down. The transformants appeared as colonies 
following overnight incubation and the transformation efficiency was calculated 
following the example, i.e.: 10 ng DNA used for transformation, 20 μl of transformation 
was plated and gave 120 colonies:  120 x 12.5 (plating factor) =1500 colonies/10 ng 
DNA = 150000 colonies/μg DNA = 1.5 x 10
5 
/μg DNA = Transformation efficiency. 
2.3.1.4 Colony PCR to analyse E. coli transformants 
Ten bacterial colonies per plate for mTK and twenty for TK3 were picked with a pipette 
tip and swirled  into 10 μl of nuclease free water (nH2O) in an autoclaved 0.2 ml PCR 
microcentrifuge tube, the cells were mixed by pipetting up and down 4 or 5 times. One 
micro litre of the colony sample was transferred into a pre-labelled PCR tube and used 
as template. The genes of interest were amplified by vector specific primers. The primer 
DNA sequences are as follows: T7 forward primer 5’-TAATACGACTCACTATAGGG-
3’ and the T7 reverse primer 5’-GCTAGTTATTGCTCAGCGG-3’. 
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The PCR cocktail sample was prepared as indicated in Table 2.3. The negative control 
(1 µl of nH2O) and positive control (1 µl of DNA from pET 30a(+) construct) were 
included. 
                             Table 2.3: Preparation of PCR reaction cocktail per reaction. 
 
 Reagents Initial concentration  Final concentration 
dNTPs  10 M 0.2 M 
T7 Forward primer  10 M 0.4 M 
T7 Reverse primer  10 M 0.4 M 
MgCl2  25 mM 0.5 mM 
Green Go Taq Flexi 
buffer  
5 X 1X 
Go Taq pol 5U/l 0.05 U/l 
The PCR reaction cocktail was prepared in a 1.5 ml eppendorf tube pre-chilled on ice to 
give the desired number of reactions (9 l of PCR reaction cocktail mix per 1 reaction). 
Sterile nH2O was used to make up the final volume. The cocktail mixture was mixed by 
vortexing briefly then 9 l was aliquoted into pre-labelled 0.2 ml PCR tubes containing 
template DNA to make a final volume of 10 l. The PCR reaction mixture was briefly 
mixed by vortex and amplified using GeneAmp® PCR system 2700 (Applied 
Biosystems). The PCR reaction was carried out following the reaction cycles below:  
 
Cycling steps:  
94C - 2 minutes to completely denature the DNA and inactivate nucleases 
94C - 30 seconds (Denaturation step) 
65C - 30 seconds (Annealing step)                        30 cycles 
72C – 1 minute (Initial extension step)    
72C - 5 minutes (Final extension step) 
 
 
The samples were analysed on a 1% agarose gel containing ethidium bromide stain 
after amplification process, the gel images were captured by the UVP Bioimaging 
Systems. 
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2.3.1.5 Preparation of mTK and TK3 plasmid DNA 
The clones that were positive for PCR were transferred into a 50 ml centrifuge tube 
containing 10 ml LB with appropriate antibiotics. The bacterial cells were grown 
overnight at 37oC while shaking. The glycerol stocks were prepared directly from 
overnight cultures, by adding an equal volume of overnight cultures and 80% sterile 
glycerol (500 µl each) and stored at -80oC. The remaining cultures were used to isolate 
plasmid DNA using Wizard® Plus SV Minipreps DNA Purification System (Promega), 
following the manufacturer’s instructions. 
Briefly, the cells were harvested by centrifugation at 6,000 rpm for 10 minutes. The 
supernatant was discarded and the pellet resuspended in 250 µl of cell resuspension 
solution and mixed by pipette. The cell suspension was transferred into a sterile 1.5ml 
microcentrifuge tube, 250 μl cell lysis solution was added to the cells. The cells were 
mixed by inverting the tube 4 times and incubated for 1-5 minutes. Alkaline protease 
solution (10 μl) was added to the cell suspension, mixed by inverting the tube 4 times 
and incubated at RT for 5 minutes.  Neutralization solution at 350 μl was added, the 
cells were mixed and spun at 14,000 rpm for 10 minutes. The supernatant was carefully 
transferred to the spin column and spun at 14,000 rpm for 1 min at RT. The flow 
through was discarded and the spin column washed twice, first with 750 μl, then 250 μl 
of column wash solution diluted with 95% ethanol. The column was spun for 1 minute 
after the first wash and 2 minutes for the last wash, the flow through was discarded. The 
column was transferred to a sterile 1.5 ml microcentrifuge tube, the plasmid DNA was 
eluted by adding 100 μl of nH2O to the column.  The column was centrifuged at 
maximum speed for 1 minute, the DNA concentration was determined by NanoDrop® 
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ND-1000 Spectrophotometer. At this stage the DNA samples can be stored at -20°C 
until further analysis. 
2.3.1.6 DNA sequencing 
The positive mTK and TK3 constructs were sequenced to verify that the coding 
sequence was in the correct reading frame and that no mutations had occurred. The 
glycerol stocks containing the constructs were streaked in agar plates containing 
appropriate antibiotics. The plates were incubated at 37oC overnight. The agar plates 
containing mTK and TK3 clones were sent to InqabaBiotech (Pretoria, SA) for DNA 
sequencing using T7 vector specific primers. The resulting sequences were analysed by 
FinchTV (http://www.geospiza.com/finchtv) and translated to amino acid sequences 
using ExPASy Bioinformatics resource portal (http://au.expasy.org/tools/dna.html). The 
forward and reverse sequences were compared with each other using the Blast 2 
sequence alignment tool (http://www.ncbi.nlm.nih.gov/BLAST/bl2seq/wblast2.cgi). 
2.3.1.7 Transformation of mTK and TK3 into expression cells  
The ArcticExpress competent cells were transformed with 10 ng recombinant mTK and 
TK3 plasmid DNA following the protocol described in section 2.1.1.3. The 
transformants were plated in LB agar plates containing 40µg/ml G418 and either 40 
µg/ml kanamycin for TK3 and 200 µg/ml ampicillin for mTK. 
  
2.3.1.8 mTK and TK3 recombinant protein expression screening and solubility test 
The fusion proteins were expressed in ArcticExpress competent cells. Eighteen to 
twenty colonies were picked from the LB agar plates and inoculated in 10 ml of LB 
containing 40 µg/ml G418  and 40 µg/ml kanamycin (TK3) or 200 µg/ml ampicillin 
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(mTK) antibiotics. The colonies were grown overnight at 37oC in a Multitron shaker 
incubator. Five hundred microliter of the overnight culture was used to prepare glycerol 
stocks and kept at -80oC for future use. The remaining overnight culture was diluted 
(1:10) with fresh LB media containing appropriate antibiotics. The cells were grown at 
37oC until the OD550nm reached 0.4-0.8. Protein expression was induced by addition of 1 
mM isopropyl-L-thio-h-D-galactopyranoside (IPTG) and the culture was moved to the 
incubator set at 15oC for 48 hours.  
To test solubility of the recombinant proteins, the bacterial cells were harvested by 
centrifugation at 3750 rpm for 10 minutes at 4oC in pre-weighed 15 ml conical tubes 
using Allegra X-15R Refrigerated Centrifuge (Beckman coulter). The supernatant was 
discarded and the cell pellet was resuspended in 500 µl BugBuster Reagent by gently 
vortexing or by pipetting up and down until the cell suspension is homogeneous. 
Following incubation at RT shaking for 10 minutes, the cell suspension was spun at 
3750 rpm for 10 minutes at 4oC to separate the soluble proteins from the insoluble 
proteins. The supernatant was transferred into a clean tube as soluble sample and the 
pellet was resuspended with 500 μl of BugBuster Reagent as insoluble sample. The 
uninduced and induced samples were analysed by SDS-PAGE. 
2.3.1.9 Analysis of protein expression by SDS-PAGE  
Recombinant protein expression was analysed by SDS-PAGE on a 12-15% acrylamide 
gel using the Mini Protean III system (Bio-Rad) with 1 mm thickness gels. Twenty µl 
of the induced and un-induced samples were mixed with an equal amount of 2X 
Laemmli sample buffer in a microcentrifuge tubes. The samples were boiled at 95oC for 
5 minutes in a block heater (Stuart Scientifica). The samples were left to cool at RT 
then pulse spun for 8 seconds at 14 000 rpm. After loading the samples on the gel, the 
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gel was run at 110 V through the stacking gel and at 120 V through the resolving gel. 
After electrophoresis the gels were stained with Coomassie staining solution for at least 
15 to 30 minutes while shaking on an orbital shaker (Storvall Life Science Incorporated, 
USA). The gels were then destained and images captured with UVP Bioimaging 
system. 
 2.3.1.10 Large Scale expression of the Recombinant Proteins 
Two samples that showed expression of mTK and TK3 were inoculated into 200 ml LB 
broth containing appropriate antibiotics (40 μg/ml kanamycin and G418 for TK3; 200 
μg/ml ampicillin and 40 μg/ml G418 for mTK) using the glycerol stocks. The cultures 
were incubated at 37°C with shaking at 250 rpm overnight.  The next morning, the cells 
were subcultured into a 2 litre fresh LB medium in a 5 litre flask with appropriate 
antibiotics and cultured following the steps in section 2.3.1.9. After the end of the 
induction period, the cells were harvested by centrifugation at 6,000 rpm for 15 minutes 
using a Sorvall RC6 plus centrifuge. The supernatant was discarded and the cell pellets 
were resuspended in 10 ml of 1X PBS. The cell suspension was sonicated on ice, 3 X 
30 seconds. The samples were spun as before, the supernatants were transferred into a 
clean tube. The pellets containing the protein of interest (both mTK and TK3 
recombinant protein are insoluble) were resuspended in the binding buffer [20 mM 
Tris-HCl pH 8.0, 500 mM NaCl, 5 mM imidazole pH 7.9, 8 M urea, 1 mM 
phenylmethylsulfonyl fluoride, and 0.5 mM DTT] (adapted from Kwon et al, 2008), 
and the cell suspensions were clarified by centrifugation as before. The supernatant was 
collected into a clean tube and used for affinity purification.  
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2.3.1.11 Affinity purification of recombinant proteins 
The recombinant proteins were purified under denaturing conditions using HIS-Select® 
Nickel Affinity Gel following the manufacturer’s instructions. 1 ml HIS-Select Nickel 
Affinity Gel was transferred into a chromatography column (referred as Ni-NTA 
column), the column was washed with 2 volumes of dH2O and equilibrated by 3 
volumes of binding/ equilibration buffer (20 mM Tris, 500 mM NaCl, 5 mM Imidazole, 
8 m Urea and 0.5 mM DTT).  
The supernatants of the insoluble fraction were subjected to purification on a Ni-NTA 
column under denatured conditions. The supernatants containing the insoluble proteins 
(mTK/ TK3) obtained from 2.3.1.10 were loaded into the equilibrated Ni-NTA column 
and incubated at RT shaking for 30 minutes. The flow through was collected into a 
clean tube. The high background of contaminating bacterial proteins was removed/ 
washed by stepwise addition of increasing imidazole concentrations at pH 7.9 (0, 10, 
30, 50, 100 mM) in a buffer containing 20 mM Tris-HCl pH 8.0, 500 mM urea, 0.5 mM 
DTT, 1 mM PMSF. The washing steps were repeated twice with 10 ml buffer. The 
target recombinant proteins were eluted using an elution buffer [20 mM Tris-HCl pH 
8.0, 500 mM urea, 300 mM imidazole pH 7.9 and 8 M urea). The column was washed 
with 1 M imidazole to remove all that was bound to the column, the beads were stored 
in 30% ethanol with 1% sodium azide. The collected fractions were analysed by SDS-
PAGE for the presence of the recombinant protein, and stained with Coomassie and 
destained as highlighted in section 2.3.1.9. 
The fractions (2 X 10 ml) that contained the protein of interest were pooled, dialysed in 
1X PBS and concentrated to 2 ml using a SnakeSkin Dialysis Tubing, 10 000 MWCO 
(22 mm X 35 feet dry diameter, ThermoScientific) 4 hours to overnight. Reverse 
 
 
 
 
 80     
dialysis was carried out using sucrose. The recombinant proteins in elution buffer were 
added into the snakeskin tubing and placed into a clean container. Sucrose was then 
sprinkled on top of the tubing and allowed to stand until required volume was achieved 
at 4oC while shaking. The protein concentration was estimated by taking absorbance at 
280 nm wavelength using NanoDrop® ND-1000 Spectrophotometer. The fusion 
proteins were stored at -20oC until required. 
2.3.1.12 Western blotting  
Twenty microliters of mTK and TK3 recombinant protein together with the flow 
through and the washes, were resolved by 12% SDS-PAGE following the same 
conditions as described in section 2.2.1.9. The proteins were electroblotted onto 
polyvinyl difluoride (PVDF) using the wet transfer. Briefly, the filter paper and the 
fibre pads (the size of the gel) were soaked in cold 1X blotting buffer for 10 minutes 
prior to use. The PVDF membrane was activated by dipping into absolute methanol for 
30 seconds and rinsed in 1X blotting buffer as soon as the gels are ready. The 
membrane sandwich was assembled according to the manufacturer’s instructions using 
forceps to handle the membranes and filter papers. The sandwich was placed into the 
cassette and into the transfer tank. The tank was filled with 1X blotting buffer, and the 
cooling block was placed into the transfer apparatus. The tank was then placed on ice 
and the protein bands transferred at 110 V for 90 min. The prestained marker was used 
to ascertain the efficient transfer of proteins from the gel to the membrane. The 
membranes were rinsed with 1X tris-buffered saline tween-20 (TBST) and incubated 
with the blocking buffer (5% Carnation non-fat dry milk in 1X TBST) for 1 hour while 
shaking on an orbital shaker at RT. The blocking solution was discarded and the 
membranes washed with 1X TBST three times for 10 minutes each.  
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The membranes were probed with 1:5000 His-probe (H-3) mouse monoclonal HRP-
conjugated antibody prepared in antibody binding buffer overnight at 4°C. The 
membranes were washed three times in 1X TBST for 10 minutes each. Then, 1 ml of 
SuperSignal® West Pico Chemiluminescent Substrate was added per blot, the reactive 
bands were captured and imaged using the UVP Bioimaging System.  
2.3.2 Cell culture 
The cell lines used in this study were obtained from the American Type Culture 
Collection (Table 2.4). The cell lines were regularly cultured in T25 cm2 culture flasks 
(Sigma) at 37°C in a 5% CO2 humidified incubator in DMEM cell culture media.  The 
media was supplemented with 10% heat-inactivated foetal bovine serum (FBS), 1% 
penicillin-streptomycin and 1% non-essential amino acid solution, this media mix will 
be referred as complete media from now henceforth. The media were changed and 
replaced with fresh complete media every three days. The procedures were performed 
in the Biological Safety Cabinet (Laminar flow) using aseptic techniques, all the regents 
to be used were sprayed with 70% ethanol before introducing them into Laminar flow. 
                                  Table 2.4: Cell lines used for screening of PHB expression. 
 
Cell line Acronym Disease Species 
Colon cancer Caco-2 Colorectal 
adenocarcinoma 
Homo sapiens 
Chinese Hamster 
Ovary cells 
CHO-K1 Normal Cricetulus griseus hamster 
Cervical cancer Hela adenocarcinoma Homo sapiens 
Breast cancer MCF 7 adenocarcinoma Homo sapiens 
Colon cancer HT-29 Colorectal 
adenocarcinoma 
Homo sapiens 
Human Fibroblasts KMST-6 Normal Homo sapiens  
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2.3.2.1 Cell splitting and trypsinization 
The cells were split when they reached ≥70% confluency, the media was removed from 
flask using 10 ml serological pipette into a waste beaker. The cells were rinsed with 3 
ml of D-PBS and discarded into a waste beaker, 3ml of 2X trypsin was added to the 
cells and incubated for 1-3 minutes at 37oC. The detachment of the cells from the flask 
was inspected with light microscope. As soon as the cells start to round up, the 
detachment was facilitated by gently tapping the flask on the surface to dislodge the 
cells. The reaction was terminated by adding 2 volumes of complete medium. The cells 
that were still attached to the flask were removed by pipetting. The cells were then 
transferred to the prelabeled 15 ml conical tubes and centrifuged at 3000 rpm for 5 
minutes. The supernatant was removed by aspiration or pipetting into a waste beaker. 
The cells were resuspended in 1-5ml complete media, cell count was performed and the 
appropriate number of cells was sub-cultured. 
2.3.2.2 Cell count/ viability: Trypan Blue Exclusion Assay 
 
Cell viability was performed using trypan blue exclusion assay by the Countess® 
Automated Cell Counter (Life Technologies) following manufacturer’s instructions. 
Briefly, 10 μl aliquot of trypsinized cell suspension was mixed with 10 μl of 0.4% 
trypan blue dye reagent. The cells were mixed by pipetting. 10 μl of the cell-dye 
mixture was loaded into a Countess™ chamber slide (Life Technologies), followed by 
cell count, the data readout was given in total cells/ml, live cells/ml, dead cells/ml, and 
percent viability. 
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2.3.3 Evaluation of PHB expression in various cell lines 
2.3.3.1 Western blot analysis of PHB expression 
a) Protein Extraction 
Several cancerous and non-cancerous cell lines from humans and one from a hamster as 
shown in Table 2.4, were cultured to screen for PHB expression. The cells were seeded 
at 5x105 cells/ml in a 6 well plate until they reached ≥ 80% confluency. Protein was 
extracted from the cells using CytoBuster Protein Extraction Reagent following 
manufacturer’s instructions. The culture medium was removed from the plate. The cells 
were washed with 2 ml 1X PBS. Upon removal of PBS, protein was extracted from the 
cells by adding 100 µl of CytoBuster reagent and incubated at room temperature for 5 
minutes. The cell debris was scraped from the 6 well plates using Nunc™ cell scrapers 
and transferred into a 1.5 ml eppendorf tube. The cells were spun at 14,000 rpm (4°C) 
for 5 minutes in an Eppendorf refrigerated microcentrifuge Model 5417R (Sigma-Aldrich). 
The soluble cytosolic fraction or supernatant containing the protein sample was 
collected into a clean tube.  The protein sample was stored at -20oC until further 
analysis.  
b) Protein Quantification  
 
The protein concentration in cell lysates was estimated using the Bradford assay with 
bovine serum albumin (BSA) as a protein standard (Bradford, 1976). Different standard 
concentrations (0, 25, 125, 250, 500, 750 and 1000 µg/ml) were prepared from a 1 
mg/ml BSA stock solution. The ingredients were mixed together with the Bradford dye 
reagent added last as illustrated in Table 2.5 in a 94 well plate. The samples were 
incubated for 30 minutes at RT. The absorbance was read at 595 nm using POLARstar 
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Omega plate reader (BMG Labtech).  The absorbencies of both the standards and 
protein samples were recorded. The samples were prepared in triplicate.  
 
                               Table 2.5: Preparations of the standards and sample for protein estimation. 
                                     STANDARD PREPARATION CELL SAMPLE 
                                                              Amount required (µl) 
[BSA] (µg/ml) 
 
BSA standard 
 
25 
 
20 
125 
 
20 
500 
 
20 
750 
 
20 
1000 
 
20 
- 
 
0 
Cell sample 0 0 0 0 0 20 
 
Bradford reagent 200 200 200 200 200 200 
       
 
The absorbance values of the standards were used to plot a standard curve: absorbance 
versus [BSA]. The equation generated by the linear regression was used to calculate the 
concentration of the protein sample using the measured absorbance.  
c) SDS-PAGE and Western blot analysis 
The samples were retrieved from -20oC and thawed on ice. The samples were analysed 
by SDS-PAGE on a 12% acrylamide gel as in section 2.3.1.9. Sample containing 20 µg 
of protein was loaded in the gel for western blot analysis following the steps in 
described in section 2.3.1.12. The membranes were probed with 1:5000 purified anti-
prohibitin rabbit antibody, followed by 1: 10 000 anti-rabbit IgG-HRP secondary 
antibody prepared in antibody binding buffer. 
2.3.3.2 Localization of PHB using immunocytochemistry 
 
The cells that showed expression of PHB (Caco-2 and MCF 7 cells) were seeded in a 6 
well plate with glass coverslip at a density of 1x104 cells/well. The cells were incubated 
for 24 hours at 37°C. The media was replaced with media containing 0.01 mM AHD-
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FITC and incubated at 37°C for 3 hours. The culture medium was discarded, and the 
cells were washed twice with 1X PBS. The cells were fixed for 10 minutes with 4% 
(v/v) paraformaldehyde and washed twice with 1X PBS then permeabilized with 0.1 % 
Triton X-100 for 5 minutes. The cells were washed thrice and the coverslips were 
transferred to a microscope slide containing a mounting media and nuclear stain 
(Fluoroshield-DAPI). The cells were visualized under Axioplan-2 Imaging Fluorescent 
Microscope (Zeiss) using green and blue filters. 
 
2.3.4 The effect of mTK and TK3 recombinant proteins by MTT assay 
 
The cellular viability was assessed by measuring the cell proliferation using a 
mitochondrial reduction activity or MTT assay. Briefly, 100 µl Caco-2 cells per well at 
1x105 cells/ml density were seeded in 96-well culture plates overnight. The medium 
was replaced with fresh medium containing TK3 or mTK at different concentrations (0- 
8 µM). The cells were treated for 24 hours at 37oC, 10 µl of 0.5 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution was added to 
each well and incubated for 4hours. The MTT solution was removed and the cells were 
then lysed with 100 µl DMSO to dissolve the insoluble formazan salt. The colour 
intensity was quantified by measuring the absorbance at 570 nm using a PolarSTAR 
Omega microplate reader (BMG Labtech), 650 nm was used as a reference wavelength. 
The cell viability was expressed as the percentage ratio of treated cells against untreated 
cells.  
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2.3.5 The design and development of the nanotherapy 
2.3.5.1 Fabrication of the gold nanoparticles 
 
The AuNPs were prepared following the classical method devised by Turkevich et al. 
(1951), using trisodium citrate as reducing agent in aqueous solution of hydrogen 
tetrachloroaurate (HAuCl4). All glassware used for this process was cleaned in aqua 
regia (3 parts HCl, 1 part HNO3), rinsed with distilled H2O, and then oven dried. An 
aqueous solution of HAuCl4 was brought to boiling in a volumetric flask and stirred 
continuously with a stirrer bar on a hot plate. An aliquot of a 38.8 mM trisodium citrate 
solution was added quickly at one time, resulting in a change in solution colour from 
pale yellow to colourless, very dark blue, purple, and finally wine red. After the colour 
change the solution was kept boiling for 30 minutes, the heat was switched off and 
allowed the solution to cool while stirring. The solution was subjected to high-speed 
centrifugation at 12,000 rpm for 15 minutes to isolate the particles. The pellet was 
washed in dH2O after discarding the supernatant. The process was repeated three times 
to eliminate the free citrate. The resulting particles were coated with negatively charged 
citrate.  
 
2.3.5.2 Characterization of functionalised gold nanoparticles 
 
The 14 nm citrate stabilized AuNPs were functionalized for biological application by 
conjugating targeting and therapeutic peptides to them. The prohibitin targeting 
molecule (AHP) was conjugated to AuNPs through biotin-streptavidin chemistry, to 
enhance the cellular uptake of the nanotherapy and increase cellular retention of the 
therapeutic peptide for sustained antiproliferative activity. A free thiol group in the 
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Cysteine residue was introduced in the therapeutic peptide to facilitate its adsorption to 
the gold surface.  
 
The resulting AuNPs including the citrate-coated NPs were characterized by UV-Vis 
absorption spectroscopy using JASCO V-570 spectrophotometer to study the peak 
absorption band. Transmission Electron Microscope (TEM) of the various AuNPs were 
collected on a Philips CM200 TEM (Mintek). The operating voltage range was 20–200 
kV with a resolution of 2.4 A°. Zeta potential measurements were performed using a 
Malvern Zetasizer Nano ZS (Advanced Materials, Mintek) operating with a variable 
power (5–50mW) He-Ne laser at 633nm.  
2.3.5.3 Quantification of AuNPs by ICP-OES 
The NPs were diluted 1:10 in 1X PBS to a final volume of 500 µl and spun at 14,000 
rpm for 5 minutes in a microcentrifuge. The pellet was lysed with 2 ml of aqua regia 
(3:1 HCl:HNO3) solution. The samples were digested by incubation at 90
oC for 2 hours, 
the samples were then diluted with 2% HCL to give a total sample volume of 10 ml. At 
this stage, the cell suspension could be stored at −20°C until analysis. 
These samples were then analysed for total gold content by a Varian 710-ES ICP 
Optical Emission Spectrometer (Varian) at the Chemistry Department (University of the 
Western Cape). The measurement was repeated 3 times for each sample submitted, the 
values reported were based on a calibration curve using a gold ICP standard (Sigma-
Aldrich). To determine the total amount of AuNPs per sample, the detected amount of 
each sample was multiplied by the dilution factor.  
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2.3.6 IN VITRO NANOPARTICLE UPTAKE AND LOCALIZATION STUDIES  
The Caco-2 cells were grown to ≥70% confluency before splitting and re-seeding at 20-
30% confluency. The cells were grown under the conditions described in section 2.3.2.1 
for 18-24 hours before the cells were treated. The cells were treated at 50 to 70% 
confluency for 24 hours. 
2.3.6.1 Effect of the nanotherapy on cell proliferation: the WST-1 assay 
 
The cytotoxicity of AuNPs on the Caco-2 cells was evaluated using water-soluble 
tetrazolium salts-1 (WST-1) cell proliferation reagent with the chemical formula: 2-(4-
Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt. 
The assay was performed following manufacturer’s instructions.  
 
The Caco-2 cells were seeded at a density of 1x105 cells/well in a 96 well plate, 100 µl 
per well.  The cells were incubated for 24 hours at 37oC in a 5% CO2 humidified 
incubator. After 24 hours, the media was removed from each well and replaced with 
100 µl of media with varying concentrations of the AuNP conjugates ranging from 0-8 
nM. The AuNPs stock was prepared at 10 mM in complete media for treatment. The 
cells that were incubated with AuNPs-free medium were considered as control samples 
(untreated cells). One well consisted of 100 µl media without cells and served as a 
blank. The cells were treated for 24 hours, then 10 µl WST-1 cell proliferation reagent 
was added to all the wells. The cells were incubated at 37°C for 3 hours then covered in 
foil and shook for 1 min in an orbital shaker at RT.  
 
The absorbance of the formazan product formed was measured at 440 nm wavelength 
(λ), with background subtracted at the λ of 630 nm using a PolarSTAR Omega plate 
reader. Each sample point was performed in triplicate. The percentage of cell viability 
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was calculated by comparing the absorbance of the test samples with the absorbance of 
the control (untreated) samples. The data reported represent the average means of 
triplicate measurement from two independent experiments. The average IC50 values of 
NPs were estimated from a plot of the percentage of viable cells versus concentration. 
2.3.6.2 Cellular uptake and localization of the AuNPs 
The cellular uptake and localization of various AuNP conjugates was investigated using 
ICP-OES and TEM, respectively. The cells were seeded at a density of 1x105 cells/well 
on a 24-well cell culture plates for ICP-OES analysis, and 1x106 T25 cm2 flask for TEM 
analysis. The cells were treated with non-toxic concentrations of the AuNPs at 4 nM 
and cultured for 24 hours.  
a) Quantification of AuNP uptake by ICP-OES analysis 
The amount of nanomaterials taken up by cells was quantified by ICP-OES. Cells were 
seeded on 24 well plates (Sigma). After reaching confluence the medium was replaced 
by the 1 ml of various nanoparticles suspension using their IC50 concentrations, 
untreated control was included. After 24 hours, the floating cells were transferred into a 
15 ml centrifuge tubes. The adherent cells on the wells were washed with PBS and 
detached by trypsin incubation and transferred into the corresponding 15ml centrifuge 
tube. The cells were spun at 3000 rpm for 3 minutes, the pellet was washed once with 2 
ml 1X PBS. One millilitre of various AuNPs at the IC50 concentration was spun down 
and used to determine the concentration used to treat the cells. To the cell lysate and 
crude AuNPs, 2 ml of aqua regia solution was added. The samples were digested and 
prepared for ICP-OES analysis following the steps described in section 2.3.4.3.  
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To determine the percentage of particles internalized by the cells, the total amount of 
gold nanoparticles administered was divided by the concentration detected by ICP-OES 
on the treated cells and multiplied 100%.  
b) Cell specimen preparation for TEM 
 
The Caco-2 cells were cultured in a T25 cm2 flask at a density of 1x106 cells /ml and 
cultured for 24 hours. The cells were exposed to various Au NPs treated with IC50 
concentrations for 24 hours. The supernatant with floating cells was transferred into 15 
ml conical tubes and spun at 3000 rpm for 3minutes. The adherent cells in the flask 
were washed with 2 ml 1X PBS twice, the supernatant was added to the floating cells. 
The floating cells were spun at 3000 rpm, the pellets were resuspended in 100 µl of 4% 
paraformaldehyde fixative (in 0.1M phosphate buffer, pH 7.2) and transferred back into 
the flasks. The volume of the 4% paraformaldehyde was adjusted to a final volume of 2 
ml. The flasks were allowed to shake at 4°C for 5 – 15 minutes. The cells were removed 
from the flask by a cell scrapper and transferred into a 2 ml eppendorf tube using a pre-
cut tip. The cell suspension was centrifuged at 3000 rpm for 5 minutes. The pellet 
samples (cell pellets) were stored in approximately 100 μl of 2.5% glutaraldehyde at 
4°C until further analysis. The samples were analysed by Jeol JEM-1011 electron 
microscope at the Tygerberg Hospital, NHLS pathology Unit.  
2.3.6.3 Mode of cell death induced by AuNP conjugates 
Several biochemical and cytometry assays were conducted to determine whether 
incorporating therapeutic peptide D(KLAKLAK)2 to the AuNPs would alter peptide 
activity.  
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a) Analysis of apoptosis cell death induced by AuNP conjugates 
 
The percentage of cells undergoing apoptosis were detected and quantified by using the 
APOPercentageTM apoptosis assay (Biocolor, UK). The cells were seeded in a 12-well 
culture plates at a density of 2x105 cells/ml and incubated for 24 hours at 37oC. The 
culture media was then removed and replaced with media containing IC50 of the 
AuNPs. The cells were then incubated for 24 hours at 37oC. Untreated and cells treated 
with apoptosis inducing agents were included as controls. 
 
After incubation, all the media from each well containing floating cells, was transferred 
to 15 ml conical tubes using a sterile pipette. The wells were washed with 1 ml DPBS 
and transferred into the corresponding 15 ml conical tubes containing floating cells. The 
cells were detached using 2X trypsin and transferred to their corresponding 15 ml 
conical tubes. Cells were harvested by centrifugation at 3000 rpm for 5 minutes at RT. 
The supernatant was discarded, the pellet was gently re-suspended in 250 µl of a 1:160 
diluted APOPercentageTM dye diluted in complete DMEM media. The cells were 
incubated for further 30 minutes at 37oC, 4 ml of 1X PBS was then added to each tube 
and centrifuged at 3000 rpm for 5 minutes at RT. The supernatant was discarded and 
the cell pellets were re-suspended in 300 µl of 1X PBS. Cell staining was measured by 
Attune Acoustic flow cytometer (Applied Biosystems, Germany) or Accuri flow 
cytometer (BD Biosciences). Acquisition was done in log mode and a maximum of 
10 000 to 30 000 events per sample were acquired and analysed using Attune software 
(Applied Biosystems, German) and Flowjo software. 
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b) Western blotting analysis of Caspase 3 activation  
Caco-2 cells were seeded at 5x105 cells/ml in a 6 well plate then treated with various 
AuNP conjugates for 24 hours. The cells were trypsinized and harvested from each 
sample by centrifugation. Protein was extracted from the cells using CytoBuster Protein 
Extraction Reagent following manufacturer’s instructions. Protein was quantified by 
Bradford assay as described previously. Caspase 3 expression levels were examined 
using SDS-PAGE and Western blotting, as described in section 2.3.1.12. Equal amounts 
of protein (10 μg) from each sample were separated by 12% SDS-PAGE and transferred 
to PVDF membrane. The membrane was probed with 1:1000 caspase 3 rabbit 
polyclonal primary antibody overnight at 4°C. After washing with TBST, the 
membrane was incubated with goat anti-rabbit HRP-conjugated secondary antibody that 
was diluted 1:10 00 in TBST for 1 hour at room temperature. Actin-HRP mouse 
monoclonal IgG1 at 1:5000 dilutions was used as a loading control. The reactive bands 
or chemiluminescent signals were captured and imaged using the UVP Bioimaging 
System.  
c) Analysis Caspase 9 activation by Flow Cytometry  
Caspase 9 activity was assessed using CaspaLux 9-M1D2 substrate (OncoImmunin, 
Inc), according to manufacturer’s instructions. Briefly, 2x105 cells/well of Caco-2 cells 
were grown in a 12-well plate, the cells treated with various AuNP conjugates at IC50 
for 24 hours. The cells treated with 50 µM cisplatin were used as positive control. The 
cells were detached using trypsin after 24 hours treatment, washed with 1X PBS and 
transferred into 2 ml eppendorf tubes.  The cells were harvested by centrifugation at 
3000 rpm for 5 minutes and 50 μl of 10 μM CaspaLux 9-M1D2 substrate solution was 
added to the cell pellet, mixed by pipetting and incubated at 37˚C for 60 minutes. The 
cells were washed once by adding 1 ml of 1X PBS and centrifuged as before. The cell 
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pellets were resuspended in 300 µl fresh PBS. Caspase 9 activity was determined and 
analysed by Accuri flow cytometer within 60 to 90 minutes.  
d) Mitochondrial dysfunction: ROS activity 
 
The intracellular ROS generation in cells exposed to the AuNP conjugates was 
investigated using the 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein 
diacetate acetyl ester (CM-H2DCFDA) fluorescence probe (Life Technologies). The 
Caco-2 cells were seeded in a 12 well plate at 2 X 105 cells/ml density and cultured at 
37oC overnight. The cells were treated with AuNPs at IC50 for 24 hours. Cells treated 
with 50 µM cisplatin were used as an apoptosis inducer control, H2O2 as a positive 
control induction of ROS. Cells were detached using trypsin, washed twice with 2 ml of 
1X PBS and resuspended in 350 µl of 7.5 μM DCFH-DA prepared in PBS. The cells 
were incubated at 37°C incubator for 30 minutes. Then 4ml of PBS was added to the 
sample and centrifuged as before. The pellets were resuspended in 350 µl 1X PBS. The 
mean fluorescence intensity in the cells was determined by Attune or Accuri flow 
cytometers.  
2.3.7 Statistical analysis 
Statistical and multiple-comparison analyses were performed within each group. Data 
were expressed as the mean ± standard deviation of the three replicates. Statistical 
analysis was conducted using the GraphPad Prism® 6 and  two-tailed Student’s t-test, 
differences among three or more groups were analysed by one or two-way analysis of 
variance (ANOVA). The differences with P <0.05 were considered statistically 
significant. The IC50 values were calculated using the GraphPad Prism
® 6 by plotting 
the log concentration of the treatment versus percentage cell viability. 
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Chapter 3:  Recombinant expression and purification of a pro-
apoptotic protein  
3.1 Introduction 
The study aims to develop a targeted anti-angiogenic nanotherapy that can be 
selectively delivered to PHB-expressing ECs in the WAT vasculature of obese subjects 
and trigger cell death in the ECs through apoptosis. The PHB-targeted nanotherapy is 
composed of a recombinant pro-apoptotic protein (TK3) that will serve as treatment.  
The pro-apoptotic protein (TK3) and the mutated protein (mTK) used in this study were 
produced through RDT, the biological effects of the two recombinant proteins were 
investigated using Caco-2 cells as a model cell line for ECs in the WAT of obese 
subjects. The recombinant TK3 protein is composed of a synthetic pro-apoptotic 
peptide, D(KLAKLAK)2 fused to a basic TAT (RKKRRQRRR) domain and caspase-3 
cleavage site (DEVD), cloned into a pET 30a+ vector as described in section 2.3.1.1. 
mTK was used as a negative control, and was composed of TAT and a scrambled 
peptide (DLSLARLATARLAI). The recombinant proteins were expressed with TAT as 
the protein transduction domain (PTD), which will facilitate cellular uptake of the 
recombinant proteins. The PTD has multiple arginine and lysine residue that facilitate 
internalization of TAT and its cargo through endocytosis (Frankel and Pabo, 1988).  
The D(KLAKLAK)2 peptide is an amphipathic, α-helical peptide composed of 14 amino 
acids in a D-enantiomer to avoid its degradation by proteases in biological systems 
(Ellerby et al., 1999). It has anti-bacterial activity and is capable of killing cells at a 
very low dosage.  This polycationic peptide has antimicrobial activity that is triggered 
once the peptide penetrates the anionic bacterial membranes and disrupts the 
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mitochondrial function in vitro (Fantin et al., 2005; Javadpour et al., 1996). The 
D(KLAKLAK)2 peptide is non-toxic to eukaryotic cells as it cannot disrupt the 
zwitterionic plasma membranes of the eukaryotic cells by itself (Ellerby et al., 1999). 
However, the internalization of the peptide through PTD into mammalian cells was 
shown to disrupt the negatively charged mitochondrial membrane and induces 
cytochrome c release leading to cell death by apoptosis (Ellerby et al., 1999; Fantin et 
al., 2005).  
The use of this peptide can be enhanced by developing targeting and internalization 
strategies into mammalian systems. TAT has been fused to D(KLAKLAK) peptide to 
enhance its internalization by the cells. However, the activity of the TAT in vivo is 
compromised by its lack of specificity (Sandoval et al., 2007; Vivès et al., 2008).  PTDs 
are readily taken up by cells following the mechanisms described in section 1.2.2. 
Targeting peptides, unlike PTDs, specifically home to target cells and can be used for 
intra- and extracellular targeting of therapeutic and diagnostic agents (Leifert et al., 
2002). Furthermore, the targeting peptides can enhance the therapeutic activity of its 
cargo and reduce toxic side effects at non-target sites through selective delivery. 
Targeting peptides are highly specific for certain biomarkers expressed by diseased 
cells and can be used to improve the efficacy of therapies. Attaching a targeting peptide 
to the D(KLAKLAK)2 peptide has been successfully used to induce cell death of 
vascular ECs in the WAT of obese mice (Kolonin et al., 2004) and HER-2 positive 
human breast cancer cells in vitro and mouse xenograft (Fantin et al., 2005). The 
strategy was effective even in cancer cells that were known to be drug resistant (Fantin 
et al., 2005). These studies demonstrated the potential application of the strategy in the 
treatment and eradication of chronic diseases.  
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3.2 Results 
3.2.1 Colony PCR: Screening for mTK and TK3 positive clones 
E. coli MC 1061 competent cells were transformed with pET22(b)+-mTK and pET30(a)+-
TK3 plasmid DNA as described in Section 2.3.1.4. Eighteen to twenty colonies for each 
construct were selected through antibiotic resistance and screened for the transformation 
of mTK and TK3 plasmids by colony PCR using T7 primers. A plasmid DNA 
amplifiable by the T7 primers was used as a positive control. The negative control with 
no DNA was included to check for non-specific amplification.  
 
Figure 3.1 shows the amplified plasmid DNA containing the mTK gene.  The amplified 
gene containing mTK in lane 1-18 was around 300 bp. The 18 ampicillin resistant genes 
tested positive with an amplicon at the expected size for the genes that had incorporated 
the mTK DNA. The positive control (+ve ctrl) showed an amplicon at 1kb.  
 
Figure 3.1: Amplification of mTK positive clones by colony PCR. Eighteen ampicillin-resistant 
colonies were selected to screen for recombinant mTK plasmids. The recombinant genes were amplified 
by PCR using T7 primers. Amplicons were analysed on a 1% agarose gel containing ethidium bromide 
stain. M=1 kb marker in bp, +ve ctrl = pET30(a+) construct used as a positive control, 1-18 = ampicillin-
resistant clones, arrow points at 300 bp amplicon representing mTK. 
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The TK3 positive clones were tested in a similar manner as mTK clones. Twenty 
kanamycin resistant colonies were amplified, all the clones that had taken up the gene 
are shown in Figure 3.2. This was confirmed by the amplicon size detected at 500 bp 
for TK3 in lane 1-20. The agarose gel electrophoresis showed no bands in the negative 
control sample (nH2O), confirming the specificity of the primers used. All the clones 
that tested positive were subcultured as described in methods for the extraction of 
plasmid DNA. 
 
Figure 3.2: Amplification of TK3 positive clones by colony PCR. Twenty kanamycin-resistant colonies 
were selected to screen for recombinant TK3 plasmids. The recombinant genes were amplified by PCR 
using T7 primers. Amplicons were analysed on a 1% agarose gel containing ethidium bromide stain. 
M=1 kb marker in bp, nH2O = nuclease free H2O was used as a negative control, 1-20 = kanamycin-
resistant clones, arrow points at 500 bp amplicon representing TK3. 
 
3.2.2 Sequence analysis of positive clones 
The positive clones for TK3 were sequenced to verify that the insert was present and 
that the coding sequence was in the correct reading frame and that no mutations had 
occurred during the cloning process. The T7 primers for the pET vector systems were 
used to amplify the inserted genes. The colonies on the agar plates were sequenced at 
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Inqaba Biotech (Pretoria), the resulting DNA sequence was analysed with FinchTV 
software and translated to amino acid sequence by using ExPASy software.  
The DNA sequences in both forward (F+) and reverse (R-) primers confirmed the 
presence of the TK3, composed of TAT, 3 repeating units of D(KLAKLAK)2 and the 
caspase-3 cleavage site (DEVD) as highlighted in Figure 3.3.  The Nde I and Xho I 
restriction sites were used to clone the genes in the pET vectors at the N- and C-
terminal, respectively. Although the sequence alignment showed mismatched bases at 
base pair 5 of the sequence generated with the forward primer and uncalled bases at 
base pair 373 and 376 sequence generated with the reverse primer, it can be concluded 
that the entire sequence of the construct has no mutations because the correct bases are 
included in the complementary sequence. The mismatched sequence can be attributed to 
sequence artefacts caused by failure of the base-caller to read the sequence accurately at 
the beginning or at the end of the sequence. 
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F+    2    TCCCGTCTAG-AATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGAAAGAAGC  60 
           |||| ||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
R-    43   TCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGAAAGAAGC  102 
 
F+    61   SMCGACAACGACGACGACTGCAGGATATCGGGTCTAAGCTCGCGAAGCTCGCGAAGAAGC  120 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
R-    103  GACGACAACGACGACGACTGCAGGATATCGGGTCTAAGCTCGCGAAGCTCGCGAAGAAGC  162 
 
F+    121  TCGCGAAGCTCGCGAAGGATGAAGTAGATGGAGGTGGATCTAAGCTCGCGAAGCTCGCGA  180 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
R-    163  TCGCGAAGCTCGCGAAGGATGAAGTAGATGGAGGTGGATCTAAGCTCGCGAAGCTCGCGA  222 
 
F+    181  AGAAGCTCGCGAAGCTCGCGAAGGATGAAGTAGATGGAGGTGGATCTAAGCTCGCGAAGC  240 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
R-    223  AGAAGCTCGCGAAGCTCGCGAAGGATGAAGTAGATGGAGGTGGATCTAAGCTCGCGAAGC  282 
 
F+    241  TCGCGAAGAAGCTCGCGAAGCTCGCGAAGGATGAAGTAGATGGAGGTGGATCCAAGCTTG  300 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
R-    283  TCGCGAAGAAGCTCGCGAAGCTCGCGAAGGATGAAGTAGATGGAGGTGGATCCAAGCTTG  342 
 
F+    301  GGCCCGAACAAAAACTCATCTCAGAAGAGGATCTGAATCTCGAGCACCACCACCACCACC  360 
           ||||||||||||||||||||||||||||| || ||||||||||||||||||||||||||| 
R-    343  GGCCCGAACAAAAACTCATCTCAGAAGAGRATSTGAATCTCGAGCACCACCACCACCACC  402 
 
F+    361  ACTGAGATCCGGCTGCTAA  379 
           ||||||||||||||||||| 
R-    403  ACTGAGATCCGGCTGCTAA  421 
 
Figure 3.3: TK3 DNA sequence (5’-3’) highlighting the restriction sites (Nde I and Xho I), TAT, D(KLAKLAK)-DEVDGGGS and Histidine (His)6 tag sequences. 
Mismatches, gaps, uncalled sequences, F+= forward primer, R- = reverse primer. 
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The DNA sequences in Figure 3.3 were translated using ExPASy software to check the 
amino acid sequence they code for. The translated sequences from both the forward (F+) 
and reverse (R-) primers, contained a PTD (TAT) at the N-terminal, followed by three 
tandem repeats of (KLAKLAK)2- fused to the caspase-3 cleavage site (DEVDGGGS) 
and a (Histidine)6 tag at the C-terminal as highlighted in Figure 3.4.  
 
5' Frame 3' 
   1 EGDIHMETRKKRRQRRRLQDIGSKLAKLAKKLAKLAKDEVDGGGS 
46  KLAKLAKKLAKLAKDEVDGGGSKLAKLAKKLAKLAKDEVDGGGS 
                                101  KLGPEQKLISEEDLNLEHHHHHH 
       
Figure 3.4: Translated sequence of TK3 amino acid sequence. Start codon, TAT, caspase cleavage 
site, pro-apoptotic peptide and (Histidine)6 tag sequences are highlighted. F+ = forward primer and R- = 
reverse primer sequences. 
 
3.2.3 Recombinant protein expression and purification 
3.2.3.1 Protein expression screen for mTK and TK3 
Large scale plasmid DNA was prepared from clones containing the mTK and TK3 
plasmid DNA. This plasmid DNA was used to transform ArcticExpress competent 
cells. An expression screen for the presence of recombinant Histidine-tagged protein 
was performed in a small scale culture. Seven TK3 and four mTK positive clones 
(which were selected based on the colony PCR screening) were subjected to IPTG 
induction to identify the clones that express the desired recombinant protein. The total 
bacterial lysates of the E. coli were resolved on a 15% SDS-PAGE as described in 
section 2.3.1.9, to analyse expression of the recombinant proteins among the bacterial 
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proteins. There was no detectable overexpression of any protein at the desired sizes for 
mTK or TK3 as shown in Figures 3.5 and 3.6, respectively.  
The expected size for the recombinant mTK protein was approximately 10 kDa. As 
shown in Figure 3.5, protein profiles of both uninduced and induced samples were 
similar and no distinguishable protein bands were observed at the molecular weight 
below 15 kDa. Similar trend in TK3 expression profiles as mTK were observed. The 
expected size for the recombinant TK3 protein was 18 kDa, no detectable protein 
expression levels were observed for TK3 following SDS-PAGE analysis as shown in 
Figure 3.6.  
 
Figure 3.5: Expression screen for recombinant mTK protein. The fusion proteins were expressed in 
the ArcticExpress competent cells, protein expression was induced in the presence of 1 mM IPTG for 48 
hours at 15oC. The 10 ml culture of induced (I) and uninduced (U) bacterial suspensions were harvested 
by centrifugation and was resuspended in 2ml 1X PBS. The protein expression was analysed by SDS-
PAGE. M- protein ladder in kDa. 
   
(kDa) 
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Figure 3.6: Expression screen for recombinant TK3 protein. The fusion proteins were expressed in the 
ArcticExpress competent cells, protein expression was induced in the presence of 1 mM IPTG for 48 
hours at 15oC. The 10 ml culture of induced (I) and uninduced (U) bacterial suspensions were harvested 
by centrifugation and was resuspended in 2ml 1X PBS. The protein expression was analysed by SDS-
PAGE. M- protein ladder in kDa. 
 
At first glance, it appeared as if the proteins of interest were not expressed at all since 
there was no over expression or presence of additional protein bands at the expected 
sizes, when compared to the unstimulated (uninduced) samples. The same expression 
patterns for the small scale test expression of the two constructs (mTK and TK3) in both 
induced and uninduced samples were observed. Kwon et al (2008) demonstrated that 
these two proteins are expressed in inclusion bodies when expressed in E. coli. It is 
therefore possible that the conditions of protein isolations used in this experiment were 
not suitable to release the entrapped proteins of interest from the inclusion bodies. 
Therefore, alternative protein extraction method using the BugBuster reagent was used 
to help extract the recombinant proteins. 
   
(kDa) 
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3.2.3.2 Solubility screening of the recombinant proteins 
Four clones for each of the two proteins were selected for scale-up (50 ml) for protein 
expression screen.  The bacterial cells were harvested and resuspended in BugBuster 
reagent to examine the expression and relative distribution of the soluble and insoluble 
proteins. Proteins present in the supernatant represent soluble proteins, while proteins in 
the pellet represent insoluble proteins. The expression level was relatively low and the 
protein bands detected on Coomassie-stained SDS-PAGE are shown in Figure 3.7 for 
mTK and 3.8 for TK3 expression.  
Different protein profiles between the supernatant (soluble proteins) and the pellet 
(insoluble proteins) were observed. A protein band at the expected size of recombinant 
protein was detected only in the pellet (P) samples, this indicated that the protein of 
interest was expressed as insoluble protein in bacterial inclusion bodies. The differential 
expression observed in the pellet samples for the two constructs is marked by circles in 
Figure 3.7 and Figure 3.8.  
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Figure 3.7: Evaluation of recombinant mTK protein solubility. The fusion proteins were expressed in 
the ArticExpress express competent cells. The recombinant proteins were induced in the presence of 1 
mM IPTG for 48 hours at 15oC. The cells were lysed in 500µl BugBuster reagent. The supernatant (S) 
was collected into a clean tube. The pellet (P) samples was resuspended in 500µl 1X PBS. Blue circles 
represent the overexpressed mTK protein.  
        
Figure 3.8: Evaluation of recombinant TK3 protein solubility. The fusion proteins were expressed in 
the ArticExpress competent cells. The recombinant proteins were induced with 1 mM IPTG for 48 hours 
at 15oC. The cells were lysed in 500µl BugBuster reagent. The supernatant (S) was collected into a clean 
tube. The pellet (P) samples was resuspended in 500µl 1X PBS. Blue circles represent the overexpressed 
TK3 protein.  
   
(kDa) 
   
(kDa) 
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Recombinant expression of the two proteins was confirmed following affinity 
chromatography to check for the ability of His-tag fusion protein to bind the Ni-NTA 
agarose beads in section 3.2.3.3 and Western blot analysis using a monoclonal anti-His 
antibody as described in section 3.2.3.4. 
 
3.2.3.3 Affinity purification of the recombinant proteins 
The recombinant proteins from mTK and TK3 were purified under denaturing 
conditions as described in section 2.3.1.11, the proteins were expressed with a (His)6-
tag at the N-terminus to enable affinity purification using Ni-NTA-agarose. The (His)6-
tag in the recombinant protein allows affinity binding to Ni2+ in the Ni-NTA matrix in 
the column. The recombinant proteins when loaded on a Ni-NTA column, two Histidine 
residues will bind with one Ni2+ ion and trap the tagged protein.  The untagged protein 
in the column will be washed out. The tagged protein is eluted by adding high 
concentrations of imidazole which competes with His for the Ni2+ binding, and 
displaces it and release the recombinant protein from nickel resin. 
 
The bacterial lysates were subjected to binding buffer to disrupt the inclusion bodies 
and isolate the recombinant mTK and TK3 proteins. The solubilised protein fractions 
were purified on the His-select Nickel affinity gel as described in section 2.3.1.11. After 
washing the column with 10 ml of gradient imidazole concentrations (0-100 mM) 
twice, the proteins were eluted by addition of 300 mM imidazole. The presence of 
recombinant protein in the eluted fractions and protein purity was examined on a 15 % 
SDS-PAGE from the collected fractions. 
 
 
 
 
 
 106     
Affinity purification of recombinant mTK and TK3 proteins is shown in Figures 3.9 and 
3.10, respectively. The total bacterial lysate, flow though and the samples from all the 
washes were analysed to determine the presence of His-fusion proteins.  
As shown in Figure 3.9, a single band at 18 kDa was observed in mTK samples starting 
from 30-300 mM imidazole concentrations. SDS-PAGE analysis of TK3 in Figure 3.10 
showed no bands at 20 -100 mM imidazole washes, the recombinant protein eluted at 
300 mM imidazole elution buffer. The two TK3 fractions from 300 mM were pooled, 
imidazole was replaced by PBS through buffer exchange and the protein was 
concentrated as described in section 2.3.1.11. The concentrated samples were stored at -
20 °C until further analysis.  
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Figure 3.9: Large scale protein expression and affinity purification of mTK. The pellet or insoluble 
fraction containing the fusion protein was resuspended in binding buffer, clarified by centrifugation and 
purified on a Ni-NTA column under denaturing conditions. The high background of contaminating 
bacterial proteins was removed by washing with the stepwise addition of increasing imidazole 
concentrations. The target proteins were eluted with 300 mM imidazole elution buffer and analysed on a 
15% SDS-PAGE and visualized by Coomassie staining. M - protein marker in kDa, TL – total lysate, 
FT– flow through.  
 
Figure 3.10: Large scale protein expression and affinity purification of TK3. The pellet or insoluble 
fraction containing the fusion protein was resuspended in binding buffer, clarified by centrifugation and 
purified on a Ni-NTA column under denaturing conditions. The high background of contaminating 
bacterial proteins was removed by washing with the stepwise addition of increasing imidazole 
concentrations. The target proteins were eluted with 300 mM imidazole elution buffer and analysed on a 
15% SDS-PAGE and visualized by Coomassie staining. M - protein marker in kDa, TL – total lysate, 
FT– flow through. 
 
   
(kDa) 
   
(kDa) 
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3.2.3.4 Western blot analysis of Histidine-fusion proteins 
Since the recombinant proteins did not have specific antibodies, an antibody against the 
(Histidine)6 tag was used to determine expression of (Histidine)6-fusion proteins. The 
flow through and washes following affinity purification of the recombinant proteins 
were subjected SDS-PAGE and the proteins were transferred to PVDF membrane for 
Western blot analysis. The sizes of the recombinant proteins were 18 kDa on the 
Coomassie stained gels after affinity purification in Figure 3.9 and 3.10.  
The chemiluminescent molecular weight marker did not show bands below 40 kDa, 
however only the samples that contained a histidine-fusion proteins at 18 kDa were 
detected on the blots as show in Figures 3.11 and 3.12. The immuno detected bands 
confirmed the expression of recombinant His-TK3 protein eluted at 300 mM imidazole, 
while mTK eluted at 30-300 mM, Figure 3.11 and Figure 3.12, respectively. The seven 
mTK fractions from 30-300 mM were pooled, imidazole was replaced by PBS through 
buffer exchange and concentrated as described in section 2.3.1.11. The concentrated 
samples were stored at -20 °C until further analysis.   
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Figure 3.11: Western blot analysis of the recombinant His-fusion proteins. The protein samples 
subjected for Ni-NTA purification were separated by 12% SDS-PAGE. The proteins were then 
transferred onto PVDF membrane and probed with His-probe monoclonal HRP conjugated antibody. 
Protein bands were visualized using enhanced chemiluminescence as described by the supplier. M- 
chemiluminescent molecular weight marker in kDa. 
 
Figure 3.12: Western blot analyses of the recombinant TK3 His-fusion proteins. The protein samples 
subjected for Ni-NTA purification were separated by 12% SDS-PAGE. The proteins were then 
transferred onto PVDF membrane and probed with His-probe monoclonal HRP conjugated antibody. 
Protein bands were visualized using enhanced chemiluminescence as described by the supplier. M- 
chemiluminescent molecular weight marker in kDa, TL –total lysate, S –supernatant, PS – supernatant 
from insoluble fraction, FT – flow through.  
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3.2.4 Analysis of the effects of recombinant proteins on Caco-2 cell line 
3.2.4.1 Evaluating PHB expression in various cell lines 
The ultimate application of the recombinant proteins was in development of a receptor 
targeted nanotherapy that will selectively bind to PHB protein, which is specifically 
expressed by vascular ECs in the WAT of obese subjects. Thus, for in vitro studies a 
cell line that express PHB protein on the surface of the cell was sought by Western blot 
and immunocytochemistry as described in section 2.3.3. 
Several cancerous and non-cancerous cell lines shown in Table 2.4 (section 2.3.2) were 
cultured to at least 70% confluency. Total protein was extracted from the cell lines 
using Cytobuster protein extraction reagent as described in section 2.3.3.1. The 
expression of PHB in the cell extracts was immuno detected using an antibody against 
PHB. As shown in Figure 3.13, only the colon (Caco-2) and breast (MCF-7) cancer cell 
lines showed binding to anti-PHB. Immunoreaction served as an indication of protein 
expression. The protein has a molecular weight of ~30 kDa.  
 
Figure 3.13: Analysis of PHB expression in cell lines.  Protein samples from cancerous and non-
cancerous cell lines were separated on 12% SDS-PAGE and immunoblotted on PVDF membrane using 
an antibody against PHB. M- chemiluminescent molecular weight marker in kDa. 
Immunocytochemistry was used to investigate localization of the PHB protein in Caco-
2 and MCF-7 cancer cell lines to confirm the subcellular expression of the protein. The 
two cell lines were incubated with PHB targeting peptide (AHP) which was attached to 
a fluorescein isothiocyanate (FITC) for 1-3 hours as described in 2.3.3.2 to determine 
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the cellular uptake of AHP-FITC and localization of PHB on the cell lines. The interest 
was on the cell line that expresses PHB as a cell surface or membrane receptor, which 
will be used as a model cell line for in vitro studies and to determine the effect of the 
targeted nanotherapy. Uptake of AHP-FITC was observed only in Caco-2 cells as 
shown in Figure 3.14, signifying that MCF-7 most probably express PHB in the 
cytoplasm and Caco-2 on the cell surface. The Caco-2 was chosen as an in vitro model 
cell line to represent ECs that express PHB on the cell’s surface. 
 
Figure 3.14: Immunocytochemistry analysis of PHB expression and localization in Caco-2 and 
MCF-7 cell lines. The two cell lines were incubated with 0.01 mM AHP-FITC for 3 hours and analysed 
for uptake using fluorescent microscopy. DAPI (blue) stains the cell nuclei, FITC (green stain) positive 
cells indicates the localization of AHP-FITC and therefore also PHB. 
 
3.2.4.2 Cytotoxicity effects of the recombinant proteins 
The anti-proliferative activity of the recombinant proteins (mTK and TK3) was 
evaluated spectrophotometrically by measuring the degree of mitochondrial reduction 
of the tetrazolium salt, MTT. The assay is based upon the enzymatic conversion of 
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MTT substrate to a formazan product by viable cells at the assay end point. The number 
of viable cells was proportional to the extent of formazan production.  
The Caco-2 cells were treated with either mTK or TK3 in triplicate for 24 hours and the 
viability of the cells were assessed by the MTT assay. The results as shown in Figure 
3.15 showed that mTK was not toxic to the cells at all the tested doses (0.25 – 8 µM). 
The mitochondrial function of the cells treated with TK3 has decreased, an indication of 
cell growth inhibition or cell death. The recombinant TK3 protein proved to be 
significantly cytotoxic from 4-8 µM when compared to untreated cells and cells treated 
with recombinant mTK protein.  The IC50 concentration of TK3 was 5 µM. 
 
Figure 3.15: Effects of increasing concentrations of mTK and TK3 recombinant proteins on 
viability of CaCo-2 cells. Cell viability was analysed using the MTT assay. Cells were treated with 
increasing concentrations of mTK and TK3 for 24 hours. Results represent the average of two 
independent experiments performed in triplicate. A two-tailed, unpaired t-test was used to analyse 
significance. *p<0.05, significant difference compared to untreated sample. 
 * 
* 
* * 
* 
* 
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The difference in cell death induced by TK3 was statistical significant at all 
concentrations tested when compared to the negative controls (untreated and cells 
treated with mTK).  
a) The effect of the recombinant proteins on cell morphology 
The cells were treated with the IC50 concentration (5 µM) of the recombinant protein to 
confirm the MTT assay results (Figure 3.15) and determine the effect of the 
recombinant proteins on the cellular morphology. The viability of the mTK treated cells 
was unaffected when compared to the untreated cells and the ones exposed to TK3 when 
viewed under the light microscope. The elongated morphology of the cells under the 
light microscope was the same for the negative controls, i.e. the cells treated with mTK 
protein and untreated cells, as shown in the images in Figure 3.16. However the cells 
treated with recombinant TK3 had reduced cell density compared to the untreated and 
cells treated with mTK. The TK3 treated cells had detached from each other and started 
shrinking, which are features associated with the cells undergoing apoptosis.  
 
 
Figure 3.16: Light microscopy images of cells treated with recombinant mTK and TK3. Caco-2 cells 
were treated with the recombinant proteins, cell morphology was studied under the light microscopy at 
20X magnification. 
Control: Untreated Treated: mTK Treated: TK3 
 
 
 
 
 114     
3.3 Discussion 
The goal for this chapter was to express the pro-apoptotic protein (TK3) using RDT 
mass production, the recombinant protein was to serve as therapy in the development of 
PHB-targeted nanotherapy. RDT was used instead of chemical synthesis, since this 
method would produce higher yield of the recombinant proteins at lower costs (Kyle, 
2009). The recombinant plasmids containing mTK and TK3 encoding DNA sequences 
were used to transform MC 1061 competent cells. Positive clones containing the mTK 
and TK3 genes were screened by colony PCR.  An amplicon at 300bp for mTK and 
500bp for TK3 (Figures 3.1 and 3.2, respectively) indicated the presence of the genes. 
The colonies were further sequenced to confirm the gene orientation and to check for 
any mutations or changes in the reading frame of the coding sequence.  Both the gene 
(Figure 3.3) and protein (Figure 3.4) sequences confirmed the presence of the two genes 
in the correct reading frame.  
The recombinant proteins were expressed in ArcticExpress™(DE3) competent cells 
trapped in inclusion bodies as insoluble proteins, refer to Figures 3.7 and 3.8. Kwon et 
al., (2008) described a similar finding. The recombinant proteins were purified under 
denaturing conditions through affinity purification. The recombinant Histidine-fusion 
protein (~18 kDa) corresponding to the expected sizes of mTK (Figure 3.9) and TK3 
(Figure 3.10) were eluted from the Ni-NTA beads. Western blot analyses of the purified 
recombinant protein samples (Figure 3.11 and 3.12) results indicated that the 
recombinant Histidine-tagged proteins were present and indicated the expression of 
both mTK and TK3 proteins. All the parameters mentioned did not have any relation to 
the protein identity or its sequence, however the sizes confirmed the presence of both 
mTK and TK3 genes and their expression.  
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Although the fusion proteins were expressed, there were challenges that were 
encountered through the expression process. The major challenge was the cytotoxicity 
nature of the pro-apoptotic protein to E. coli cells as confirmed by reduced biomass 
harvested after protein expression. Several chemically competent expression bacterial 
strains, different IPTG concentrations and temperatures were tested and gave similar 
results. The bacterial strains used were BL 21(DE3) pLysS, BL21-CodonPlus (DE3)-
RIL, Rosetta™(DE3) pLysS and the ArcticExpress™(DE3) competent cells. Secondly, 
since the protein was insoluble, it proved to be very difficult to identify the proteins of 
interest using SDS-PAGE analysis at the small scale as shown in Figure 3.5 and 3.6. 
The recombinant proteins were active in their denatured form and proved to be stable 
and functional in this form when stored at -20oC. And there was no need for refolding 
the recombinant proteins to its native form. 
The recombinant Histidine-tagged proteins did not lose their activity when used to treat 
the Caco-2 cells. The Caco-2 cell line was used as the model cell line because the cells 
express the PHB protein (Lenaerts et al., 2007) on their cell surface, the protein that 
was shown to be overexpressed in the obese state and serve as a receptor for the 
targeting molecule (Kolonin et al, 2004) used in the study. The cells expressing the 
PHB protein were sought by subjecting several non-cancerous and cancerous cell lines 
to Western blot analysis (Figure 3.13). Human colon carcinoma (Caco-2) and breast 
cancer (MCF-7) cell lines showed PHB expression and further analysed by 
immunocytochemisty to determine PHB localization. Only the Caco-2 cells showed the 
uptake and internalization of the AHP-FITC (Figure 3.14), and were chosen as a model 
cell line for in vitro studies. The Caco-2 cell line is derived from a human colon 
adenocarcinoma, and differentiate spontaneously in vitro under standard culture 
conditions (Pinto et al, 1983).   
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The activity of the cells in response to the recombinant proteins was studied in vitro on 
the Caco-2 cell line. The control protein (mTK) was not toxic at all concentrations 
tested when compared to the untreated samples and TK3 as shown in Figure 3.15. TK3 
behaved in an expected manner, by inducing cell death in all the concentrations used 
(Figure 3.15). At 8 µM the protein had killed >80% of cells. Kwon et al., (2008) 
showed a similar response when the two recombinant proteins were used to treat CHO, 
MCF-7 and B16F10. TK3 killed the cells in a dose-dependent concentration while mTK 
showed no effect on cell proliferation at all concentrations tested (Kwon et al., 2008). 
In summary, the recombinant mTK and TK3 proteins were expressed in E.coli 
ArcticExpress™(DE3) competent cells and purified as described in this chapter. The 
recombinant proteins showed desired response in Caco-2 model cell line as shown in 
Figure 3.15. The next step required was to use these two proteins in the development of 
targeted nanotherapy and determine whether the protein still retained its pro-apoptotic 
activity when conjugated to AuNPs, and also determine whether the recombinant 
protein’s therapeutic effect could be channelled to specific targets by attaching a 
targeting peptide. 
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Chapter 4: The development of PHB-targeted nanotherapy for target 
specific induction of apoptosis 
4.1 Introduction 
PHB-targeted nanotherapy was developed by conjugating the recombinant pro-
apoptotic protein expressed and purified in Chapter 3 and a PHB-targeting peptide 
(AHP) to AuNPs. The resulting PHB-targeted nanotherapy was expected to induce 
apoptosis when internalized by the ECs in the WAT vasculature of obese subjects. By 
so doing, the adipocytes will be forced to metabolise the excess calories and starve to 
death, followed by reduction of AT mass and total body weight in an obese animal 
model. The AuNPs served as delivery agents and several negative controls were 
included to prove that the antiproliferative effect on the cells was due to the therapeutic 
peptide not the AuNPs. The effects of the AuNP conjugates were tested on PHB-
expressing cell line (Caco-2).  
Although the gold core is considered to be non-toxic, independent studies have 
demonstrated the toxicity of the AuNPs through in vitro and in vivo studies (Cho et al., 
2009; Freese et al., 2012; Sabella et al., 2011), and that the toxicity can be easily 
channelled to specific cells by modifying the AuNP surface with biomolecules and 
facilitate their uptake and targeted delivery (Kumar et al., 2012). The use of AuNPs as 
drug delivery agents has shown great potential in cancer clinical studies (Libutti et al., 
2010). Pre-clinical studies have also demonstrated that the AuNP bio-conjugates are 
more efficient than the biomolecules on their own (Sperling et al., 2008). Although 
these nanomaterials have beneficial aspects, literature shows conflicting data regarding 
the toxicity of AuNPs raising serious issues regarding its possible risks for human 
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health and the environment (Caruthers et al., 2007). The bulk gold material is bio-inert 
(Brown et al., 2008; Murphy et al., 2008), however, alteration of their physico-chemical 
properties for biological application has been associated with undesirable results that 
raise adverse effects on biological systems (Caruthers et al., 2007; Cunningham, 2014).  
The NPs are of similar size to typical cellular components, and may easily bypass 
natural mechanical barriers. The resulting effects might not be inherently benign and 
they might affect biological behaviours at the cellular, subcellular, and protein levels 
(Service, 2004; Donaldson et al., 2004; Oberdorster et al., 2005; Royal Society, 2004). 
These NPs can penetrate both the cell and nuclear membranes and accumulate in 
tissues, interfering with cellular functions leading to genotoxicity, possibly cell death 
through their interaction with cellular organelles (Gibson et al., 2011; Li et al., 2003). 
Therefore, NP interaction with cellular components might affect biological mechanisms 
possibly leading to adverse tissue reaction as highlighted in Figure 4.1. The NPs are 
usually charged and can easily adsorb serum proteins leading to cyto- or genotoxicity 
(Nel et al., 2009). The possible lethal effects of AuNPs on cells cannot be ignored. The 
fate and effect of AuNPs upon their entrance into the living cells is still questionable 
(Sperling et al., 2008) and requires investigations that can ascertain their safety and 
biocompatibility. This chapter aims to explore the effect of the untargeted and targeted 
AuNPs on Caco-2 cancer cells using cell biological and biochemical assays. 
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Figure 4.1: Possible mechanisms by which nanomaterials interact with biological tissue. Examples 
illustrate the importance of material composition, electronic structure, bonded surface species (e.g., 
metal-containing), surface coatings (active or passive), and solubility, including the contribution of 
surface species and coatings and interactions with other environmental factors (e.g., UV activation) (Nel 
et al., 2009). Figure reprinted with permission from Elsevier AAAS. 
 
 
4.2 Results 
4.2.1 Conjugation of the recombinant proteins to AuNPs 
The mTK and TK3 recombinant proteins were expressed as Histidine-tagged proteins as 
described in section 3.2.3.2 and 3.2.3.3. The (Histidine)6-tag at the C-terminus was 
retained for attaching the recombinant proteins to nitrilotriacetic acid (NTA) modified 
AuNPs. The design of the AHP-targeted nanotherapy is shown in Figure 4.2. 
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Figure 4.2: Schematic diagram of the PHB-targeted nanotherapy. The recombinant proteins and the 
AHP targeting peptide were conjugated to AuNP-GSH-NTA. 
 
4.2.1.1 Synthesis and characterization of NTA-gold nanoparticles 
The AuNPs were synthesized following reduction of gold aurate and modified by the 
addition of NTA using glutathione (GSH) as a linker (Taute et al., 2014). Figure 4.3 
shows the optical properties of AuNP-GSH-NTA compared to citrate AuNPs as 
characterised by UV-Vis spectroscopy. The maximum absorption spectrum for AuNPs 
and AuNP-GSH-NTA observed was 523 nm with an absorbance of 0.97 and 0.95, 
respectively. 
 
 
 
 
 121     
 
Figure 4.3: Optical properties of AuNP and AuNP-GSH-NTA determined by UV-vis spectroscopy. 
 
The size and concentration of the AuNPs was determined from the UV-vis data as 
described by Haiss et al., (2007). The AuNP concentration was calculated based on the 
formula:  
                                                       C=A450/ɛ450 
where: C = concentration, A450 = absorbance at 450nm, ɛ450 = molar extinction 
coefficient at 450nm. The concentration of the AuNP-GSH-NTA was 1.36X10-7 M and 
their diameter was ~5nm. 
Different concentration of NiSO4 (0-1 mM) was used to activate the AuNP-GSH-NTA 
before the recombinant proteins were attached. NiSO4 concentration of 0.3 mM was 
found to be the most effective. The AuNP-GSH-NTA were activated with 0.3 mM 
NiSO4 and functionalized with increasing concentration of mTK and TK3 recombinant 
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proteins. The flocculation behaviours of the modified AuNPs were investigated by 
colorimetric and optical changes of the NPs after addition of 10% NaCl using a UV–vis 
spectrophotometer. The flocculation rate of the modified AuNPs was depended on the 
concentration of the protein added, the AuNPs flocculated at all concentration tested. 
4.2.2 Development of targeted nanotherapy using D(KLAKLAK)2 peptide  
4.2.2.1 Design of the AuNP conjugates 
When conjugation of recombinant proteins to AuNPs-GSH-NTA failed, custom-
designed D(KLAKLAK)2-SH peptide was synthesized by AnaSpec and used to 
construct the PHB-targeted nanotherapy as discussed below. The design of the AuNP 
conjugates is shown in Figure 4.4. 
 
Figure 4.4: Schematic diagram of the AuNP design. AGK = has both targeting and therapeutic 
peptides, AGTK = has TAT, targeting and therapeutic peptides. GC = citrate coated AuNPs, GP = 
PEGylated AuNPs, GK = AuNPs with therapeutic peptide, and AG = targeted pegylated AuNPs.  
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The various AuNP conjugates used in this study are listed in Table 4.1 with their 
acronyms. These acronyms will be used to refer to the AuNPs. Naked metal NPs tend to 
be unstable in organic solvents, to prevent aggregation in solution PEG (HS-PEG-OH) 
was used as a stabilizer and emulsifying agent for all AuNP conjugates. Encapsulation 
of the metal core with PEG creates a dielectric shell around the metal core, this provides 
means of protection for the AuNPs from the surrounding environment or opsonisation 
when used in biological system. The functionalities on the shell were manipulated by 
adding targeting and therapeutic peptides for biomedical applications. 
Table 4.1: Preparation of various AuNPs for biological application and their acronyms. 
 
Final AuNP conjugate Acronyms 
                     Ratios 
PEG-OH 
PEG-
STREP 
Biotin-
AHD TAT KLAKLAK 
Citrate AuNPs GC 0 0 0 0 0 
AuNP-PEG GP 11 0 0 0 0 
AHP-AuNP-PEG AG 10 0.5 0.5 0 0 
AuNP-KLAKLAK)2 GK 10 0.5 0 0 0.5 
AHP-AuNP-(KLAKLAK)2 AGK 9.5 0.5 0.5 0 0.5 
AHP-AuNP-TAT-
(KLAKLAK)2 AGTK 9 0.5 0.5 0.5 0.5 
 
The biotinylated prohibitin-targeting peptide (AHP-Biotin) was attached to AuNPs 
using streptavidin. The targeting peptide will increase the specificity and sensitivity of 
the attached pro-apoptotic [D(KLAKLAK)2-SH] peptide. The pro-apoptotic peptide was 
incorporated to the AuNPs through the thiol group and served as a therapeutic peptide. 
TAT was added to AGTK particles to determine if an extra PTD can enhance the AuNP 
uptake and therapeutic potential as compared to AGK. 
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4.2.2.2 Synthesis and characterization of gold nanoparticles 
The AuNPs were synthesized following the sodium citrate reduction method established 
by Turkevich as described in section 2.3.5.1. Different molecules were coupled to the 
citrate-AuNPs through different chemistries to develop biologically active or 
functionalized AuNPs. The citrate-coated AuNPs and AuNP-peptide conjugates were 
sterilized by filtration and the optical properties of those AuNPs were characterized by 
UV-Visible spectroscopy. The size distribution, shape and quality of the NPs was 
studied by TEM and electrical conductivity examined by Zeta (ζ-) potential.  
Absorption spectrum of gold colloids has been used to indicate immobilization of other 
molecules on the surface of the gold colloids based on their λmax or localized surface 
plasmon resonance (LSPR). Gold nanoparticles exhibit a strong absorption band in the 
visible region that can be used to determine whether modification of the NP surface has 
been successful (Ghosh et al 2004; Philip, 2008).  The colloidal LSPR is dependent on 
several factors such as the size, solvent and surface modification and is useful in 
distinguishing AuNP conjugates as well as to monitor adsorption or conjugation of 
biomolecules on the surface of the AuNPs.  
The effect of modifying the surface of citrate coated AuNPs (GC) on the LSRP is 
shown on Figure 4.5.  The interaction of the metal particles with the stabilizing agents 
or biomolecules induced the LSPR changes reflected in the absorption spectral features 
of AuNP conjugates. The UV-Vis absorption properties of the colloidal nanoparticles 
were compared to the other AuNP conjugates in Figure 4.5. The change in optical 
properties of the AuNP-peptide conjugates suggested the formation and adsorption of 
biomolecules on the surface of GC. The UV−Vis spectrum of GC with a defined 
plasmon resonance peak at 519 nm was observed. There was a red shift and either 
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increase or decrease in the peak intensities after the addition of AHP and 
D(KLAKLAK)2 peptides on GC as an indication of a change in the dielectric constant of 
the AuNP surface. Compared to GC, the peak intensity for AGK increased and 
maximum absorption wavelength shifted from 519 nm to 524 nm. The degree of red 
shift for AGTK was the same as AGK. Reduced peak intensity for AG and GK and 
increased absorption maxima from 519 nm to 525 nm was observed. For GP, the λmax 
was 519 nm with a slight increase in peak intensity. The shift in the absorption peak 
was attributed to the presence of other molecules on the surface of the citrate AuNPs. 
 
Figure 4.5: UV-Vis spectrophotometer absorption spectrum of citrate capped AuNPs and their 
respective AuNP-peptide conjugates. GC = citrate coated AuNPs, GP = PEGylated AuNPs, AG = 
targeted GP, GK = AuNPs with therapeutic peptide, AGK = has both targeting and therapeutic peptides, 
AGTK = has TAT, targeting and therapeutic peptides. 
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The size distribution, quality and morphology (shape) of the AuNPs was characterized 
by TEM analysis. Representative TEM micrographs of the different AuNPs are shown 
in Figure 4.6. The TEM micrographs of all the AuNPs showed particles with uniform 
spherical shapes that had an average diameter of 14 nm (±2 nm). The AuNPs dispersion 
showed no signs of aggregation. GC particles appeared to be more separated as 
compared to the other AuNPs that seem to associate closely with each other.  
 
Figure 4.6: Representative TEM micrographs of the AuNP conjugates. GC = citrate coated AuNPs, 
GP = PEGylated AuNPs, AG = targeted GP, GK = AuNPs with therapeutic peptide, AGK = has both 
targeting and therapeutic peptides, AGTK = has PTD, targeting and therapeutic peptides. Scale bars in 
the micrographs are used to represent magnification of AuNPs. 
The ζ-potential or the surface charge of the AuNP conjugates as a measure of their 
charge and stability was measured using a Malvern Zetasizer Nano ZS. The ζ-potential 
determines the behaviour of the colloids in solution, range between +100 mV to -100 
mV can be used to determine the colloidal stability (Clogston and Patri, 2011; Leroy et 
al., 2011). NPs with a ζ-potential between −10 and +10 mV are considered to be 
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neutral, while particles with ζ-potential greater than +30 mV are said to be strongly 
cationic and strongly anionic if the ζ-potential is less than −30 mV (Clogston and Patri, 
2011). These values can also determine how readily the NPs will aggregate in solution. 
NPs with ζ-Potential values greater than +25 mV or less than -25 mV are highly stable 
and will resist aggregation. While NPs with lower ζ-potential values closer to zero can 
easily coagulate or flocculate when dispersed in solution (Clogston and Patri, 2011). 
In Figure 4.7, the ζ-potential of GC was found to be -42.5 mV. The value increased 
after bio-conjugation of targeting and therapeutic peptides. Of all the AuNPs 
synthesized, GP had the highest ζ-potential at -2 mV followed by AG (-11 mV), AGTK 
(-11.7 mV), AGK (-12.4 mV) and GK (-16.9 mV).  The changes are attributable to 
molecules attached to the AuNP surface and their charges. The change in ζ-potential 
suggests modification of the AuNP surfaces and values can also be used to predict how 
these AuNPs are going to behave when used in biological system.  
 
 
Figure 4.7: ζ-potential of the AuNPs determined using Malvern Zetasizer as a measure of AuNP 
stability and charge. GC = citrate coated NPs, GP = PEGylated NPs, AG = targeted GP, GK = AuNPs 
with therapeutic peptide, AGK = has both targeting and therapeutic peptides, AGTK = has PTD, targeting 
and therapeutic peptides.  
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The molecules attached on the AuNPs reduced their ζ-potential when compared to the 
citrate coated AuNPs (GC) which are strongly anionic. GP has highest ζ-potential 
compared to the other AuNPs, the value has significantly been reduced from -42.5 mV 
for GC, and this is attributed to the PEG polymer attached to GP. PEG polymer is 
hydrophilic (Veronese and Pasut, 2005) and have been used to passivate the GP 
particles and made them to have a neutral charge. The other AuNPs with targeting and 
pro-apoptotic peptides became moderately negatively charged compared to GC and GP.  
This is due to the change in PEG ratio and addition of the pro-apoptotic peptide. This 
can be attributed to the large number of positively charged lysine residues in the 
peptide.   
4.2.3 Quantification of AuNPs and conjugates by ICP-OES 
The concentrations of the AuNP conjugates were determined using UV-Vis data 
through the equation described by Haiss et al., (2007). The stock concentration for all 
AuNP conjugates was 20 nM. ICP-OES was used to verify if these AuNPs contained 
the same number of Au metal at the same concentration. Equal amount of the AuNPs 
(as described in section 2.3.5.3) was digested with aqua-regia and Au metal quantified 
by ICP-OES.  
ICP-OES is an analytical technique used to detect trace element in suspensions from 
concentration as low as 1 part per trillion. The elements are first ionized by acid bath in 
oxidizing acids (HCl and HNO3). The metal concentration is determined by running the 
samples with a known concentration of the target analyte, in this case TraceSELECT® 
gold was used as a standard. 
Figure 4.8 indicates the number of detectable Au atoms in the AuNP conjugates. The 
highest amount of Au metal was detected on citrate coated AuNPs (GC) at 10.42 ppm, 
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followed by pegylated AuNPs (GP) at 5.77 ppm when compared to the other AuNP-
conjugated with either targeting (A) and/ or therapeutic (K) peptides  that was lower 
than 3.15 ppm.   
 
Figure 4.8: Quantification of AuNPs by ICP-OES. To determine the amount of gold present in each 
sample, the samples were diluted 1:10 in dH2O. Elemental analysis was carried out by ICP-OES.  GC = 
citrate coated AuNPs, GP = PEGylated AuNPs, AG = targeted GP, GK = AuNPs with therapeutic 
peptide, AGK = has both targeting and therapeutic peptides, AGTK = has PTD, targeting and therapeutic 
peptides.  
The variations in the quantity of gold detected is due to the biomolecules attached to the 
surface of the AuNPs, further confirming that the targeting and the pro-apoptotic 
peptides were successfully conjugated to the NPs. The ICP-OES data suggested that in 
order to correct the variability in the concentration of the AuNPs, the following ratios 
had to be used per 1part of GC:  1.8 GP, 4.96 AG, 3.64 GK, 3.35 AGK and 3.32 
AGTK. 
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4.2.4 Therapeutic potential of targeted nanotherapy 
Biochemical assays were used to determine the therapeutic potential of PHB-targeted 
nanotherapy on the model cell line (Caco-2 cell line). The WST-1 assay was used to 
monitor cell viability, CM-H2DCFDA probe to quantify ROS generation and the 
APOPercentageTM Apoptosis assay to determine possible apoptotic cell death induced 
by exposure of cells to various AuNP conjugates.  
The citrated coated AuNPs (GC) and the pegylated AuNPs (GP) have neither a 
targeting nor a therapeutic peptide, therefore these AuNPs are not expected to be taken 
up by the cells or cause cell death. The GP particles have PEG as a stabilizing agent, 
PEG is known for its passivation properties (Roberts et al., 2002; Ryan et al., 2008).  
AG is made of GP and has a targeting peptide that recognises the PHB receptor. These 
AuNPs will be taken up by the cells but is not expected to be toxic due to the presence 
of PEG on their surface.  GK have a therapeutic peptide but since they did not have a 
targeting peptide, these AuNPs is expected not to be taken up by cells or cause cell 
death. The therapeutic or pro-apoptotic peptide attached to it, shall only have an effect 
when internalized by the cells (Ellerby et al., 1999).  AGK and AGTK have both the 
targeting and therapeutic peptides attached to the AuNPs. These AuNPs are expected to 
bind to the PHB receptor on the Caco-2 cells and be internalized by the cells. Once 
internalized, the therapeutic peptide is expected to disrupt the mitochondrial membrane 
causing cytochrome c release and caspase activation that will trigger cell death by 
apoptosis. The only difference between the two AuNPs, is that AGTK has an additional 
PTD (TAT) which is expected to enhance the uptake of AGTK and increase its 
therapeutic efficacy compared to AGK. 
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4.2.4.1 Effect of AuNP conjugates on Caco-2 cell viability: WST-1 assay 
To determine if the NPs exhibited cytotoxic effects on the Caco-2 cell line, the cells 
were exposed to increasing concentrations of various AuNP conjugates for 24 hours. 
Cell viability was measured using the WST-1 cell proliferation assay, a colorimetric 
assay used to measure metabolic activity of cells. The assay relies on the conversion of 
the tetrazolium salt (WST-1) through the action of mitochondrial dehydrogenase into a 
yellow coloured product that is measurably by spectrophotometer at 440nm. The colour 
change is directly proportional to the amount of mitochondrial dehydrogenase in a 
sample reflective of live cells.  
Figure 4.9 compares the cell viability of cells treated with the various AuNPs against 
untreated cells. The viability of cells after exposure to AuNPs decreased, especially at 
high concentrations (2-8 nM) for all AuNPs used except GP. GP showed negligible 
response even at 8nM. Increased cytotoxicity was observed in the cells treated with 
AuNPs that contained the therapeutic and/ or targeting peptide in a dose dependent 
manner. The viability assay indicated a signiﬁcant cytotoxicity in cells that were treated 
with AG, GK, AGK and AGTK. At the highest concentration (8 nM), the targeted 
AuNPs reduced the viability to less than 30% with respect to the control. No significant 
difference was observed in cells treated with GP at all tested concentrations. 
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Figure 4.9: Viability and proliferation of Caco-2 cells after 24 h exposure to various AuNPs. The 
cells were exposed to different amounts of nanoparticles ranging from 0.5 to 8 nM. Cell viability was 
measured by the WST-1 proliferation assay. The result represents the mean ± standard deviation of two 
independent experiments, each performed in triplicates. GC = citrate coated NPs, GP = PEGylated NPs, 
AG = targeted GP, GK = NPs with therapeutic peptide, AGK = has both targeting and therapeutic 
peptides, AGTK = has PTD, targeting and therapeutic peptides. A two-tailed, unpaired t-test was used to 
analyse significance. *p<0.05, significant difference compared to untreated sample.  
Surprisingly, the targeted-PEGylated AuNPs (AG) and the untargeted NPs with the 
therapeutic peptide (GK) were shown to be toxic to the Caco-2 cells. This suggests that 
the GK AuNPs were able to be taken up by the cells and cause cell death. AG was 
expected to behave in a similar manner as GP whether internalized or not since they 
have a protective layer (PEG) on the surface. The interference test was performed to 
determine whether AuNPs interferes with the WST-1 formazan reaction product by 
incubating 8nM AuNPs with the dye reagent. No interference was observed for all six 
AuNPs used (data no shown). The concentration that caused 50% (IC50) cell death was 
determined by GraphPad® Prism 6 for all AuNPs, IC50 values are shown in Table 4.1. 
* 
* 
* 
* 
 
 
 
 
 133     
IC50 values for GC and GP was higher than 8 nM, 6.17 nM for AG, 6.23 nM for GK, 
6.23 nM for AGK and 6.13 nM for AGTK.  
                      Table 4.1: The IC50 values of various AuNP conjugates after their exposure to Caco-2 cells. 
 
Cell line IC50 (nM) 
GC >8 
GP >8 
AG 6.17 
GK 6.23 
AGK 6.23 
AGTK 6.13 
 
 
4.2.4.2 Cellular uptake of AuNPs by Caco-2 cells as determined by ICP-OES 
To quantify AuNP uptake, elemental analysis was carried out by ICP-OES to determine 
the amount of the metals that were taken up by the cells. After 24 hours of treatment 
with 5 nM of differently functionalized AuNPs, the cells were lysed by aqua regia and 
analysed for gold uptake by ICP-OES as described in section 2.3.6.2a). The amount of 
gold detected from each sample was equivalent to the amount of AuNP taken up by the 
cells. Figure 4.10 shows the percentage uptake of AuNPs by cells, as a function of the 
initial amount applied.  
The GC AuNPs were taken up more by the cells compared to the other nanoparticles 
which showed a very small amount of AuNPs compared to the initial amount applied 
(less than 10%). At 65%, the overall amount of gold taken up by the cells treated with 
citrate coated AuNPs (GC) was signiﬁcantly higher than the cells treated with the other 
AuNP conjugates. This was unexpected since the ζ-potential (Figure 4.7) showed that 
the GC NPs are highly negatively charged. Since these NPs have a similar charge as the 
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lipid bilayer, the two are supposed to repel each other. This was further investigated by 
TEM to determine the localization of the AuNPs. 
For the bio-conjugated AuNPs, AG has highest uptake at 8.01% compared to the other 
targeted NPs. AGK and AGTK uptake was 4.91 % and 3.83 %, respectively. GK uptake 
was comparable to AGK at 4.97. GK has no targeting peptide and was not expected to 
be taken up as much as the NPs containing targeting peptide (AG, AGK and AGTK).  
 
Figure 4.10: Quantification of internalized AuNPs in Caco-2 cells by ICP-OES. The cells were 
incubated with 5 nM of nanomaterials at 37°C for 24 hours. Cells were washed, lysed in aqua regia (3:1 
hydrochloric acid: nitric acid) and analysed for gold concentration by ICP-OES. The percentage of 
nanoparticles taken up by the cells was determined as a function of the total amount of AuNPs applied.  
GC = citrate coated AuNPs, GP = PEGylated NPs, AG = targeted GP, GK = AuNPs with therapeutic 
peptide, AGK = has both targeting and therapeutic peptides, AGTK = has PTD, targeting and therapeutic 
peptides.  
 
* 
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4.2.4.3 Intracellular localization of AuNPs by TEM 
The cellular uptake and localization of nanomaterials was investigated by incubating 
the cells with 5 nM concentration of GC, AGK and AGTK for 24 hours. Untreated cells 
were used as a control. Intracellular localization of NPs was analysed by TEM. The 
TEM micrographs (Figure 4.11) demonstrated that the internalized GC NPs were 
located in the cytoplasm (red arrows) and cell membrane surfaces (green arrows) with 
no signs of cytotoxicity. Some AGK nanoparticles were detected in the cytoplasm and 
some bound on the cell surfaces. However, no AuNPs were detected in the cytoplasm or 
in other cellular compartments, such as nuclei or mitochondria for the cells treated with 
AGTK. 
In addition to the intracellular localization of the AuNPs, the TEM analyses showed that 
cell exposure to GC did not alter the cell morphology of the cells when compared to 
cells treated with AGK and AGTK. Cells exposed to GC still retained the elongated 
shape seen in untreated cells. When compared to the untreated cells, the morphology of 
the cells treated with AGK and AGTK had been altered. Their nuclear shape and size 
were altered.  
 
 
 
 
 136     
 
Figure 4.11: Localization of AuNPs in Caco-2 cells analysed by TEM. Cells were incubated with 5nM AuNPs for 24 hours. After exposure, cells were fixed with 
4% paraformaldehyde and stored in 2.5% glutaraldehyde until further analysis. AuNP uptake was examined by TEM. The red arrows points at AuNPs localised within 
the cytoplasm and green arrows indicate the AuNPs on the cell surface. I and II represents micrographs treated with same NPs from different grids. GC = citrate coated 
AuNPs, AGK = has both targeting and therapeutic peptides, AGTK = has TAT, targeting and therapeutic peptides. N - nucleus, L – lysosome. 
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4.2.5 Investigation into the mode of cell death induced by AuNPs conjugates 
The cytotoxicity and mode of cell death induced by various AuNP conjugates (GC, GP, 
GK, AG, AGK and AGTK) were further investigated by cell biology and biochemical 
assays. 
4.2.5.1 Cellular morphological changes induced by AuNPs in Caco-2 cells 
Once the AuNPs reach their target, the cell membrane is the first barrier that the AuNPs 
come into contact with. The interaction between the AuNPs and the cell membrane can 
affect intracellular biochemical events and induce toxicity that can be detected by 
morphological changes through light microscopy. Any disturbances in the 
phospholipids bilayer compromises the integrity of the cell and serve as an indication of 
altered cellular functions. Typical cellular features of Caco-2 cells are shown in 
untreated cells in Figure 4.12. Caco-2 cells grow and differentiate into monolayers 
characterized by elongated shape that resemble the small intestinal epithelium 
structurally and functionally under microscopy (Herold et al., 1994). No morphological 
changes were observed in cells treated with GC and AG. The cell density and shape was 
similar to untreated cells.  The same was observed in cells treated with GP (data not 
shown).  
Cells treated with GC, AG and GK had the same cell density as the untreated control 
cells, while cells treated with AGK and AGTK had reduced cell density. The shape and 
size of cells treated with GK, AGK and AGTK was also different in comparison to the 
untreated cells. Cells treated with GK displayed vacuoles which were not observed in 
any of the other treatments. The formation of “holes” may be induced by the presence 
D(KLAKLAK)2 peptide on the surface of AuNPs, that could influence the interaction of 
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the NPs with the lipid bilayer and result in unexpected toxicity shown in Figure 4.9. 
Although the results for cells treated with GP is not shown, these NP had the same 
effect as GC and AG.  
 
Figure 4.12: Light microscopy depicting cell morphology after the Caco-2 cells were exposed to 
various AuNPs for 24 hours.  The cells were grown in a 12 well plate and treated with IC50 of the AuNP 
conjugates, the cellular morphology were viewed under light microscope at 20X magnification and 
captured by the Leica camera. GC = citrate coated AuNPs, AG = targeted GP, GK = AuNPs with 
therapeutic peptide, AGK = has both targeting and therapeutic peptides, AGTK = has TAT, targeting and 
therapeutic peptides.  
 
4.2.5.2 Detection of intracellular oxidative stress induced by AuNP conjugates 
Mitochondrial dysfunction in cells seals the fate of the cell. The effect of the AuNP 
conjugates on mitochondrial function and oxidative stress was assessed to determine the 
health status of the cells. The amount of ROS within the cells was examined to 
determine whether the AuNPs induce the cellular oxidative stress. The CM-H2DCFDA 
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probe was used to detect and quantify the intracellular ROS produced by the cells. CM-
H2DCFDA is a nonfluorescent ROS indicator that is oxidized to 2’,7’-
dichlorofluorescin (DCF) in the presence of ROS. CM-H2DCFDA is a cell permeable 
fluorogenic probe that can be used to assess oxidative stress in cultured cells (Wu and 
Yotnda, 2011). This probe detects ROS such as hydroxyl, peroxyl, nitric oxide, oxide 
anion, peroxynitrite, hydrochlorous acid and hydroxyl radical species within the cell. 
When the CM-H2DCFDA probe is taken up by the cells, the cellular esterases 
deacetylate the probe to a non-fluorescent compound that is later oxidized by ROS into 
highly fluorescent compound, DCF. The fluorescence correlates to the amount of ROS 
generated in the cells, and can be detected and quantified by flow cytometry. 
The intracellular ROS levels were examined in Caco-2 cells treated with different 
AuNPs by flow cytometric analysis as described in section 2.3.6.3d). Figure 4.12 shows 
the level of ROS activity induced by exposing the cells to various AuNP conjugates 
(GC, GP, GK, AGK and AGTK). An increase in cell fluorescence was an indication of 
ROS production in the cells. The untreated cells and cells treated with cisplatin were 
used as controls. Cells treated with AGTK showed higher ROS levels compared to 
other AuNPs tested. Untargeted AuNPs (GP) had a negligible effect on cellular levels 
of ROS as indicated in Figures 4.13 when compared to untreated cells. The increased 
ROS levels in cells treated with cisplatin GC, GK, AGK and AGTK were statistical 
significant. The findings could suggest that the cytotoxicity induced by the AuNPs is 
somehow mediated through the induction of increased levels of oxidative stress through 
the effects of ROS production within the cell. 
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Figure 4.13: ROS activity in response to AuNPs treatment. Cells were treated with various AuNPs for 
24 hours and ROS levels were assessed by incubating the cells with 10 μM CM-H2DCFDA at 37 °C for 
30 min. The fluorescence staining was analysed with the Attune flow cytometer. For each sample 10 000 
events were recorded.  GC = citrate coated AuNPs, GP = PEGylated AuNPs, AG = targeted GP, GK = 
AuNPs with therapeutic peptide, AGK = has both targeting and therapeutic peptides, AGTK = has PTD, 
targeting and therapeutic peptides. A two-tailed, unpaired t-test was used to analyse significance. 
*p<0.05, significant difference compared to untreated sample, a = p<0.05 AGTK significantly different 
compared to other AuNP conjugates. 
 
4.3 Discussion  
The application of nanotechnology in medicine is looking very promising, in particular 
for development of effective therapies for chronic diseases; bringing about the exciting 
era of nanomedicine. Nanomaterials have physico-chemical properties that make them 
useful in therapeutics, diagnostics and drug targeting when conjugated to biomolecules 
(Provenzale and Silva, 2009; Lysik and Wu-Pong, 2003). Several drugs based on 
nanotechnology are currently undergoing clinically trials for targeted treatment of 
a 
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cancer. Of interest to this study, are human trials conducted using gold nanoparticle 
formulations as drug delivery vehicles in photothermal therapy (Libutti et al., 2010; 
ClinicalTrials.gov numbers; NCT00356980, NCT00436410 and, NCT00848042). The 
field has grown since and has potential to revolutionize medicine, advancing the 
treatment and diagnosis of chronic diseases. However, applications of NPs in 
therapeutics are limited by their possible toxicity.  The unique physico-chemical 
properties of NPs not only increase their usefulness in biomedical applications, but their 
ability to interact with biological systems can also increase their cytotoxicity. It is 
essential that the toxicity of the NPs be tested in pre-clinical studies before they can be 
considered for human trials (Caruthers et al., 2007).  
The goal of the present chapter was to develop a PHB-targeted nanotherapy and 
examine the effects of targeted and untargeted AuNPs on the viability of human Caco-2 
cells. This cell line was chosen because it expresses PHB as a cell surface receptor that 
can bind to the PHB-targeting peptide (AHP) as shown in Figure 3.13. The AuNPs were 
produced by reduction of HAuCl4 adapted from Turkevich et al (1951). AuNPs were 
characterized by UV-Vis spectroscopy (Figure 4.5) and TEM analysis (Figure 4.6). A 
shift in the peak position of the AuNP’s SPR with respect to citrate capped AuNPs was 
used as an indicator for successfully capping of the AuNP surfaces with the peptide 
molecules as shown in Figure 4.5.  
The potential cytotoxicity of the AuNP conjugates and their uptake was studied using 
cell biology and biochemical assays in in vitro studies. The cytotoxicity and effect of 
the AuNP conjugates on cell viability was evaluated on the Caco-2 cell line using the 
WST-1 assay. The viability of cells treated with GP was higher than 90% at all the 
concentrations tested as shown in Figure 4.9. Higher concentrations (2 -8 nM) of GK 
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and AG unexpectedly negatively influenced the cell viability. GK does not have a 
targeting peptide and was therefore not expected to be taken up by cells and have toxic 
effects. AG has a targeting peptide and expected to be taken up by the cells but not have 
toxic effects. The cell death induced by GK, AG, AGK and AGTK was dose-
dependent. Both AGK and AGTK have both the targeting and therapeutic peptides and 
when taken up and internalized by the cells, these AuNPs were expected to cause cell 
death. AGTK was expected to have more pronounced effect on cell viability than AGK 
since it has TAT that is expected to enhance its uptake and therapeutic activity. 
However, Table 4.1 shows no significant difference in the activity induced by AGTK 
compared to AG, GK and AGK. Judging from these data, both the targeted and 
untargeted particles (including the negative controls) had a comparable response at the 
same concentrations (Figure 4.9).  
The amount of internalized AuNPs in Caco-2 cells was quantified and compared using 
ICP-OES to determine the relationship between cytotoxicity and the amount of AuNPs 
taken up by the cells. ICP-OES is a more sensitive and accurate method to quantify 
small amounts of metals in samples. It can detect differences in the gold concentrations 
of the order of parts per billion. Again, the internalization of AuNPs was lower for the 
targeted AuNP conjugates compared to GC (Figure 4.10). TEM analysis was conducted 
to confirm localization of the GC, AGK and AGTK in Caco-2 cells. The cells were 
incubated for 24 h with the mentioned AuNPs. TEM images (Figure 4.11) showed that 
GC internalization was higher than that of peptide-AuNP conjugates. GC NPs were 
localized in the cytoplasm but also on the cell membrane. Lower numbers of AuNPs 
were observed in cells treated with AGK and no AuNPs were detected in cells treated 
with AGTK. Conjugating targeting peptides to the NPs were expected to improve the 
ability of the AuNPs to target and enter into cells expressing PHB. This is expected to 
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allow higher concentrations of therapeutic particles to accumulate in cells expressing 
PHB and enhance cytotoxicity within these cells. This may explain why so few particles 
were detected in cells treated with AGK and AGTK. Cells taking up these AuNPs (i.e. 
AGK and AGTK) are expected to die, as such the contents in dead cells might not be 
recoverable. 
The TEM data confirmed the ICP-OES results, by showing that GC particles were taken 
up more readily than AGK and AGTK. Although the PHB-targeted nanotherapies 
(AGK and AGTK) proved to be toxic (Figure 4.9), the peptides were considered 
unsuccessful due to their lack of selectivity when compared to the other AuNP 
conjugates. Their activity was hardly convincing because their biological response in 
Caco-2 cells was comparable to GK and AG. Certain parameters in the design of the 
AuNPs were suspected to influence the AuNP uptake and their cellular toxicity, such as 
the inability of the D(KLAKLAK)2 to detach from the NPs once internalized. These 
parameters were changed in the design of the modified PHB-targeted nanotherapy as 
described in the next chapter.  
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Chapter 5: Conjugation of modified D(KLAKLAK) to AuNPs for 
development of the ideal PHB-targeted nanotherapy  
5.1 Introduction  
The PHB-targeted nanotherapy developed in Chapter 4 did not perform to expectations, 
although it showed some desirable traits (e.g. toxicity towards the model cell line, 
Figures 4.9) the response was questionable as it was similar to the negative controls. 
The drawbacks were addressed by changing the design of the AuNPs in order to 
improve its specificity and sensitivity as discussed below. 
Drug specificity and sensitivity is crucial in development of treatment for chronic 
diseases, and yet proves to be a major challenge that delays the progress in developing 
disease specific therapies. Available drugs are either wrong for the specified disease, 
used at a very low dose to effectively reverse the condition or highly toxic to unaffected 
tissues to give it enough time to completely cure the affected areas. Although the drugs 
have beneficial health effects, their side effects outweigh their usefulness (William, 
2010). These drawbacks can be easily avoided through the use of targeted nanotherapy 
which is not without challenges, discussed in Chapter 4.  
Development of nanotherapy with precise biological activities in target cells has 
potential in treatment of chronic diseases. The strategy of using bifunctional AuNPs 
could increase the specificity and binding capacity of the therapy and confer the 
therapeutic effect only on the target cells. The success of the described targeted therapy 
could facilitate the development of precision medicine, diagnostics, that can 
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differentiate distinct cellular states and target specified cell types and spare the 
surrounding cells. 
 
5.2 Results 
5.2.1 Analysis of TAT-D(KLAKLAK)2 biological activity on cancer cells 
The pro-apoptotic D(KLAKLAK)2-DEVD-SH peptide was obtained from Dr Maya 
Makatini (Advanced Materials Division, Mintek). The synthesis was done via N-
fluorenyl-9-methoxycarbonyl (Fmoc) standard solid phase peptide synthesis using D-
amino acids. Caspase 3 cleavage site (DEVD) was incorporated between the thiol group 
and the therapeutic peptide to allow separation of the pro-apoptotic peptide from the 
AuNPs once internalized by the cells.  
 
To test the antiproliferative activity of the redesigned peptide [D(KLAKLAK)2-DEVD-
SH] in vitro, this pro-apoptotic peptide was synthesized with a PTD (TAT) on the N-
terminus of the peptide to facilitate entry into cells. The activity of TAT- 
D(KLAKLAK)2-DEVD-SH was tested on a panel of cancer cell lines which included: 
Caco-2, HT-29 and MCF-7. The cell lines were treated with increasing concentrations 
(0-250 µg/ml) of the fusion peptide for 24 hours. The viability of the cells was 
investigated using the WST-1 assay. A dose response activity was observed in all 3 
cancer cell lines as shown in Figure 5.1. The peptide was significantly toxic to all 3 cell 
lines at all doses tested. At concentrations of 100- 250 µg/ml, the peptide had killed 
more than 70% of the cells. 
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Figure 5.1: Anti-proliferative activity of TAT- D(KLAKLAK)2-DEVD-SH on colon and breast 
cancer cells.  The cells were treated with increasing concentrations of TAT- D(KLAKLAK)2-DEVD-SH 
and cell viability was assessed using the WST-1 assay. Data is presented as mean ±SEM estimated using 
one way ANOVA test and Student Ttest. *P<0.05 indicates statistical significance when compared to 
untreated. 
 
The activity of synthetic TAT- D(KLAKLAK)2-DEVD-SH was high at the very low 
concentration as shown in Figure 5.1. The highest potency of TAT-D(KLAKLAK)2-
DEVD-SH was observed in Caco-2 cells (30.8 µg/ml) followed by MCF-7 (37.1 µg/ml) 
cells then HT-29 cells (41.7 µg/ml) as shown in Table 5.1.  
 
      Table 5.1: IC50 values for TAT-D(KLAKLAK)2 on cancer cell lines.  
 
Cell line IC50 (µg/ml) 
Caco-2 30.8 
HT-29 41.7 
MCF-7 37.1 
 
  * * 
 * 
* 
* 
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The major problem concerning the use PTDs for delivery is their lack of selectivity to 
target a specific cell type. Figure 5.1 shows that the TAT- D(KLAKLAK)2-DEVD-SH 
peptide was toxic to the colon (HT 29 and Caco-2) and breast (MCF-7) cancer cell 
lines. Although, the capacity of PTDs to deliver a bioactive molecule to cells has 
opened avenues for intracellular targeting, specificity is required for in vivo targeting. 
This can be achieved by using targeting peptides such as AHP that home to specific cell 
receptors. In this study, a PHB-targeted nanotherapy was developed by replacing TAT 
with AHP targeting peptide to increase the selectivity of the therapeutic peptide as 
described in section 5.2.2.  
 
5.2.2 Development and analysis of anti-proliferative activity of the AuNP-
conjugates 
5.2.2.1 Design of the AuNP-conjugates 
The targeting (AHP) and pro-apoptotic [D(KLAKLAK)2-DEVD-SH] peptides were 
synthesized via Fmoc as described in 5.2.1. AuNP conjugates were synthesized and 
functionalized for biological application by Dr Frankline Keter (Advanced Materials 
Division, Mintek) following the methodology described in section 4.2.2. The design 
together with the acronyms used for the AuNP conjugates is illustrated in Figure 5.2. A 
in the acronyms signifies the targeting peptide, G –gold nanoparticles, D –DEVD a 
caspase 3 cleavage site, N- non-targeting peptide (scrambled version of A), K- 
therapeutic or pro-apoptotic peptide and S- scrambled peptide with no known biological 
activity. 
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Figure 5.2: Schematic diagram of the AuNP design. AGDK = AuNPs with targeting and therapeutic 
peptides (PHB-targeted nanotherapy), GDK = untargeted AuNPs with therapeutic peptide, NGDK = 
AuNPs with scrambled targeting and therapeutic peptides, AGDS = targeted AuNPs with scrambled 
peptide. 
 
AGDK is the experimental PHB-targeted nanotherapy, containing both the PHB 
targeting and the pro-apoptotic peptides.  Once taken up by the cells that express PHB, 
the pro-apoptotic peptide [D(KLAKLAK)2-DEVD-SH] will disrupt the mitochondrial 
membrane resulting in cleavage of D(KLAKLAK)2 by caspase 3 and induce cell death 
by apoptosis. AGDK is the only AuNP expected to kill the cells, the other AuNPs (GC, 
GDK, NGDK, AG and AGDS) were used as a negative controls. GC has neither the 
targeting nor therapeutic peptide, as such the AuNPs were not expected to be taken up 
by the cells or affect their cell viability. The AG and AGDS have a targeting peptide and 
when taken up by the cells are not expected to have any toxicity towards the cells since 
it does not have a pro-apoptotic peptide. GDK and NGDK AuNPs are also not expected 
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to be toxic since they did not have the targeting peptide and are therefore not expected 
to be taken up by the cells. 
 
5.2.2.2 Characterization of AuNPs and conjugates   
The physico-chemical properties of the AuNP conjugates were characterized as in 
Chapter 4 using UV-Vis, TEM and ζ-potential. The optical properties of the AuNPs 
after attaching the biomolecules were compared to the citrate coated AuNPs (GC). A 
red shift in the maximum absorption peak of GC (523 nm) was observed in the AuNPs 
that contained the bio-active molecules (Table 5.2). The shift in the absorption spectra 
signifies a modification of the surface of the AuNPs. 
 
Table 5.2: AuNP optical properties. 
 
AuNPs and conjugates λmax (nm) Absorbance at λmax  
GC 523 0.9 
AG 523 1.0 
AGDS 526 1.2 
GDK 528 1.1 
NGDK 524 0.9 
AGDK 524 0.8 
 
TEM analysis was conducted to determine the size distribution and shape of the AuNP 
conjugates. All the AuNPs still retained the average size of 14 nm. The TEM 
micrographs in Figure 5.3 show that the nanoparticles were mostly spherical in shape 
with few irregular or triangular shaped NPs. They were all mono dispersed with no sign 
of aggregation or clumping.  
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Figure 5.3: Representative TEM micrographs of the AuNP conjugates. GC = citrate coated AuNPs, 
AG = targeted PEGylated AuNPs, AGDS = targeted AuNPs with scrambled peptide, GDK = untargeted 
AuNPs with therapeutic peptide, NGDK = AuNPs with scrambled targeting and therapeutic peptides, 
AGDK = AuNPs with targeting and therapeutic peptides (PHB-targeted nanotherapy). Scale bars in the 
micrographs are used to represent magnification of AuNPs. 
 
The surface charge of the AuNP conjugates was measured using ζ-potential to 
determine the electrokinetic potential of the colloidal NPs. The variation in ζ-potential 
among the AuNPs samples is shown in Figure 5.4. GC had lowest value of -35.9 mV. 
The values increased after bio-conjugation of targeting and therapeutic peptides. Of all 
the synthesized AuNPs, NGDK had the highest ζ-potential at -3.7 mV followed by AG 
(-5.8 mV), GK (-12.7 mV), AGDK (-13.2mV) and AGDS (-15.9 mV).  The changes in 
the charge are attributable to molecules attached to the AuNP surface and indicate 
modification of the AuNP surfaces. This is a physical property which is exhibited by 
any particle in a suspension which can be used to predict how these AuNPs are going to 
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behave when used in biological system. AuNPs with a large negative (AGDS) or 
positive (NGDK) ζ-potential values will repel each other and there will be no 
aggregation of the NPs. AuNPs with small ζ-potential will easily flocculate since the 
force between them is not strong enough to cause repulsion. 
 
Figure 5.4: Zeta potential of the AuNP conjugates determined using Malvern Zetasizer. GC = 
citrate coated AuNPs, AG = targeted PEGylated AuNPs, AGDS = targeted AuNPs with scrambled 
peptide, GDK = untargeted AuNPs with therapeutic peptide, NGDK = AuNPs with scrambled targeting 
and therapeutic peptides, AGDK = AuNPs with targeting and therapeutic peptides (PHB-targeted 
nanotherapy). 
 
5.2.2.3 Nanoparticle quantification by ICP-OES 
The concentrations of the AuNP samples were first determined using UV-Vis data, the 
stock concentration for all was 20 nM. ICP-OES was used to quantify the amount of Au 
metal from equal amount of the AuNPs (as described in section 2.3.5.3. The highest 
 
 
 
 
 152     
amount of Au metal as shown in Figure 5.5 was detected on citrate coated AuNPs (GC) 
at 10.76 ppm. The bio- functionalized AuNP concentration of Au atoms was around 2 
ppm in all the other AuNPs, the difference among the five AuNPs (AG, AGDS, GDK, 
NGDK and AGDK) was negligible. 
 
Figure 5.5: Quantification of AuNP conjugates by ICP-OES. To determine the amount of gold present 
in each sample, the samples were diluted 1:10 in dH2O. Elemental analysis was carried out by ICP-OES. 
GC = citrate coated AuNPs, AG = targeted PEGylated AuNPs, AGDS = targeted AuNPs with scrambled 
peptide, GDK = untargeted AuNPs with therapeutic peptide, NGDK = AuNPs with scrambled targeting 
and therapeutic peptides, AGDK = AuNPs with targeting and therapeutic peptides (PHB-targeted 
nanotherapy). 
 
5.2.2.4 Therapeutic activity of the nanotherapy in cancer cells using the WST-1 
assay 
The toxicity of the AuNP conjugates was screened against three different cancer cell 
lines: two colon cancer cell lines (Caco-2 and HT-29), and a breast cancer cell line 
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(MCF-7). Of the three cell lines, Caco-2 was shown to express PHB on the cell surface, 
while MCF-7 express PHB within the cell and HT-29 does not express PHB as shown 
in Figure 3.13.  
The activity of AG, AGDS, GDK as shown in Figure 5.6 was negligible on the Caco-2 
cell line, at the highest dosage of 8 nM, more than 90 % of the cells were still viable. 
The NGDK was not toxic from 0.5 to 4 nM, however a significant decrease in cell 
viability was unexpectedly observed at 6 and 8 nM. At 8 nM, the NGDK had killed over 
90% of the cells. This is unexpected result since NGDK was conjugated with a 
scrambled version of the targeting peptide and should therefore not be taken up by PHB 
expressing cells. The PHB-targeted nanotherapy (AGDK) was highly toxic to PHB 
expressing cells at all tested concentrations as shown in Figures 5.6A. AGDK showed 
significant toxicity even at the lowest concentration (0.5 nM) when compared to the 
other AuNP conjugates. 
The effect of the AuNP-conjugates was compared among the MCF-7 breast cancer and 
HT-29 colon cancer cell lines to determine the specificity of the AuNP toxicity. The 
MCF-7 cells express the PHB receptor as a cytosolic protein and HT-29 cells does not 
express the protein at all. The cells were exposed to various increasing concentrations 
of the AuNP conjugates for 24 hours. The cell viability was determined as before, using 
the WST-1 assay. None of the AuNPs (AGDS, AG, GDK, NGDK and AGDK), were 
expected to have toxic effects on the MCF-7 and HT-29 cells. AGDK in particular 
should not be toxic to MCF-7 and HT-29 cells since they do not express PHB on the 
surface. Figure 5.6(B and C) shows that AGDS, AG, GDK and AGDK were not toxic to 
MCF-7 and HT-29 cells. However, as was the case for Caco-2 cells, MCF-7 and HT-29 
cells were susceptible to NGDK at concentrations of 4-8 nM. 
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Figure 5.6:  Effect of targeted and untargeted NP conjugates on Caco-2 cells. Toxicity in Caco-2 (A), 
HT 29 (B) and MCF-7 (C) cells was investigated by WST-1 assay after 24 hour treatment with AuNPs. 
AG = targeted PEGylated AuNPs, AGDS = targeted AuNPs with scrambled peptide, GDK = untargeted 
AuNPs with therapeutic peptide, NGDK = AuNPs with scrambled targeting and therapeutic peptides, 
AGDK = AuNPs with targeting and therapeutic peptides (PHB-targeted nanotherapy). A two-tailed, 
unpaired t-test was used to analyse significance. *p<0.05, difference statistically significant when 
compared to untreated samples. 
* 
* 
* 
* 
* 
* * 
* * * 
* 
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Figure 5.7 shows the results for cells treated with 8 nM of various AuNP conjugates for 
Caco-2, MCF-7 and HT-29 cells in a bar graph. The data was extrapolated from Figure 
5.6A-C and clearly demonstrates the selective toxicity of AGDK to Caco-2 cells. 
 
Figure 5.7: Selectivity of AGDK compared with other AuNP conjugates on Caco-2, MCF-7 and HT-
29 cells treated with 8 nM AuNP conjugates.  AG = targeted PEGylated AuNPs, AGDS = targeted 
AuNPs with scrambled peptide, GDK = untargeted AuNPs with therapeutic peptide, NGDK = AuNPs with 
scrambled targeting and therapeutic peptides, AGDK = AuNPs with targeting and therapeutic peptides. 
Arrow points at cells treated with AGDK and their effect on the three cell lines. A two-tailed, unpaired t-
test was used to analyse significance. *p<0.05 
The IC50 concentrations (Table 5.3) for AGDK and NGDK in Caco-2 cells were 
determined to be 0.3 nM and 7.5 nM, respectively. 
 
Table 5.3: IC50 of AuNP conjugates on Caco-2 cell line. 
 
AuNP conjugates IC50 (nM) 
AGDK 0.3 
NGDK 7.5 
AG  >8 
 GDK >8 
 AGDS >8 
                       
* * 
* 
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5.2.2.5 Cellular uptake of AuNPs by cancer cells as determined by ICP-OES 
Uptake of the AuNPs by Caco-2, HT-29 and MCF-7 cancer cell lines was quantified by 
ICP-OES to determine the concentration of the metals that was taken up by the cells as 
described in section 2.3.6.2a). Figure 5.8 shows the percentage of gold recovered from 
the cells as function of the total content of AuNPs the cells were exposed to. For all 
three cell lines, the amount of gold was significantly higher in cells treated with GC 
compared to the other AuNP conjugates.  
 
Figure 5.8: Quantification of internalized AuNPs in cancer cell lines by ICP-OES. The cells (were 
incubated with various nanomaterials at 37°C for 24 hours. Cells were washed, lysed in aqua regia and 
analysed for gold content by ICP-OES. The percentage of nanoparticles taken up by the cells was 
determined as a function of the total amount of AuNPs applied. GC = citrate coated AuNPs, AG = 
targeted PEGylated AuNPs, AGDS = targeted AuNPs with scrambled peptide, GDK = untargeted AuNPs 
with therapeutic peptide, NGDK = AuNPs with scrambled targeting and therapeutic peptides, AGDK = 
AuNPs with targeting and therapeutic peptides (PHB-targeted nanotherapy). A two-tailed, unpaired t-test 
was used to analyse significance. *p<0.05, significant difference compared to untreated sample, a = 
p<0.05 AGDK significantly different compared to other AuNP conjugates in MCF-7 and HT-29. 
The average amount of gold recovered from cells treated with GC was 65% for Caco-2, 
76.9% for MCF-7 and 58% for HT-29 cells. For treatments with AuNPs with the 
* 
* 
* 
a 
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targeting peptide (AG, AGDS and AGDK), the gold content in Caco-2 cells was 
significantly higher compared to HT-29 and MCF-7 cells that lack the PHB receptor on 
the surface of the cell. The amount of gold detected in Caco-2 cells treated with targeted 
AuNPs (AG, AGDS and AGDK) was significantly higher than the cells exposed to 
AuNPs without the targeting peptide (GDK and NGDK). The amount of gold recovered 
in cells treated with GDK and NGDK were comparable in all the cell lines. 
5.2.2.6 Intracellular localization of AuNPs by TEM 
TEM analysis was used to determine cellular localization of the GC, AG, AGDS, GDK, 
NGDK and AGDK in Caco-2 cells. The cells were treated with IC50 concentrations for 
24 hours, TEM was used to examine the intracellular distribution of the six AuNPs after 
fixation. Representative TEM micrographs of Caco-2 cells treated with the different 
AuNPs are shown in Figure 5.9. Clusters of AuNPs in cells treated with GC, AG, 
AGDS, NGDK and AGDK were detected mostly in the cytoplasm. No particles were 
found on the cell surface or inside the cells exposed to GDK. The cells subjected to GC, 
AG, AGDS and GDK retained the typical elongated morphology of Caco-2 cells with no 
signs of cytotoxicity as compared to cells exposed to NGDK and AGDK. The cells 
treated with AGDK show a circular nucleus with distorted cellular features and shape, 
indicating cellular toxicity. 
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Figure 5.9: Localization of AuNPs in Caco-2 cells by TEM. Cells were incubated with various AuNPs at IC50 concentration for 24 hours. After exposure, cells were 
fixed with 4% paraformaldehyde and stored in 2.5% glutaraldehyde until further analysis. AuNP uptake was examined by TEM. The red arrows points at NPs 
localised within the cytoplasm and green arrows indicate the NPs on the cell surface. N - Nucleus, C - Cytoplasm. GC = citrate coated AuNPs, AG = targeted 
PEGylated AuNPs, AGDS = targeted AuNPs with scrambled peptide, GDK = untargeted AuNPs with therapeutic peptide, NGDK = AuNPs with scrambled targeting 
and therapeutic peptides, AGDK = AuNPs with targeting and therapeutic peptides (PHB-targeted nanotherapy).  
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5.2.3 Cell death analysis: investigation of possible apoptotic cell death 
To assess the mode of cell death following exposure of cells to AuNP-conjugates, 
several apoptotic cell death parameters were studied. The most commonly used markers 
of apoptosis such as phosphatidyl serine (PS) externalization at the cell surface, caspase 
(3 and 9) activation and oxidative stress were investigated. PS exposure and ROS 
induction in the Caco-2 cell line was determined by flow cytometry. Caspase activation 
was studied by both flow cytometry and Western blot analyses. 
5.2.3.1 Effect of AuNPs on cell morphology 
The first and most readily noticeable effect following exposure of cells to toxic 
substances is the alteration of cellular features such as shape and size. The cell 
membrane has physical features designed to modulate cell signalling, maintain the 
integrity and stability of the internal environment. The surface charge and size of 
nanomaterials are thought to play a role in the cellular membrane disruption. Interaction 
of NPs and the cell through membrane protein, may induce the changes that can be used 
to assess the cell integrity (Arvizo et al., 2010).  
The three cancer cell lines used in this study differentiate into monolayers in cell 
culture. After treatment with the 0.3 nM AGDK, 7.5 nM NGDK and 50 µM Ceramide (a 
positive control) distinct morphological changes (such as cell shrinkage, rounding, 
membrane blebbing and cell detachment) were observed under the light microscope as 
shown in Figure 5.10 indicating unhealthy cells. The effect of AGDK was only seen in 
the Caco-2 cells and not in HT-29 or MCF-7 cells. NGDK and Ceramide were toxic to 
all three cell lines. Ceramide is a known apoptosis inducer and used as a positive 
control (Park et al., 2011; Siskind, 2005).  
 
 
 
 
 160     
 
Figure 5.10: Light microscopy depicting cell morphological of Caco-2, MCF-7 and HT-29 cells after exposure to various AuNPs for 24 hours.  The cells were 
grown in a 12 well plate and treated with IC50 of the AuNPs, the cellular morphology were observed under light microscope and captured by the Leica camera. AG = 
targeted PEGylated AuNPs, NGDK = AuNPs with scrambled targeting and therapeutic peptides, AGDK = AuNPs with targeting and therapeutic peptides (PHB-
targeted nanotherapy). 
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Cells exposed to AG did not show any sign of distress, their cellular features appeared 
normal. As shown in Figure 5.10, no morphological changes were observed on cells 
treated with AG, the cells were comparable to untreated cells in all cell lines. Cells 
treated with AGDS and GDK was similarly unaffected (data not shown). Cells treated 
with AGDK and NGDK appeared to be clustered with a few cellular extensions, the cells 
detached from each other as compared to control cells. 
5.2.3.2 Analysis of apoptotic effects induced by AuNP conjugates in Caco-2 cells 
The D(KLAKLAK)2 peptide has pro-apoptotic activity and has been shown to induce 
cell death through apoptosis when internalized by cells (Ellerby et al., 1999; Kwon et 
al., 2008). The APOPercentageTM apoptosis assay was used to confirm that the 
D(KLAKLAK)2-DEVD-SH peptide still retained its apoptotic ability after conjugation 
to AuNPs following the protocol described in section 2.3.6.3 a). The APOPercentageTM 
assay employs the disodium salt of 3,4,5,6,-tetrachloro-2' ,4' ,5' ,7'–tetraiodofluorescein 
to stain cells that are undergoing apoptosis, purple-red. The APOPercentageTM dye can 
only be taken up by apoptotic cells that are undergoing the membrane flip-flop and 
translocation of the PS to the outer leaflet. Apoptosis was quantified by measuring the 
dye incorporated in apoptotic cells using Accuri flow cytometer, following the protocol 
that was developed by Meyer et al., (2008).  
Caco-2 cells were exposed to various AuNP conjugates at IC50 concentrations for 24 
hours and stained with APOPercentageTM dye as described in section 2.3.6.3 a). After 
24 hours of treatment, negligible numbers of apoptotic cells were observed in cells 
treated with AG, AGDS and GDK as shown in Figure 5.11. The number of apoptotic 
cells in those treatments was not significantly different when compared to untreated 
cells. Cells treated with 50 µM of cisplatin were used as a positive control. Cisplatin is 
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a known apoptosis inducer (Okamura et al., 2004). Only two of the AuNPs (AGDK and 
NGDK) were able to induce significant levels of apoptosis in Caco-2 cells as shown in 
Figure 5.11. The levels of apoptosis in cells treated with AG, AGDS and GDK was not 
significantly higher than the untreated controls.   
 
Figure 5.11: Analysis of apoptotic cells by APOPercentageTM staining. Caco-2 cells were treated with 
various AuNPs using their IC50 for 24 hours. Apoptotic cells were analysed by Accuri flow cytometer. 
Results shown as the average of replicate samples. AG = targeted PEGylated AuNPs, AGDS = targeted 
AuNPs with scrambled peptide, GDK = untargeted AuNPs with therapeutic peptide, NGDK = AuNPs with 
scrambled targeting and therapeutic peptides, AGDK = AuNPs with targeting and therapeutic peptides 
(PHB-targeted nanotherapy). A two-tailed, unpaired t-test was used to analyse significance. *p<0.05, 
significant difference compared to untreated sample and other AuNP conjugates. 
 
Cells treated with the AGDK showed significantly higher number of apoptotic cells 
(50%) when compared to the untreated and positive controls. Only 24% of the cells 
treated with 7.5 nM of NGDK were apoptotic and 31% for those treated with 50 µM 
Cisplatin.  
* 
* 
* 
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5.2.3.3 Analysis of caspase activity  
D(KLAKLAK)2 has been shown to induce apoptotic cell death via caspase activation 
(Ellerby et al., 1999; Kwon et al., 2008). Activation of caspase 3 and 9 in Caco-2 cells 
induced by AuNP exposure was investigated in order to confirm the role of 
D(KLAKLAK)2 in the induction of apoptosis. Both caspase 9 and 3 are important 
apoptosis-associated proteins involved in the early and late stage apoptotic pathway, 
respectively as reviewed by Fan et al., (2005). The initiator caspase 9 is involved in the 
formation of the apoptosome complex responsible for caspase 3 activation. Caspase 3 is 
a key effector caspase that executes cell death in apoptotic cells. Activation of caspase 3 
is responsible for most apoptosis hallmarks and seals the fate of the cell. Once the pro-
enzyme is proteolytically cleaved other caspases become activated resulting in cell 
death through apoptosis (Fan et al., 2005, Boatright and Salvesen, 2003).  
a) Analysis of caspase 3 activation by Western blot  
Ten microgram of protein sample obtained from the total protein fraction of cells 
treated with various AuNP-conjugates at their IC50 was analysed by western blot assay. 
Representative immunoblot of caspase 3 activity in Caco-2 cells after 24 hours of 
treatment with various AuNP conjugates is shown in Figure 5.12A. The caspase 3 
antibody used in Figure 5.12A recognises the 32 kDa proenzyme and the cleaved 
subunits at 20, 17 and 11 kDa. Pro-caspase 3 was absent in the positive control 
(Cisplatin treated cells) and cells treated with AGDK. This suggests that the pro-caspase 
3 was activated and cleaved. Pro-caspase 3 was present in cells treated with GC, AG, 
AGDS, GDK and NGDK. The cleaved products of pro-caspase 3 were only detected in 
cells treated with NGDK, suggesting that pro-caspase 3 was activated in these cells but 
not to the same extent as in AGDK and Cisplatin treated cells. This corroborates the 
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APOPercentage data shown in Figure 5.11. Figure 5.12B shows samples 
immunoblotted with the Actin antibody demonstrating equal protein loading. 
 
Figure 5.12: Western blot analysis of Caspase activation in Caco-2 cells. Cells were treated with 
AuNP conjugates for 24 hours. Protein expression was determined by western blotting using specific 
antibodies. A – Caspase 3 western blot and B - Actin western blot was used as a loading control. GC = 
citrate coated AuNPs, AG = targeted PEGylated AuNPs, AGDS = targeted AuNPs with scrambled 
peptide, GDK = untargeted AuNPs with therapeutic peptide, NGDK = AuNPs with scrambled targeting 
and therapeutic peptides, AGDK = AuNPs with targeting and therapeutic peptides (PHB-targeted 
nanotherapy). 
 
b) Analysis of Caspase 9 activation by flow cytometry 
In the mitochondrial mediated apoptosis pathway, caspase 9 is known to activate 
effector caspases (3/6 and 7) resulting in cell death via apoptosis (Fan et al., 2005). A 
fluorogenic caspase 9 (CaspaLux® 9-M1D2) substrate was used to detect caspase 9 
activation in cells treated with AG, AGDS, GDK, NGDK (7.5 nM) and AGDK (0.3 nM). 
CaspaLux® 9-M1D2 substrate is an enzymatic assay that is used to measure enzyme 
(caspase 9) activity, the substrate is composed of two identical fluorescent monomers 
that are covalently linked together by a caspase 9 cleavage site (LEHD peptide). The 
LEDH peptide dimerizes the two fluorescent probes forming a loop structure which 
keep the two probes at close proximity and quench their fluorescence. The substrate can 
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passively diffuse across all membranes of intact cells. Once inside the cell, the LEDH 
linker will be cleaved by the active caspase 9 and releases the fluorescent probes. The 
probes generate a fluorescent signal within the cells that can be used to measure 
intracellular protease activities in live cells. The fluorescence can be quantified by 
either fluorescence microscopy or flow cytometry.  
 
 
Figure 5.13: Evaluation of caspase 9 activity by flow cytometry in Caco-2 cells exposed to various 
AuNP conjugates. AG = targeted PEGylated AuNPs, AGDS = targeted AuNPs with scrambled peptide, 
GDK = untargeted AuNPs with therapeutic peptide, NGDK = AuNPs with scrambled targeting and 
therapeutic peptides, AGDK = AuNPs with targeting and therapeutic peptides (PHB-targeted 
nanotherapy). A two-tailed, unpaired t-test was used to analyse significance. *p<0.05, significant 
difference compared to untreated sample, b = p<0.05 AGDK significantly different compared to NGDK.  
 
Caco-2 cells were exposed to various AuNP conjugates at IC50 concentrations for 24 
hours. Post treatment, caspase 9 activity was evaluated by subjecting the cells to 
CaspaLux® 9-M1D2 fluorogenic substrate as described in section 2.3.6.3 c).  The 
experiment was performed once in triplicate. Intracellular levels of caspase 9 or caspase 
9 activity was significantly increased in cells treated with PHB-targeted nanotherapy 
* 
* 
* 
b 
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(AGDK) when compared to cells treated with the control AuNPs (AG, AGDS, GDK, 
NGDK) and the cisplatin as a positive control. As shown in Figure 5.13, the CaspaLux
® 
9-positive cells were significantly higher for AGDK (97%) treated cells in relation to the 
negative and positive controls. The data suggests that caspase 9 activation does occur 
and the cell death is mediated through the intrinsic apoptosis pathway.  
  
5.2.3.2 Detection of intracellular oxidative stress induced by AuNPs: ROS activity 
CM-H2DCFDA was used to monitor generation of ROS in Caco-2 cells after treatment 
with the various AuNPs with IC50 concentration at 6, 12 and 24 hours as described in 
section 4.2.5.2. The amount of reactive oxygen intermediates in intact cells was 
quantified by flow cytometry as described in section 2.3.6.3 d).  
The intracellular ROS levels induced by exposing the cells to various AuNP conjugates 
for 6 to 24 hours are shown in Figure 5.14. The untreated cells and cells treated with 
either 50 µM cisplatin or H2O2 were included as controls. Increased intracellular ROS 
levels were observed in cells treated with the positive control (H2O2) at all time points. 
Only cells treated with AGDK and NGDK undergo oxidative stress. There is a time 
dependent increase in the number of cells undergoing oxidative stress for both AGDK 
and NGDK. Cells treated with AGDK undergo oxidative stress from 6 hours while 
NGDK induce oxidative stress only from 12 hours.  AGDK and H2O2 had significantly 
higher amount of ROS (13 and 28%, respectively) compared to the other groups. Cells 
treated with GC, AG, AG, AGDS and GDK showed no significant difference in ROS 
levels when compared to untreated cells at 6-24 hours.  
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Figure 5.14: ROS levels in Caco-2 cells in response to AuNPs treatment. Cells were treated with 
various AuNP conjugates for 24 hours and the ROS levels were determined using the CM H2DCFDA 
probe. Cell fluorescence was analysed with the Accuri flow cytometer. AG = targeted PEGylated AuNPs, 
AGDS = targeted AuNPs with scrambled peptide, GDK = untargeted AuNPs with therapeutic peptide, 
NGDK = AuNPs with scrambled targeting and therapeutic peptides, AGDK = AuNPs with targeting and 
therapeutic peptides (PHB-targeted nanotherapy). A two-tailed, unpaired t-test was used to analyse 
significance. *p<0.05, significant difference compared to untreated sample, a = p<0.05 AGDK 
significantly different compared to other AuNP conjugates, b = p<0.05 AGDK significantly different 
compared to NGDK. 
* 
* 
* 
 b 
* 
* 
* 
b 
* 
* 
a 
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5.3 Discussion 
Targeted nanotherapy offers hope for the treatment of chronic diseases by developing 
drugs that specifically inhibit the actions of molecular targets known to promote the 
growth of pathological tissues. Preclinical and human trials conducted using such 
therapies provides a concrete evidence of the therapeutic potential of regimens that 
might be capable of treating debilitating diseases such as cancer (Kumar et al., 2014; 
Libutti et al., 2009)  and obesity (Hossen et al., 2010).  
A PHB-targeted nanotherapy that showed specificity and increased efficacy in target 
cells was developed in this study. The D(KLAKLAK)2 peptide is not capable of entering 
cells on its own and can therefore not affect cell viability. Incorporating the PHB 
homing peptide on the nanotherapy has increased its specificity and efficacy as 
determined by WST-1 assay in vitro in three cancer cell lines, refer to Figures 5.6 (A-
C). Exposing the three cell lines to increasing dosage of the AuNP conjugates showed 
that AGDK triggered cell death only on PHB-expressing cell line (Caco-2 cells), and not 
the other two cell lines and confirmed the specificity of the targeted nanotherapy 
(Figure 5.7). The negative controls (GDK, AG and AGDS) did not deter the cell viability 
even at the highest dosage used. Surprisingly NGDK, a negative control with scrambled 
targeting peptide sequence showed toxicity on all cell lines at the higher doses. The 
mechanism on how this NPs (NGDK) are taken up by the cells is under investigation. 
The targeting (AHP) peptide signiﬁcantly enhanced the AGDK specificity, resulting in 
increased cytotoxicity on the cell line that overexpress the target receptor (PHB) in vitro 
and significantly improved the sensitivity of the therapeutic peptide leading to reduced 
IC50 compared to the other AuNPs as shown in Table 5.3. AGDK killed 50% of the cells 
at only 0.3 nM compared to 7.5 nM for NGDK. The target selectivity was increased 
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resulting in enhancement of therapeutic index of the potential anti-obesity therapy. 
Thus, this demonstrates that nanotechnology drug-delivery systems coupled to targeting 
moieties could be able to overcome the non-specificity and bystander effects of 
currently available therapies by targeting disease-specific markers.  
Results from cytological images in Figure 5.10 clearly exhibited cellular changes 
consistent with the typical hallmarks of apoptotic demise 24 hours post- treatment for 
cells treated with AGDK, NGDK and Cisplatin. This result was subsequently confirmed 
using biochemical assays, where activation of caspases (3 and 9) and externalization of 
PS was investigated. AGDK was capable of altering key biochemical events leading to 
apoptotic cell death within 24 hours post-treatment.  The D(KLAKLAK)2-DEVD-SH 
peptide attached to AuNPs induced cell death when internalized with the help of AHP 
peptide and caused cell death by apoptosis. APOPercentage data in Figure 5.11 
observed a remarkably high percentage of apoptotic cells at the low concentration of 0.3 
nM for AGDK compared to the negative and positive controls. The pro-apoptotic effects 
of the targeted nanotherapy was further confirmed by activation of caspase 3 (Figure 
5.12) and 9 (Figure 5.13), which was higher for cells treated by AGDK followed by 
NGDK. These data correlated strongly with the APOPercentage data.  Results from in 
vitro studies showed that targeted nanotherapy had a more pronounced cytotoxic effect 
than the other AuNP-conjugates which had negligible impact on cellular function at a 
very high dosage. These results indicate that neither targeting peptide nor the 
therapeutic peptide have effect on cell viability on their own and are incapable of 
inducing cell death unless the therapeutic peptide is taken up by the cells. These data 
confirmed that D(KLAKLAK)2-DEVD-SH was responsible for the death of PHB 
expressing cells in response to AGDK and NGDK treatment.  
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The AuNPs used as drug delivery agents in this study improved the eﬃcacy and 
toxicity of the PHB-targeted nanotherapy. Modifying the AuNP surface by chemical 
conjugation of bio-active molecules influenced the interaction of the AuNPs with cells, 
and their effects by increasing the cellular uptake and activity of the nanotherapy. 
Similar effects have been reported on the use of AuNPs as delivery vehicles for gene 
therapy (Huo et al., 2014) and anticancer therapies (Kumar et al., 2012; Chen et al., 
2014; Xiao et al., 2012). The NP-based delivery systems have been extensively studied 
in cancer preclinical studies, the multimodal systems are effective in selective targeting 
of diseased cells and tissues through the use of antibodies (Karmani et al., 2014), 
aptamers (Xiao et al., 2012) and targeting ligands (Chen et al., 2014). The targeted 
nanotherapeutics has progressed successful to human trials, with a lot of drug 
candidates still in the pipeline. The recently evaluated human clinical trials for targeted 
nanotherapies provide evidence that these systems can provide improved and better 
treatment strategies (ClinicalTrials.gov numbers; NCT00356980, NCT00436410 and, 
NCT00848042). 
The versatility of AuNPs as drug carriers was reported by Chen and colleagues, where 
multifunctional NPs were constructed for theranostic purposes. The AuNPs were 
targeted at folate expressing cancer cells and induced cell death through apoptosis, 
while the events were imaged in real-time (Chen et al., 2014). These studies further 
extend that the overall concept could be useful in treatment of chronic diseases. The 
ability to target theranostic agents to diseased tissues provides a viable approach to 
reduce off-target effects and increase the drug efficacy even at a very low dosage (Cho 
et al., 2008; Ruoslahti et al., 2010). Targeting the underlying pathophysiology of the 
disease through disease-specific markers can discriminate between healthy and diseased 
cells and eradicate the cells without any harm to normal cells (Ruoslahti et al., 2010).  
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The test nanotherapy understudy can serve as an alternative treatment for obesity, the 
effect of the targeted therapy will be studied in a rat model of obesity to help understand 
the interactions between targeted AuNPs and biological systems. The AuNPs proved to 
be effective drug delivery systems and are biocompatible, when targeted to specific 
cells can deliver and release a therapeutic payload at the target site. The in vitro data 
showed that AGDK was more efficacious (IC50 = 0.3 nM) than NGDK (IC50 = 7.5 nM). 
The study demonstrated PHB-targeting through AHP in Caco-2 cells, and that using the 
targeting peptide it is possible to safely deliver AHP-cargo to target cells. The cells that 
express PHB (Caco-2) were killed by the targeted nanotherapy AGDK.   
The cells served as a model cell line for ECs in the WAT of obese subjects and 
indicated that the ECs can be targeted by this therapy. Targeting the ECs with AGDK 
can result in cell death, increases lipolysis in the adipocytes and starve the cells to 
death. In a study done by Thovhogi et al, a similar strategy was tested and this study 
shows the targeted biodistribution of QDs and AuNPs conjugated to AHP peptide in 
diet-induced obese rats. The targeted NPs were administered for 24 hours, uptake of the 
NPs in various tissues was studied through ICP OES (Thovhogi et al., 2013; Thovhogi 
et al., 2015). Localization of the QDs was studied by in vivo imaging. The techniques 
indicated that the AHP-targeted NPs were localized selectively in the WATs (Thovhogi 
et al., 2013). Similar findings were published on the selectivity and specificity of AHP 
to target PHB on obese mice (Kolonin et al., 2004; Hossen et al., 2012). This suggests 
that the therapy can be safely delivered intracellularly to trigger cytotoxic effects, and 
can be more potent than the current therapies. 
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Chapter 6: General Discussion, concluding remarks and future 
perspectives. 
6.1 General Discussion 
 
Pharmacotherapy is used as an adjunct in obesity management. Although the drugs used 
in the management of obesity are effective in reducing body weight for the period in 
use, they are limited by nonspecificity and off-target side effects (Bray, 2000; Hainer et 
al., 2008).  Nonspecific distribution through the body results in insufficient drug dosage 
reaching the desired tissue, toxicity towards both normal and diseased cells has resulted 
in withdrawal of useful anti-obesity drugs such as sibutramine. Currently, orlistat is the 
only drug that can be used on a long term basis to manage obesity (William, 2010). The 
greatest challenge faced by anti-obesity drugs after lack of drug specificity, is the 
maintenance of weight loss. Clearly research into less toxic, more potent therapies is 
required. Ideally, an effective treatment for obesity should be able to reach the affected 
or diseased tissues and cells with minimal toxicity to healthy cells, escape bio-
degradation while retaining their activity in the blood circulation and be able to confer 
the ability to selectively kill only the target cells.  
Lack of drug specificity and sensitivity reduces the drug’s therapeutic index. In an 
attempt to avoid detrimental effects to healthy tissue, the drug dosage and frequency of 
conventional therapies are often reduced (Breunig et al., 2008). Nanotechnology-based 
delivery systems coupled with targeted therapy has the potential to address these issues. 
Nanomaterials have a large surface area which increases their capacity to carry drugs or 
biomolecules. These features can be exploited for bio-medical applications by attaching 
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bio-active molecules for either diagnostic and/or therapeutic purposes. The use of 
nanotechnology to deliver therapeutics to target tissues and cells has been the highlight 
of nanomedicine (Kumar et al., 2014; Libutti et al., 2009). Through targeted therapy 
alone, the major issues associated with current anti-obesity therapies could be resolved 
(Cho et al., 2008; Ruoslahti et al., 2010). Targeted therapy has shown improvements in 
cancer patients’ survival rate, quality of life and reduced bystander cytotoxicity 
(Ruoslahti et al., 2010). The objective with targeted therapy is to increase the specificity 
and sensitivity of the therapy to selected cells, without causing harm to surrounding 
healthy tissues (Cho et al., 2008; Ruoslahti et al., 2010). These qualities can be 
magnified through nanotechnology. Nanomaterials offer the potential to be effective 
drug carrier systems without compromising the drug’s activity (Conti et al., 2006; Sinha 
et al., 2006).                                                                                                                                                                          
 
Nanotechnology-based targeted therapies that are tissue-specific and have potential to 
be non geno- and cytotoxic to healthy cells can be used as an alternative to the current 
management strategies to help combat obesity. In this study, biological active 
molecules (peptides) were attached to 14 nm AuNPs to develop a receptor targeted 
nanotherapy that can improve drug transportation and drug efficacy by targeting the 
PHB cell receptor, which is only expressed by the target cells. A number of challenges 
were encountered in the process of developing this nanotherapy, the first two attempts 
described in Chapter 4 were unsuccessful. The first attempt involved the conjugation of 
recombinant proteins (the expression of these proteins was described in Chapter 3) to 5 
nm AuNP-GSH-NTA as discussed in section 4.2.1.1. The AuNP-GSH-NTA aggregated 
when the recombinant proteins were conjugated to it and this to could be attributed to 
NP instability caused by the ratios of materials used to stabilize the AuNP.  
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In the second attempt AuNPs were successfully synthesized and functionalized for 
biological application by attaching targeting (AHP) and therapeutic [D(KLAKLAK)2-
SH] peptides as described in section 4.2.2.1. The AuNPs unfortunately showed that the 
PHB-targeted nanotherapy (AGK and AGTK) had similar effects as the negative 
controls (AG and GK) when used to investigate their toxicity in vitro, as shown in 
Figure 4.9. Certain parameters were changed to develop more potent targeted 
nanotherapy as described in Chapter 5, the major change was the addition of the 
caspase 3 (DEVD) cleavage site into D(KLAKLAK)2-SH peptide. The receptor targeted 
nanotherapy (AGDK) showed selective targeting and cell specificity demonstrated in 
colon and breast cancer cell lines as shown in Figure 5.6 (A-C). The extent of cellular 
uptake or internalization of targeted nanoparticles was dependent on the surface 
characteristics of the AuNPs, the targeted nanotherapy selectively targeted the cells that 
expressed PHB on the cell surface and proved its potential as an anti-obesity treatment.  
 
Targeting enhanced the efficacy of the PHB-targeted nanotherapy and restricted the 
toxicity of the treatment to specified target cells under in vitro conditions. With an IC50 
of 0.3 nM the targeted test nanotherapy (AGDK) was 25X more potent than the 
untargeted AuNPs (NGDK) which had IC50 of 7.5 nM (Table 5.3). The cell viability of 
PHB expressing cells were significantly reduced at all concentrations, compared to the 
negative controls. Biochemical analysis was used to examine whether the 
morphological changes the cells displayed when exposed to the AGDK were the results 
of apoptotic cell death. Figures 5.10 - 5.13 show that the majority of the cells died 
through apoptosis. The data confirmed that the activity of the pro-apoptotic peptide 
[D(KLAKLAK)2] was retained after it was conjugated to the AuNPs. These results 
indicate that AuNPs are well suited as delivery agents of therapeutic materials to treat 
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obesity due to their tunable cellular uptake and low toxicity. The study confirms and 
extends the tremendous potential of targeted therapy using AuNPs as drug delivery 
agents. NP-mediated drug delivery system in cancer are extensively studied, examples 
of established gold nanoparticle-based formulations in clinical trials include 
Aurimmune (ClinicalTrials.gov numbers, NCT00356980 and NCT00436410) and 
Aurolase (ClinicalTrials.gov number, NCT00848042).  
Caco-2 as a model cell line simulates more closely the vascular ECs in WATs of obese 
subjects, as the cells express the PHB receptor that is overexpressed in obese WAT 
vasculature. These cells were used to investigate the effects of PHB-targeted 
nanotherapy (AGDK), the therapy successfully caused cell death. The effect was only 
observed in target (Caco-2) cells, sparing HT-29 and MCF-7 cells. This strongly 
indicated the specificity of the nanotherapy, and a similar response can be expected in 
PHB expressing ECs. Cutting off the blood supply to the WATs (anti-angiogenesis) by 
killing the ECs in the WAT vasculature through the use of AGDK can reduce nutrient 
and oxygen supply to the adipocytes resulting in the reduction of the total body weight 
and obesity reversal. This work proves that PHB-targeted nanotherapy can be a feasible 
strategy for treatment of obesity by targeting the cells that are responsible for 
development of obesity through its vasculature. 
AGDK was able to target and induce apoptotic cell death in cells expressing PHB 
(Caco-2), which can be translated to the targeting of ECs in WAT. This indicates that 
effective and selective biologic effects can be achieved through PHB targeting, and that 
the receptor-mediated cell death proved to be an attractive strategy for obesity reversal. 
The efficient delivery of drugs into PHB-positive cells forms the basis for the concept 
of targeted therapy in obesity. The data generated in this study demonstrated that AGDK 
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can be used to inhibit of angiogenesis in the WAT vasculature of obese subjects and 
cause weight loss. 
6.2 Concluding remarks and future perspectives 
The study demonstrated the potential utility of targeted nanotherapy, its efficacy and 
sensitivity in vitro and therefore provides the proof of principle for antiangiogenic 
therapy for obesity. Through the use of cell culture model system, the study proved that 
a targeted nanotherapy is feasible for obesity treatment by exploring PHB-targeted 
nanotherapy. Future perspectives include investigation of possible anti-obesity effects 
of the targeted vascular nanotherapy in diet induced obesity rat models.  Avenues to be 
explored are not limited to the effect of targeted nanotherapy on body weight (BW), 
effect of discontinuation of nanotherapy on BW while continuing on the high fat (HF) 
diet or change to low fat diet. 
To corroborate the in vitro toxicity of the PHB-targeted nanotherapy described in 
Chapter 5, in vivo investigations are necessary and can better clarify the mechanisms 
governing the AuNPs toxicity. Animal models of obesity are excellent models for 
toxicology and genetic studies of human obesity, and has many advantages, for example 
the induction of obesity only takes weeks to perform, and the animals have a high 
(~80%) gene homology to human (Fenton and Carr, 1951). The diet-induced animal 
models of obesity were established over six decades ago (Fenton and Carr, 1951; 
Mickelsen et al., 1955), and has since been approved as acceptable models to study 
human obesity and its related diseases (Buettner et al., 2006). 
Animal models have a complex physiologic system and represent a much better model 
system when compared to in vitro cell cultures and can provide meaningful information 
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about the body’s response to targeted nanotherapy. The in vivo toxicity is determined by 
many parameters including the drug dosage, route of administration, metabolism, 
excretion and immune response (Zhang et al., 2010). The size similarity between NPs 
and cellular components raises concerns with regard to in-vivo use of NPs, as their size 
and charge allows for easy cell penetration and protein interaction and thus modulate 
their functions (Leroueil et al., 2007; Verma et al., 2008; Fischer and Chan, 2007). The 
interaction between NPs and the biological components such as proteins, lipids and 
cells, could lead to unique biodistribution, metabolism, clearance, and immune response 
(Fischer and Chan, 2007; Wu et al., 2013).  
The PHB-targeted nanotherapy under study can be a plausible therapeutic approach for 
obesity treatment. Several studies have shown that AHP targeted cargoes can be 
selectively delivered to PHB-expressing ECs in WATs of obese mice (Hossen et al., 
2012; Kolonin et al., 2004) and rats (Thovhogi et al., 2015). The data presented in 
Chapter 5 suggests that AGDK can be targeted to the ECs of WAT of obese subjects and 
induce cell death by apoptosis. Cutting off the blood supply to the WAT can result in 
tissue weight loss that can be translated into obesity reversal. The WAT growth is 
angiogenic dependent and by targeting the cells that promote angiogenesis and 
inhibiting their growth, the physiological processes in the affected tissue can be restored 
(Cao, 2010). Moreover, eliminating the cells that express PHB could lead to sustainable 
weight loss and reversal of obesity-induced diseases. Thus, targeted vascular 
nanotherapy could potentially provide a better strategy that might be superior to many 
of the current obesity therapies. 
The ability to target therapeutic agents to pathological cells offers a viable approach for 
the treatment of obesity, the therapy can reduce off-target effects, improves drug 
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sensitivity and efficacy. The targeted nanotherapy under study presents a lot of exciting 
promises as a potential and an alternative strategy for treatment of obesity. The nano-
based therapy (AGDK) has showed pronounced efficacy in Caco-2 cells, the therapy’s 
selectivity was demonstrated by their lack of toxicity on cells that does not express cell 
surface PHB. Figure 5.6 showed the importance of channelling toxicity of the treatment 
to diseased cells, targeting increased the therapy’s biocompatibility and activity and this 
can help prevent adverse immune response when used in vivo.  
The PHB-targeted nanotherapy showed pronounced effects on the Caco-2 cells. Since 
Caco-2 cells originate from colon cancer patient, PHB targeting might also be able to 
help in the treatment of colon cancer. Expression of PHB in colon cancer patients need 
to be investigated, the protein has been shown to be upregulated in tissue samples of 
colon cancer patients (Chen et al., 2010; O'Dwyer et al., 2011).  There is no information 
published about PHB’s expression in the tissue’s vasculature, it could be interesting to 
use the same strategy in colon cancer. However, the current strategy can be used to kill 
the colon cancer cells directly. The strategy requires further investigation to determine 
the effect of the PHB-targeted therapy in animal models of colon cancer. Surprisingly 
colon cancer is common in obese subjects (Kimura et al., 2014; Neumann et al., 2015), 
this therapy may therefore be used as a dual targeting in this case. 
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